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3HB   3-hydroxybutyric acid 
3HDec   3-hydroxydecanoic acid 
3HO   3-hydroxyoctanoic acid 
AC   adenylyl cyclase 
ADRB2  β2 adrenergic receptor 
AP-2   clathrin adaptor protein β2-adaptin 
C10   decanoic acid 
cAMP   cyclic AMP 
CKR   chemokine receptor 
CR   complement receptor 
D1R   D1 dopamine receptor 
DAG   diacylglycerol 
DAMP  damage-associated molecular pattern 
DHA   docosahexaenoic acid 
DMR   dynamic mass redistribution 
D-Phe   D-phenylalanine 
D-PLA  D-phenyllactic acid 
D-Trp   D-tryptophan 
ERK1/2  extracellular signal-regulated kinase 1/2 
FA   fatty acid 
FFAR   free fatty acid receptor 
fMet   N-formyl-methionine 
FPR   formyl peptide receptor 
GAP   GTPase-activating proteins 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
GPCR   G protein-coupled receptor 
GRK   GPCR kinase 
HCA   hydroxycarboxylic acid receptor 
HEK293T  human embryonic kidney cells 
IκBα   inhibitor of NFκB 
IL   interleukin 
ILA   indole-3-lactic acid 
IP3/IP3  inositol-1,4,5-trisphosphate 




L-PLA   L-phenyllactic acid 
LPS   lipopolysaccharides 
M1   classically activated macrophage 
M2   alternatively activated macrophage 
MAPK  mitogen-activated protein kinase 
MCFA   medium chain fatty acid 
M-CSF  macrophage colony-stimulating factor 
msGPCR  metabolite-sensing GPCR 
NFκB   nuclear factor κB 
PAMP   pathogen-associated molecular pattern 
PAR2   proteinase-activated receptor 2 
PI3K   phosphoinositide 3 kinase 
PIP2/PIP2  phosphatidylinositol-4,5-bisphosphate 
PIP3/PIP3  phosphatidylinositol-3,4,5-trisphosphate 
PLC   phospholipase C 
PLD   phospholipase D 
PRex   PIP3-dependent Rac exchange factor 
PTH   parathyroid hormone 
PTHR   parathyroid hormone receptor 
Radil   Ras-associating and dilute domain-containing protein 
RGS   regulators of G protein signaling 
Rho   Ras homology 
RhoGEF  Rho guanine nucleotide exchange factors 
ROS   reactive oxygen species 
SCFA   short chain fatty acid 
SUCNR1  succinate receptor 
TLR   toll-like receptor 







The superfamily of G protein-coupled receptors  
G protein-coupled receptors (GPCRs) constitute the largest group of transmembrane receptors 
responsible for the transduction of various extracellular stimuli to intracellular signals [1]. To 
date over 800 GPCR sequences have been identified in the human genome. Phylogenetic 
analyses led to the generation of the GRAFS classification system consisting of five main 
families - Glutamate, Rhodopsin, Adhesion, Frizzled/taste2, and Secretin [2]. The largest of the 
five main families is the rhodopsin family, which contains the olfactory receptors and accounts 
for a total number of 719 GPCRs [3].  
The extracellular stimuli that exert their signal through GPCRs include light and olfactory 
stimuli, as well as hormones, nucleotides, lipids, chemokines, and metabolites [4–9]. As the 
diverse list of ligands already suggests, GPCRs play an important role in the regulation of 
various physiological and pathophysiological processes. They are e.g. required for proper 
neurological function, since several neurotransmitter systems involve GPCRs. Consequently, 
these GPCRs are also connected to mental and neurological disorders such as anxiety, 
depression, schizophrenia, Parkinson’s Disease and Alzheimer’s Disease [10, 11]. Furthermore, 
tissues like the thyroid and the pancreas, more specifically the pancreatic islets, which are 
essential for controlling metabolic processes through their endocrinological function express 
several GPCRs making them interesting research targets for the treatment of diabetes and obesity 
[12, 13]. The members of one of the most well-known GPCR families, the β-adrenergic 
receptors, fulfill key roles in the regulation of cardiac function e.g. through the modulation of 
heart rate and myocardial contractility [14]. Additionally, GPCRs are directly connected to 
human health due to their diverse function in the immune system where they modulate 
differentiation and activation of different types of immune cells, besides playing a role in viral 
infections and auto-immune disorders [15–20]. Specifically, the functions of GPCRs in immune 
cells are discussed in more detail below. Last but not least, up- and down-regulation of the 
expression of a multitude of GPCRs is connected to disease progression in various cancer types; 
they are implicated in tumorigenesis, proliferation, invasion, and metastasis [21–23].  
Owing to these widely spread (patho-) physiological functions and their easy accessibility due to 
their localization at the plasma membrane, GPCRs are prominent drug targets. In fact, one third 
of the drugs currently approved by the Food and Drug Administration of the US act upon 
GPCRs. This translates to 475 drugs that target 108 unique GPCRs [24]. These numbers show 
that besides being popular drug targets, a large number (~ 73 %) of the human non-olfactory 




and growing with an especially great interest in finding new cancer treatments through 
understanding the role of GPCRs in the tumorigenic context [21, 23–25].  
 
Signal transduction of GPCRs 
The best known characteristic of GPCRs are their seven transmembrane domains which are 
connected by three intra- and three extracellular loops, the N-terminus is located extracellularly 
and the C-terminus inside the cell [26].  
Activation of a receptor by its respective agonist results in conformational changes of the 
receptor, which leads to the activation of a heterotrimeric G protein that is coupled to the 
receptor intracellularly [27, 28]. The activated G protein induces distinct signaling processes 
inside the cell. Heterotrimeric G proteins consist of a Gα subunit and the tightly associated Gβ 
and Gγ subunits [27–29]. An activated GPCR increases the GDP to GTP exchange rate of the 
Gα subunit and binding of GTP results in the dissociation of the heterotrimeric G protein into the 
Gα and Gβγ subunits [30].  
The Gα proteins are divided into four major families – Gi/o, Gs, Gq/11, and G12/13. While Gαi 
proteins reduce and Gαs proteins increase the intracellular cyclic AMP (cAMP) concentration by 
respectively inhibiting or activating adenylyl cyclases (ACs), Gαq proteins act through the 
activation of phospholipase C β (PLCβ), which converts phosphatidylinositol-4,5-bisphosphate 
(PIP2) to inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [31, 32]. The members of 
the fourth family (G12/13) convey their signal through mechanisms that are more diverse. This 
includes the activation of Ras homology (Rho) guanine nucleotide exchange factors (RhoGEFs) 
resulting in the activation of the small GTPase RhoA. Further mechanisms include binding to the 
C-terminal tail of cadherins, thereby inhibiting their adhesive function, and interacting with 
different proteins including radixin, A-kinase anchoring proteins, non-receptor tyrosine kinases, 
phospholipase D (PLD), and protein phosphatases [32–35].  
However, as mentioned above, Gβ and Gγ subunits are also part of the heterotrimeric G protein 
and so far, five distinct Gβ and 12 distinct Gγ subunits have been identified. The signal 
transduction of Gβγ subunits is multifaceted. PLCβ, adenylyl cyclases, ion channels, GPCR 
kinases, phosphoinositide 3 kinase (PI3K) β, PI3Kγ, protein kinase D, calmodulin, Raf-1 protein 
kinase as well as proteins involved in chemotaxis and cell migration (e.g. PIP3-dependent Rac 
exchange factor - PRex, Ras-associating and dilute domain-containing protein - Radil) are all 
known effectors of Gβγ subunits [36–39]. This is further diversifying the intracellular responses 





Additionally, besides classical/canonical G protein signaling, GPCRs also transduce their signals 
independently of G proteins. This process termed non-canonical signaling can involve activation 
of e.g. GPCR kinases and β-arrestins, JAK/STAT, Src family tyrosine kinases, and mitogen-
activated protein kinases (MAPKs) (like ERK, JNK/SAPK) [30, 40–42].  
 
Internalization and trafficking of GPCRs 
Besides receptor activation and induction of downstream signaling, termination of the signal 
transduction is critical to prevent aberrantly continued signaling. Part of this process is the 
termination of the G protein signaling through hydrolysis of GTP to GDP by the intrinsic 
enzymatic activity of the Gα subunit, which in turn allows the re-association of the Gα and the 
Gβγ subunits. To further regulate and adjust this termination mechanism depending on the 
activated receptor and desired signal duration and intensity, several GTPase-activating proteins 
(GAPs) can enhance the GTP hydrolysis rate of the activated Gα subunit by interacting with it. 
This includes e.g. regulators of G protein signaling (RGS) proteins, phosphodiesterases and 
PLCβ [29, 31, 43].  
Another important part of the regulation of GPCR signaling is receptor internalization and 
trafficking. Internalization and subsequent processes are essential for the attenuation of 
Figure 1: Primary GPCR-signaling pathways involving heterotrimeric G proteins. Receptor-mediated activation of 
Gαs leads to elevated intracellular cAMP levels mediated by stimulation of adenylyl cyclase, whereas activation of Gαi 
induces a decrease of intracellular cAMP levels. Activation of Gαq-coupled receptors causes stimulation of 
phospholipase C. Gβγ subunits can activate or inhibit many different effectors, amongst them ion channels, PLCβ and 




signaling, as well as re-sensitization and downregulation of GPCRs e.g. in the continued 
presence of the receptor ligand; additionally there are implications for sustained downstream 
signaling of GPCRs [44–46]. Following activation at the plasma membrane, which is true for a 
large number of GPCRs, receptors are phosphorylated by second-messenger kinases (such as 
protein kinase A and protein kinase C) or members of a distinct family of GPCR kinases 
(GRKs). This subsequently leads to the uncoupling of the receptors from their respective G 
protein, followed in some but not all cases by binding of β-arrestins.  
There are four different arrestins. Two of them, visual arrestin (arrestin-1) and cone arrestin 
(arrestin-4), are exclusively expressed in the eye [47, 48]. The other two, β-arrestin 1 (also called 
arrestin-2) and β-arrestin 2 (also called arrestin-3), are expressed ubiquitously. Arrestins were 
initially discovered as proteins with the capacity to desensitize G protein signaling of GPCRs 
following agonist exposure [48–50]. However, regarding β-arrestins we now know that they are 
involved in numerous processes, including internalization, transactivation of growth factor 
receptors, MAPK signaling, ubiquitination, and cytoskeletal reorganization [48]. Especially their 
function in desensitization and internalization has been widely studied. Both play important roles 
in these processes, but whether β-arrestin 1 or 2 is recruited and which β-arrestin is required for 
proper internalization depends on the respective receptor [51, 52].  
The uncoupling of receptor and G protein, termed desensitization, is usually ensued by receptor 
internalization through an endocytic pathway [1, 44]. There are different endocytic routes for 
GPCR internalization. The best characterized is clathrin-mediated endocytosis. In brief: 
subsequent to the desensitization of the receptor a ligand-occupied receptor-β-arrestin 1/2 
complex is formed, which recruits the clathrin adaptor protein β2-adaptin (AP-2) and clathrin 
itself, causing it to cluster in clathrin-coated pits, that undergo internalization via GTPase 
dynamin 2-dependent formation of clathrin-coated vesicles [44, 53, 54]. A second, less studied 
mode of internalization of GPCRs is caveolae-dependent endocytosis. Caveolae are membrane 
invaginations that consist mainly of cholesterol and sphingolipids, but also contain caveolin. The 
mechanism of induction of caveolae-dependent endocytosis is not yet clear, however, activation 
of a phosphorylation cascade is thought to be involved. Following the induction the receptor is 
targeted to caveolae and internalization is achieved through a dynamin-dependent process [55–
57]. Hence, a common denominator of both endocytic routes is their dependence on the large 
GTPase dynamin-2; it is required for pinching off the invagination (clathrin-coated pits or 
caveolae) from the plasma membrane [58]. Besides its critical function in endocytosis dynamin-2 
is involved in major cellular processes like actin polymerization, formation of lamellipodia and 
apoptosis [59, 60] and more importantly it is directly implicated in mediating downstream 




β-arrestins. However, although β-arrestins often play a central role in clathrin-dependent 
endocytosis and may also be critical for caveolae-dependent internalization of GPCRs, this is not 
true for all receptors and there are β-arrestin-independent internalization pathways [63, 64]. In 
summary, internalization of GPCRs seems to be more diverse than initially thought. Depending 
on the individual receptor and potentially the activating agonist, different components may be 
involved in the endocytic pathway [58, 65].  
After internalization the resulting GPCR-containing vesicles can undergo three different fates: 
1. targeting to early endosomes and quick recycling back to the cell surface, 2. targeting to late 
endosomes and slow recycling back to the cell surface, 3. targeting to late endosomes followed 





However, besides its function for recycling and degradation of internalized receptors 
intracellular trafficking of GPCRs presumably also plays a role in signal transduction. Studies in 
recent years have shown that some GPCRs are still capable of signaling from intracellular 
Figure 2: The role of internalization and trafficking in GPCR signaling. The initial steps of GPCR signaling, ligand binding, conformational 
changes and G protein activation, take place at the plasma membrane. This is followed by receptor phosphorylation and desensitization, 
resulting (in most cases) in the recruitment of β-arrestin and subsequent internalization. Previously, this was thought to terminate receptor 
signaling. However, we now know that some GPCRs exhibit sustained signaling from endosomes. This includes both G protein-dependent 
and -independent signaling. Receptors are then either targeted to lysosomes for degradation or recycled back to the cell surface.  




endosomal membranes. This endosomal signaling is also called sustained signaling and spans 
both canonical and non-canonical GPCR signaling [66, 67]. Endosomal signaling is neither a 
property of all GPCRs nor do all agonists of a respective receptor induce it. This poses another 
regulatory mechanism to fine tune duration, intensity and desired physiological outcome of 
GPCR signaling [66–68]. Examples for GPCRs exhibiting endosomal signaling are the 
D1 dopamine receptor (D1R), the β2 adrenergic receptor (ADRB2), and the parathyroid hormone 
receptor (PTHR) [69–72]. In fact, a study showed that dopamine-induced cAMP accumulation 
mediated by D1R is completely internalization-dependent and occurs at the endosomal level 
[70]. On the other hand, ADRB2-induced cAMP signaling in response to isoprenaline is 
promoted both from the plasma membrane and from endosomes. Further, signaling from both 
compartments seems to be crucial for the overall cellular cAMP response within minutes after 
exposure to the agonist [69]. In case of the PTHR sustained signaling is apparent, when the 
receptor is activated by parathyroid hormone (PTH) but not when it is activated by PTH-related 
protein. This links sustained signaling to agonist-specific differences in downstream signaling 
[66, 71, 72]. Thus, in this context biased agonism, a strongly debated topic in the GPCR 
community, also needs to be addressed.  
 
Biased signaling: Functional selectivity as a property of GPCR agonists 
Traditionally, the receptor theory was based on the assumption that receptors only signal when 
activated by a ligand and are otherwise quiescent [73]. Further, it was postulated that agonists 
have a single intrinsic efficacy. Depending on this efficacy an agonist is a full or partial agonist, 
inducing full activation of receptor signaling or only activating it to some extent, respectively. 
An antagonists has no intrinsic efficacy [73–75]. However, we now know that receptors can be 
constitutively active, i.e. signal in the absence of a ligand. This led to the discovery of inverse 
agonism, which describes the reduction of the constitutive activity of a receptor by a specific 
agonist [74, 76]. Additionally, research has shown that an agonist may have multiple intrinsic 
efficacies at the same receptor, acting as both a full and partial agonist, even antagonist, 
depending on which of the activated signaling pathways is measured [74, 77–79]. The 
phenomenon that one agonist preferentially activates a certain signaling pathway and does not 
activate or only partially activates another, while a second agonist preferentially activates a 
different pathway within the same cellular system and acting upon the same receptor, was termed 
functional selectivity or biased agonism [74, 80, 81].  
This concept originally arose from studies of different agonists of the M1 muscarinic 




activate only one of the two Gα proteins [82, 83]. Distinct conformational changes induced by 
different agonists are thought to be the structural basis of biased agonism [75, 77, 84]. The 
concept of biased agonism is of great interest regarding drug design since it implies the 
possibility of designing drugs with less undesired side effects by activating only the specific 
signaling cascades responsible for the desired physiological outcome [81, 85, 86]. Many studies 
were conducted with surrogate agonists that were specifically designed and screened to induce 
the conformational changes leading to the intended activation pattern. However, besides 
functional selectivity of the agonist, expression levels of signaling components such as 
G proteins and β-arrestins also play an important part in biased signaling. Expression levels of 
signaling molecules differ e.g. between cell types and organisms and this difference between 
cellular systems is referred to as system bias [81, 87]. This needs to be considered when 
screening for biased agonists as drugs. Nonetheless, the implication of biased agonism expands 
further than just drug design, still little is known about naturally occurring biased agonism.  
Furthermore, most of the investigations on biased agonism focused on inducing only β-arrestin 
recruitment (non-canonical) vs. only G protein (canonical) signaling in response to the respective 
ligand [80, 85, 86]. But signaling bias may, as described for the PTH receptor, also arise from 
differences in the induction of sustained canonical signaling [66, 71, 72] or from differences in 
intracellular trafficking and complex formation, potentially affecting recycling of the GPCR [45] 
as well as induced intracellular changes. Extracellular signal-regulated kinase 1/2 (ERK1/2) e.g. 
is retained in the cytosol following the activation by proteinase-activated receptor 2 (PAR2), 
when the receptor internalizes and intracellularly forms a complex with β-arrestin 1 and activated 
ERK. In contrast, when PAR2 does not internalize together with β-arrestin 1 ERK1/2 is activated 
via a different mechanism and shows no cytosolic retention but translocates to the nucleus [68]. 
ERKs have a vast number of substrates both in the nucleus (e.g. transcription factors) and 
cytoplasm (e.g. cytoskeletal elements) [88]. Hence, depending on the agonist-induced 
internalization pathway, recruited components and altered subcellular localization of ERK1/2 
different ERK substrates with distinct functions are activated [88–90]. The complexity of 
downstream signaling further complicates the investigation of biased agonism and makes it 
difficult to properly measure and quantify functional selectivity, especially regarding high-
throughput screening for drug discovery [81]. Altogether, biased agonism is an intriguing yet 





The family of hydroxycarboxylic acid receptors 
The hydroxycarboxylic acid receptor (HCA) family consists of three members, HCA1(GPR81), 
HCA2 (GPR109A) and HCA3 (GPR109b) [91]. HCA1 is activated by the anaerobic glycolysis 
product lactate, HCA2 by the ketone body 3-hydroxybutyric acid (3HB) and the described 
endogenous agonist of HCA3 is the fatty acid oxidation intermediate 3-hydroxyoctanoic acid 
(3HO) [91]. Besides 3HO, 3-hydroxydecanoic acid (3HDec) as well as the aromatic D-amino 
acids D-phenylalanine (D-Phe) and D-tryptophan (D-Trp) were shown to activate HCA3 [92, 
93]. Due to the nature of their ligands HCAs, among other receptors activated e.g. by TCA-cycle 
intermediates, fatty acids (FAs) of different chain length or amino acids, belong to a group of so-
called metabolite-sensing GPCRs (msGPCRs) [9, 94, 95]. Evolutionarily, HCA1 is the oldest of 
the three receptors. HCA2 arose from a gene duplication of HCA1, while HCA3 in turn 
presumably arose from a gene duplication of HCA2. Further, HCA1 and HCA2 are both present 
in the genome of all mammals, while HCA3 is only present in higher primates like chimpanzee, 
orangutan and humans [91, 96]. The three receptors exhibit a high sequence homology, HCA2 
and HCA3 only differ in 17 amino acids and the extended C-terminus of HCA3 [96, 97]. 
Furthermore, they are all Gαi-coupled receptors that also induce the phosphorylation and 
activation of ERK1/2 [92, 98–100].  
The three family members all show expression in adipocytes, where they are implicated in 
inhibiting lipolysis in response to their endogenous agonists. HCA1 serves as a negative feedback 
loop to inhibit lipolysis following postprandial glucose uptake by adipocytes, while HCA2 and 
HCA3 serve as a negative feedback loop for the regulation of lipolysis and fatty acid oxidation 
under prolonged fasting conditions to prevent excessive breakdown of stored fat [91, 101]. 
Moreover, HCA2 and HCA3 are highly expressed in different types of immune cells e.g. 
neutrophils, monocytes, and macrophages and induction of receptor-dependent chemotaxis has 
been shown [91, 93, 96, 101].  
Previously, the HCAs gained interest as targets to treat obesity and other medical conditions 
connected to lipid metabolism due to their function in regulating lipolysis and because the anti-
dyslipidemic drug nicotinic acid acts upon HCA2 [102–104]. In recent years, several other 
functions of HCA2 were identified that further increased interest in it as a potential drug target; 
among these are neuroprotective, anti-inflammatory, and tumor suppressor functions [105–108]. 
Some of these HCA2-dependent tumor suppressing and anti-inflammatory processes were shown 
to be mediated by butyrate, another agonist of HCA2, which is produced in high concentrations 
by intestinal microbiota, potentially connecting HCA function to the microbiome [108, 109].  
HCA3 was originally discovered as the low affinity receptor for nicotinic acid [110]. Although, 




cell survival have been described for HCA3 [91, 101, 111], its physiological function is still 
insufficiently understood.  
 
The G protein-coupled receptor 84 
GPR84 is a Gαi-coupled receptor activated by medium-chain fatty acids (MCFAs) (C9-C14) and 
their 2- and 3-hydroxy derivatives. Moreover, activation of GPR84 induces phosphorylation and 
activation of ERK1/2 as well as Akt, and upregulates nuclear factor κB (NFκB) [112–114]. 
GPR84 is highly expressed in immune cells like neutrophils, monocytes, and macrophages and 
its expression is further increased by inflammatory stimuli [112, 115]. Various studies have 
linked GPR84 to the regulation of processes like phagocytosis, chemotaxis, and upregulation of 
pro-inflammatory cytokine release in monocytes, macrophages and neutrophils [112–114, 116]. 
Furthermore, a study in mice showed that GPR84 expression is increased in fat pads of mice fed 
a high-fat diet, likely due to pro-inflammatory cytokine release (e.g. tumor necrosis factor, TNF) 
by infiltrating macrophages that are commonly seen in obesity. They further found that, in 
presence of TNF, stimulation of adipocytes with MCFAs results in lower adiponectin expression, 
which is linked to diabetes type 2 and coronary heart diseases [117, 118]. Taken together, this 
implicates GPR84 as a link between fatty acid metabolism and the immune system, suggesting it 
is an important player in obesity-related chronic inflammation [117, 119]. Furthermore, 
expression of GPR84 is upregulated in acute myeloid leukemia, where it is implicated in playing 
an important role in aberrant β-catenin signaling in leukemic stem cells and thereby contributing 
to disease maintenance [120].  
Because GPR84 is presumably involved in the regulation of important immunological processes, 
it is a potential drug target and as a result a number of studies aimed at developing potent 
GPR84-specific surrogate agonists [114, 116]. Using two of these potent and selective surrogate-
agonists a recent study showed biased agonism at GPR84 in the human macrophage cell line 
U937. Both compounds enhanced phagocytosis, but only one induced chemotactic migration 
[116]. This finding highlights how selection of the agonist can alter GPR84 signaling and the 
resulting physiological outcome.  
Although MCFAs were reported as ligands of GPR84 more than 10 years ago, the receptor 
officially still remains orphan [112, 121]. There are a couple of reasons why MCFAs as 
endogenous agonists have been controversially debated; poorly defined mode of interaction of 
MCFAs with the receptor, moderate potency especially in cells endogenously expressing GPR84 
and the issue whether concentrations of circulating MCFAs within the body reach levels high 




site for MCFAs. They also identified two more distinct sites, where previously reported 
surrogate ligands bind to GPR84. These ligands act as allosteric activators increasing the potency 
of MCFAs at GPR84. The authors suggest that molecules produced endogenously may bind to 
these sites in vivo and substantially increase the potency of MCFAs at GPR84 [124]. Taken 
together, these findings render it likely that MCFAs act as endogenous agonists at GPR84.  
 
Transmembrane receptors in immune cells 
Immune cells express a large number of different receptors crucial for their function including 
toll-like receptors (TLRs) and GPCRs. TLRs are pattern recognition receptors, which are 
activated by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs). In humans the TLR family is comprised of 10 members, which are further 
divided into two subfamilies based on their cellular localization [125, 126]. While TLR1, TLR2, 
TLR4, TLR5, TLR6, and TLR10 are expressed on the cell surface, the rest (TLR3, TLR7, TLR8, 
TLR9) is found in intracellular compartments such as the ER, endosome, lysosome, or 
endolysosome [126–128]. Further, TLRs acting from the cell surface mainly sense microbial 
membrane components, whereas intracellular TLRs are activated by nucleic acids derived from 
bacteria and viruses [125, 127, 129]. A well-known PAMP and popular tool in immunological 
research are lipopolysaccharides (LPS), constituents of the outer membrane of gram-negative 
bacteria [130]. LPS bind and activate TLR4, inducing signaling processes that lead to cellular 
changes enabling the rapid clearance of pathogenic bacteria. These include synthesis and release 
of cytokines (e.g. TNF), increased survival and production of reactive oxygen species (ROS) 
[131–133]. However, although TLRs are crucial for the recognition and killing of bacteria, 
GPCRs are also strongly implicated in regulating critical cellular functions of the innate immune 
system [15, 134, 135]. The impact that GPCRs have on immune cell function can either be 
direct, when the activation of a GPCR alone causes an effect e.g. induction of chemotaxis, or 
indirect, through modulating the response to other stimuli such as TLR ligands. These indirect 
effects may occur upon co-stimulation or through priming. Priming means that due to the 
previous exposure to certain stimuli such as e.g. cytokines or various GPCR ligands, the 
response of an immune cell to a subsequent activating stimulus like LPS is altered, either 
enhancing or dampening the induced inflammatory response [136, 137]. 
The functions of GPCRs in immune cells range from mediating chemotaxis, cytokine 
production/release, ROS formation and phagocytosis, to affecting immune cell development, 
differentiation and polarization [15, 138–141]. Differentiation and polarization are of particular 




differentiation are growth factors like granulocyte-macrophage colony-stimulating factor (GM-
CSF) and macrophage CSF (M-CSF). Further cues induce the polarization of macrophages to 
classically activated (M1) or alternatively activated (M2) macrophages. M1 macrophages exhibit 
a pro-inflammatory phenotype and mediate host defense against pathogens, amongst other by 
secreting pro-inflammatory cytokines and producing nitric oxide. M2 macrophages show an anti-
inflammatory phenotype and are important for the resolution of inflammation, tissue repair and 
remodeling. Stimuli that can induce polarization of macrophages are LPS and different cytokines 
such as interferon γ (M1), interleukin 4 (IL-4), and IL13 (M2) [142–144]. However, 
differentiation and polarization of monocytes/macrophages are complex processes and their 
exact regulation is still not fully understood. On that note, different GPCRs have been implicated 
in modulating these processes [15, 145–147].  
Widely studied GPCRs present in immune cells are chemokine receptors (CKRs), complement 
receptors (CRs), and formyl peptide receptors (FPRs). There are more than 20 different 
chemokine receptors and numerous different chemokines, which are produced by different cell 
types in response to bacterial products, viruses and substances causing cell damage [138]. 
Chemokines subsequently recruit leukocytes to the site of inflammation or cell damage by 
inducing site-directed chemotaxis through activating CKRs. Besides chemotaxis, CKRs are also 
involved in the regulation of other crucial processes in immune cells [138, 139]. In monocytes 
activation of CKRs mediates e.g. integrin activation, differentiation and expression/release of 
cytokines, in macrophages they are involved in differentiation, survival, respiratory burst and 
phagocytosis, while they play a role in the activation, degranulation and induction of ROS 
formation in neutrophils [139, 147–149]. CRs, on the other hand, play a key role in the clearance 
of pathogens through phagocytosis. They recognize complement proteins. Complement proteins 
are soluble proteins found in the blood and other body fluids that bind to the surface of 
pathogens. This process is called opsonization. Opsonized pathogens are recognized by 
phagocytic cells like macrophages and neutrophils through CRs expressed on their cell surface 
and subsequently undergo phagocytosis [140, 150]. Besides this, fragments of complement 
proteins (e.g. C5a) can also interact directly with CRs on neutrophils and monocytes. This results 
in increased adhesion to endothelial cells and induction of site-directed migration, exocytosis of 
granules, and ROS production [150–152]. FPRs recognize polypeptides that carry an N-formyl-
methionine (fMet), an amino acid found in prokaryotes but not eukaryotes, and thereby sense the 
presence of bacteria. The major function of FRPs is induction of gradient-driven migration in 
response to fMet-peptides in innate immune cells [141, 150]. Nonetheless, they also actively 
contribute to mediating phagocytosis, ROS production and cytokine release in neutrophils [135, 




Besides these rather well-characterized GPCRs, there are several other receptors expressed in 
neutrophils, monocytes and macrophages, whose functions are less well understood. This 
includes a number of msGPCRs. Due to the nature of their agonists, msGPCRs expressed on 
immune cells connect metabolism, diet and the gut microbiome to the immune system and 
potentially function as drivers or suppressors of diseases involving chronic inflammation [109]. 
Most of the msGPCRs appear to transduce anti-inflammatory signals, while for some data 
suggests a function in modulating pro-inflammatory processes. Furthermore, some msGPCRs 
may also be involved in immune cell differentiation, e.g. HCA2 and HCA3 have recently been 
shown to be upregulated during monocyte to macrophage differentiation [145]. Examples of 
metabolite-sensing receptors expressed on innate immune cells that have been shown to induce 
anti-inflammatory responses are free fatty acid receptors (FFARs) for short- (FFAR2) and long-
chain fatty acids (FFAR4) as well as HCA2 [109]. FFAR4 and HCA2 both exert their anti-
inflammatory function through inhibiting the secretion of pro-inflammatory cytokines such as 
TNF and IL-6 [109, 154–156]. In case of FFAR4 these effects were mediated entirely through β-
arrestin 2-dependent as opposed to G protein signaling [156]. β-arrestin 2 is known to modulate 
NFκB activation and subsequent expression of target genes through stabilizing the inhibitor of 
NFκB (IκBα) [157]. Thus, β-arrestin 2 recruitment may be an indicator for anti-inflammatory 
properties of a receptor.  
Besides receptors mediating anti-inflammatory effects, there are at least two known msGPCRs 
involved in modulating pro-inflammatory responses, namely SUCNR1 and GPR84. Dendritic 
cells were shown to concentration-dependently migrate towards succinate likely mediated by the 
activation of SUCNR1. Furthermore, stimulation of SUCNR1 by succinate enhanced TLR-
induced production of pro-inflammatory cytokines TNF and IL-1β in dendritic cells [158]. As a 
signaling system SUCNR1 is linked to local stress conditions such as hypoxia, which result in 
higher local succinate concentrations [109]. As mentioned above, GPR84 is involved in pro-
inflammatory functions in neutrophils, monocytes and macrophages; this includes induction of 
chemotaxis, phagocytosis and enhanced cytokine release [112–114, 116].  
Most of the metabolites acting as agonists at the aforementioned GPCRs are usually present in 
the human body irrespective of an infection with pathogenic bacteria or stress-induced tissue 
damage. Due to this circumstance, it is likely that the metabolite-receptor pairs exert some of 
their effects in vivo through priming. For example, priming of THP-1 cells, a human monocytic 
cell line, with FFAR4-agonist docosahexaenoic acid (DHA), an ω-3 fatty acid, significantly 
reduced the inflammatory cytokine (IL-6, IL-1b, TNF) release in response to a subsequent 
stimulation with LPS, when compared to unprimed cells [156, 159]. Moreover, a recent study 




inflammatory responses and neuronal damage in a mouse model of ischemic stroke through 
FFAR4 [160]. Thus, showing for at least one metabolite-receptor pair that priming with 
msGPCR-agonists can considerably alter stress-/damage-induced immunological responses in 
vivo.  
 
Rationale and goals of the dissertation 
Although there are several different cell surface proteins important for immune cell function, 
gaining a better insight into the signaling properties of GPCRs, expressed on immune cells, is 
essential to understand the complex processes underlying inflammation.  
The two msGPCRs HCA3 and GPR84 are in the focus of the present dissertation. They are 
highly co-expressed in different types of immune cells and share at least one agonist, namely 
3-hydroxy decanoic acid (3HDec). Their high expression in immune cells suggests that they play 
a role for the modulation of immunological processes. In case of GPR84, there are already some 
studies on its function. However, it still requires further investigations, especially since most 
studies were performed analyzing solely different surrogate agonists. In contrast, HCA3 is still 
poorly understood due to the fact that it is only present in higher primates, leading to a lack of 
accessible animal models and thus, making it difficult to study its physiological function(s).  
HCA3 is the evolutionarily youngest member of the HCA family, which arose from a gene 
duplication of HCA2. Both receptors exhibit a high sequence homology and only differ in 17 
amino acids and the extended C-terminus of HCA3. Known functions of HCA3 are inhibition of 
lipolysis as part of a negative feedback loop under prolonged fasting conditions and induction of 
chemotaxis in neutrophils, which are both also known functions of HCA2. This raises two major 
questions: 1. What is the advantage of expressing a third HCA? and derived from this 2. Are 
there functions of HCA3 that are unique to this member of the HCA family and what are those? 
Thus, one aim of my thesis project was to shed light on this by functionally analyzing HCA3 of 
different primate species using various agonists (chapter I).  
In the process of preparing the first manuscript, we identified bacteria as a plausible source for 
the previously described HCA3 agonists D-Phe and D-Trp, through extensive review of 
literature. Further, we discovered that D-phenyllactic acid (D-PLA), a metabolite of D-Phe, 
specifically and potently activates HCA3. D-PLA is produced in considerable concentrations by 
lactic acid bacteria used to ferment food. Hence, agonists of endogenous (3HO) as well as 
exogenous, bacterial origin activate HCA3. This provoked us to look at potential differences in 




least one agonist and are both activated by multiple agonists, we studied both receptors in respect 
to their signal transduction simultaneously.  
The majority of studies on biased agonism focused on using the concept of inducing biased 
signals for drug design to acquire drugs with less undesired side effects. The question whether or 
not GPCRs exhibit biased signaling in response to their naturally occurring agonists is 
considerably understudied. Natural biased signaling may be especially important for immune cell 
receptors with multiple ligands to differentiate between the stimuli and induce distinct 
intracellular signaling, leading to the appropriate cellular changes. In this context, the goal was to 
elucidate the specific pathways and components involved in HCA3 and GPR84 signaling in 
response to their natural agonists to gain a better understanding of their respective function and 
potential interplay in (immune) cells that co-express the two receptors (chapter II).  
In summary, the present thesis aimed to increase our knowledge about the msGPCRs HCA3 and 
GPR84 expressed on immune cells. The results of this research are one more step towards 
understanding the connection between metabolism, diet/gut microbiota and the immune system, 
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Abstract
The interplay of microbiota and the human host is physiologically crucial in health and
diseases. The beneficial effects of lactic acid bacteria (LAB), permanently colonizing the
human intestine or transiently obtained from food, have been extensively reported. How-
ever, the molecular understanding of how LAB modulate human physiology is still limited.
G protein-coupled receptors for hydroxycarboxylic acids (HCAR) are regulators of immune
functions and energy homeostasis under changing metabolic and dietary conditions. Most
mammals have two HCAR (HCA1, HCA2) but humans and other hominids contain a third
member (HCA3) in their genomes. A plausible hypothesis why HCA3 function was advanta-
geous in hominid evolution was lacking. Here, we used a combination of evolutionary, ana-
lytical and functional methods to unravel the role of HCA3 in vitro and in vivo. The functional
studies included different pharmacological assays, analyses of human monocytes and phar-
macokinetic measurements in human. We report the discovery of the interaction of D-phe-
nyllactic acid (D-PLA) and the human host through highly potent activation of HCA3. D-PLA
is an anti-bacterial metabolite found in high concentrations in LAB-fermented food such as
Sauerkraut. We demonstrate that D-PLA from such alimentary sources is well absorbed
from the human gut leading to high plasma and urine levels and triggers pertussis toxin-sen-
sitive migration of primary human monocytes in an HCA3-dependent manner. We provide
evolutionary, analytical and functional evidence supporting the hypothesis that HCA3 was
consolidated in hominids as a new signaling system for LAB-derived metabolites.
Author summary
Although it has been known for 15 years that HCA3 is present in humans and other homi-
nids but absent in all other mammals, no study so far aimed to understand why HCA3
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was functionally preserved during evolution. Here, we take advantage of evolutionary
analyses which we combine with functional assays of hominid HCA3 orthologs. In search
for a reasonable scenario explaining the accumulated amino acid changes in HCA3 of
hominids we discovered D-phenyllactic acid (D-PLA), a metabolite produced by lactic
acid bacteria (LAB), as the so far most potent agonist specifically activating HCA3. Fur-
ther, oral ingestion of Sauerkraut, known to contain high levels of D-PLA, caused subse-
quent plasma concentrations sufficient to activate HCA3. Our data interpreted in an
evolutionary context suggests that the availability of a new food repertoire under changed
ecological conditions triggered the fixation of HCA3 which took over new functions in
hominids.
These findings are particularly important because they unveiled HCA3, which is not
only expressed in various immune cells but also adipocytes, lung and skin, as a player
that transfers signals of LAB-derived metabolites into a physiological response in humans.
This opens up new directions towards the understanding of the versatile beneficial effects
of LAB and their metabolites for humans.
Introduction
The interplay of microbiota and the human host is physiologically crucial in health and dis-
eases. Lactic acid bacteria (LAB) are microorganisms present in many foods and the intestine
of most mammals. There are extensive reports about the beneficial role of LAB on the immune
system [1]. Short-chain fatty acids (SCFAs) and lactate are known metabolites of LAB that
have been shown to play an important role in the maintenance of the gut barrier function [2].
SCFAs can induce effects in the host through activation of specific G protein-coupled recep-
tors (GPCRs) expressed in intestinal epithelial cells and immune cells that are located in the
intestinal mucosa [3].
The present study focuses on GPCRs belonging to the family of hydroxycarboxylic acid
receptors (HCAR) which are regulators of immune functions and energy homeostasis under
changing metabolic and dietary conditions. At least two HCAR subtypes are present in mam-
malian genomes.
HCA1 (formerly GPR81) is activated by lactate and HCA2 (formerly GPR109a, HM74A,
PUMA-G) is activated by the ketone body D-3-hydroxybutyrate (D-3HB) but also by the
SCFA butyrate. Both receptors mediate anti-lipolytic effects in adipocytes through Gi-protein
coupling [4]. Further, HCA2 is known to be expressed in enterocytes, colonocytes and several
types of immune cells including neutrophils and macrophages mediating anti-inflammatory
effects [3].
A third HCAR subtype, HCA3 (formerly GPR109b, HM74), was recently identified in
the human genome but is absent in the mouse genome [5]. The amino acid sequence of
the human HCA3 differs from HCA2 in 16 positions and an extended C terminus (Fig 1A).
These differences are sufficient to change agonist specificity of HCA3 towards being activated
by the fatty acid β-oxidation intermediate 3-hydroxyoctanoate (3HO), but not by D-3HB,
likely also mediating anti-lipolytic effects under fasting conditions [6]. Further, aromatic D-
amino acids were found to activate HCA3 and elicit chemotactic responses in human neutro-
phils [7]. However, a plausible hypothesis why HCA3 function is of advantage in humans is
currently missing.
Here, we reconstructed the evolutionary history of HCARs and experimentally show that
HCA3 is functionally present in humans and all other great apes. After gene duplication and
Lactic acid bacteria-derived D-phenyllactic acid activates HCA3
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Fig 1. Phylogeny and evolutionary history of HCAR and agonist specificity of human HCA1, HCA2 and HCA3. (A) Human HCA1 vs HCA2 and human HCA2 vs
HCA3 show 50% and 95% amino acid identity, respectively. (B) Schematic HCAR phylogeny in vertebrates indicating the appearance of HCA3-specific amino acid
positions and structural features (detailed tree in S1 Fig). (C) Snake-plot of human HCA3 with positions highlighted that are characteristic for HCA3 in comparison
to HCA2 orthologs (detailed alignment in S3 Fig). (D) CHO-K1 cells were transiently transfected with human HCA1, HCA2, HCA3, and empty vector (control) and
seeded in fibronectin-coated Epic plates. DMR responses were recorded upon stimulation with 5 mM lactate, 1 mM D-3-hydroxybutyrate (D-3HB) and 100 μM of 3
hydroxyoctanoate (3HO). Shown is the agonist-induced shift in pm as mean ± SEM of four independent experiments carried out in triplicates.
https://doi.org/10.1371/journal.pgen.1008145.g001
Lactic acid bacteria-derived D-phenyllactic acid activates HCA3
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distinct structural changes HCA3 gained the ability to recognize 3HO as an agonist but lost D-
3HB specificity. Moreover, we identified D-phenyllactic acid (D-PLA), a metabolite produced
by LAB as the so far most potent naturally occurring agonist acting at HCA3. High levels of
D-PLA can be found in LAB-fermented products, such as Sauerkraut (S1 Table). LAB fermen-
tation is an ancient process that happened even before humans took advantage of it. It is
known that global transitions affected the last common ancestor of early hominoids causing
changes in its diet, rendering ingested fruits and leaves more likely to be fermented before
ingestion [8]. We provide functional and phylogenetic evidence supporting the hypothesis that
increased intake of LAB-fermented food likely posed a positive selective pressure maintaining
HCA3 function in hominids. We further hypothesize that HCA3 presence was advantageous in
the interplay between ingested and gastrointestinal microbiome and the hominid host by tak-
ing over functions in the immune system.
Results
HCA3 arose from a duplication of HCA2 before the split of great apes and
gibbons
Feedback regulation of the energy metabolism is vital for organisms exposed to variable dietary
supply. Receptors for intermediates of the energy metabolism, such as hydroxycarboxylic
acids, already appeared in early vertebrate evolution [9]. Mining of public sequence databases
revealed the presence of at least one HCA1 ortholog in the genome of cartilaginous, lobe- and
ray-finned fishes, amphibians, and mammals but not in any sauropsidian species (birds, rep-
tiles) (Fig 1B, S1 Fig, S2 Table). HCA2 is present in all mammals and arose from an HCA1 gene
duplication in early mammalian evolution (Fig 1B, S2 Fig, S2 Table).
We found that HCA3, the evolutionarily youngest HCAR, is present in the genomes of
all great apes and siamang, but absent in all other gibbon genomes investigated so far [10].
Because automated genome assembly can cause problems in assigning highly homologous
sequences, we manually reanalyzed the genomic sequence traces for the presence of HCA2 and
HCA3 and verified the findings by amplifying, cloning and sequencing HCAR from great apes,
siamang, and white-cheeked gibbon. Our analysis showed that HCA3 arose from a duplication
of HCA2 before the split of great apes and gibbons (Fig 1B) but underwent pseudogenization
in most gibbon species.
Subtypes resulting from gene duplication can have several fates, which include but are not
limited to pseudogenization or gain of new function. In the latter case one copy may accumu-
late mutations and acquire unique functionality without risking the fitness of the organism,
which is ensured by the remaining homolog. To test whether the persistence of HCA3 in great
apes and some gibbons caused changes in evolutionary constraints of HCAR subtypes we per-
formed Phylogenetic Analysis by Maximum Likelihood (PAML) [11]. Ape HCA1 evolved
with an evolutionary rate (ω = 0.189) significantly (p = 0.0258) different compared to all other
mammalian HCA1 (ω0 = 0.105) whereas no significant difference in evolutionary constraint of
ape HCA2 compared to other mammalian HCA2 orthologs was detected (S3 Table). We fur-
ther tested whether HCA3 evolved with a different evolutionary rate than HCA1 and HCA2 in
species carrying all three HCAR subtypes. We found that HCA3 evolved with a significantly
(p = 0.0064) higher evolutionary rate (ω = 0.257) than HCA1 and HCA2 (ω = 0.103), but signif-
icantly different from 1 (S3 Table).
Our data indicates that HCA3 is not drifting into neutrality (pseudogenization) in great
apes but rather gained new functionality, a hypothesis we further addressed using functional
analyses.
Lactic acid bacteria-derived D-phenyllactic acid activates HCA3
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Functional analyses of hominoid HCAR reveal evolutionary conservation of
known endogenous agonists
To study whether structural differences contribute to the distinct functional properties of the
three HCAR we heterologously expressed the human HCA1, HCA2 and HCA3 in CHO-K1
cells and performed functional assays using the dynamic mass redistribution technology
(DMR; Corning Epic System). Compared to classical second messenger assays, DMR assays
provide the advantage that cellular responses are recorded time-resolved and independently of
the activated signaling cascades. Receptor activation is monitored kinetically, thus revealing
potential differences in activation kinetics mediated by different agonists.
As reported, lactate only activates HCA1 [12, 13], D-3HB activates HCA2 and with a delayed
signal onset also HCA3 [14] and 3HO activates HCA3 but not HCA2 (Fig 1D) [6]. All HCAR
are Gi protein-coupled receptors, i.e. activation of the receptor by an agonist leads to inhibition
of adenylyl cyclases, thus resulting in a decrease in intracellular cAMP levels. Concentration-
response curves of different agonists can be determined using cAMP inhibition assays. This
extends the functional characterization since it reveals information about constitutive HCAR
activity (basal cAMP) and allows the quantification of the agonistic activity at the respective
HCAR by determination of EC50 and Emax values. EC50 values reflect the potency of an agonist,
i.e. the concentration of an agonist required to produce 50% of its maximal effect; the lower
the EC50, the higher the potency of an agonist. Emax (efficacy) is the maximum effect induced
by the agonist, i.e. when Emax is reached increasing the agonist concentration will not produce
a greater magnitude of the effect.
We performed cAMP inhibition assays on all hominoid HCARs as well as mouse HCA1
and HCA2 and analyzed them with the already established endogenous agonists lactate, D-
3HB and 3HO (Table 1, Fig 2). Considering the observed differences in expression levels
(Table 2), we detected no significant differences in Emax and EC50 values upon stimulation
with the respective endogenous agonists when comparing within HCA1, HCA2, and HCA3
orthologs (Table 1). However, the fact that D-3HB stimulates HCA3 orthologs (Figs 1D, 2A
and 2C) to some extent supports its evolutionary origination from HCA2. In contrast, 3HO
Table 1. Functional characterization of HCA1, HCA2, and HCA3 orthologs. CHO-K1 cells were transfected with receptor constructs and cAMP accumulation was
determined. The basal cAMP level of mock-transfected CHO-K1 stimulated with 2 μM forskolin (control) was 41.1 ± 1.9 nmol/well in DMEM and 13.8 ± 1.3 nmol/well in
HBSS and set 100%. Analyses of HCA1 were carried out in DMEM. HCA2 and HCA3 were assayed in HBSS. Emax values are shown as % of mock-transfected CHO-K1
stimulated with 2 μM forskolin in absence of agonist. Emax and EC50 values were determined from concentration-response curves using GraphPad Prism. A general expla-
nation of EC50 and Emax values is provided in the results section Functional hominoid HCAR analyses with known endogenous agonists. Data is given as mean ± SEM (basal

































human 66.2 ± 5.2 31.1 ± 2.8 2.4 (1.1–5.1) 260.5 ± 11.8 48.5 ± 6.9 0.53 (0.38–0.74) 56.3 ±1.5 22.2 ± 2.6 1.6 (0.91–2.95)
chimpanzee 73.8 ± 4.5 40.1 ± 2.0 4.1 (3.7–4.6) 239.9 ± 13.9 61.3 ± 3.7 0.77 (0.55–1.1) 51.5 ± 1.6 28.2 ± 1.0 3.7 (2.2–6.1)
gorilla 87.1 ± 5.6 36.7 ± 5.7 2.3 (1.6–3.3) 304.3 ± 18.5 69.5 ± 2.6 0.51 (0.37–0.70) 53.4 ± 1.8 19.7 ± 1.0 2.4 (2.0–3.0)
orangutan 61.2 ± 1.8 35.6 ± 3.7 4.6 (3.7–5.8) 200.7 ± 3.9 65.7 ± 8.8 0.68 (0.60–0.78) 58.0 ± 1.6 31.2 ± 3.6 7.4 (6.9–7.9)
siamang 78.2 ± 1.0 32.1 ± 2.3 5.1 (4.9–5.3) 138.1 ± 6.0 57.3 ± 4.9 1.02 (0.74–1.41) 55.2 ± 1.6 24.2 ± 1.5 2.4 (1.2–4.6)
white-cheeked
gibbon
101.9 ± 4.7 28.2 ± 2.6 2.5 (2.0–3.1) 200.1 ± 14.3 50.0 ± 7.8 0.45 (0.31–0.65) - - -
mouse 97.5 ± 0.6 37.1 ± 3.9 2.9 (2.2–3.8) 206.7 ± 4.5 57.3 ± 9.2 1.03 (0.69–1.54) - - -
https://doi.org/10.1371/journal.pgen.1008145.t001
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had no activity on HCA2 orthologs, indicating a gain of functionality in great ape HCA3 after
gene duplication (Figs 1D, 2D and 2E).
D-3HB activates siamang HCA2 with about 3-5-fold lower potency when compared to the
human ortholog (Fig 2B) and siamang HCA2 is activated by 3HO at high concentrations (Fig
2E). These findings and the fact that HCA3 is only present in siamang but not in any other gib-
bon species initiated further PAML analyses.
Evolutionary analyses suggest a loss of constraint on siamang HCA2 and
HCA3
We found that HCA2 and HCA3 of siamang evolve with an ω that is not significantly different
from 1 (S3 Table). This indicates a loss of constraint on siamang HCA2 and HCA3. Further,
Fig 2. Functional characterization of ape HCA2 and HCA3 orthologs. CHO-K1 cells were transiently transfected with receptor constructs and agonist-
induced inhibition of forskolin-induced cAMP accumulation was determined. HCA2 and HCA3 orthologs were stimulated with (A) 5 mM D-
3-hydroxybutyrate (D-3HB) and (B) 50 μM 3-hydroxyoctanoate (3HO). (A, B) Data is shown as percent inhibition of the forskolin-induced cAMP signal (min
to max bars with line at mean). Concentration-response curves upon stimulation of human and siamang HCA2 (C, D) and HCA3 (E, F) with D-3HB (C, E), and
3HO (D, F) are shown as fold over forskolin-stimulated cAMP level in the absence of agonist of each ortholog. Human HCA2 is specificall activated by D-3HB
(C), but not the HCA3 agonist 3HO (D). In contrast, siamang HCA2 is activated by D-3HB with lower potency when compared to the human ortholog (C), but
also by 3HO to some extent (D). Data is given as mean ± SEM of at least three independent experiments each carried out in triplicates.
https://doi.org/10.1371/journal.pgen.1008145.g002
Lactic acid bacteria-derived D-phenyllactic acid activates HCA3
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when compared within all other available gibbon HCA1 and HCA2 orthologs, we found
that siamang HCA1 evolves under purifying selection, but indeed siamang HCA2 exhibits an
ω (ω = 0.643), not significantly different from 1. Thus, we found that, in contrast to all other
HCAR orthologs, the agonist profiles of siamang HCA2 and HCA3 are less distinguishable and
therefore less conserved.
In sum, our combined evolutionary and functional analyses support a loss of evolutionary
constraint on the siamang HCA2 and HCA3 orthologs (Fig 2, S3 Table).
Aromatic D-amino acids activate human HCA3 with highest potency
Sequence alignment of HCA3 orthologs revealed that from all amino acid positions which dif-
fer from HCA2 seven amino acid positions are conserved in all HCA3 orthologs (Fig 1B, 1C
and S3 Fig). Further, we found that Ser91 and Thr173 (referring to positions in human HCA3
NP_006009.2) are great ape-specific HCA3 positions, while Tyr
86 and Trp142 are only con-
served in human, chimpanzee, bonobo, and gorilla HCA3 (Fig 1B, 1C and S3 Fig).
Since 3HO activated all hominoid HCA3 orthologs with comparable potency, we next ana-
lyzed whether potencies of the HCA3 agonists D-phenylalanine (D-Phe) and D-tryptophan
(D-Trp) [7], vary between orthologs. We confirmed HCA3-specificity of both agonists (S4 Fig)
and found that both, D-Phe and D-Trp, activate human HCA3 with highest potency when
compared to all other ape orthologs (Table 3, S4 Fig). Although Irukayama-Tomobe et. al
showed both aromatic D-amino acids to be HCA3-specific agonists, they did not identify rele-
vant sources of D-Phe and D-Trp to put their findings in a physiological context [7]. By com-
prehensive research of literature, we here draw the link to fermented foods and beverages
which are a likely source for D-Phe and D-Trp in concentrations sufficiently high to activate
HCA3. Several classes of bacteria produce and secrete aromatic D-amino acids (e.g. Acetobac-
ter, Bifidobacterium, Brevibacterium, Lactobacillus, Micrococcus, Propionibacterium, Strepto-
coccus) [15–17] and for all of them residence in the human gastrointestinal tract has been
demonstrated [18]. Moreover, D-amino acids were found to be present in body fluids and cer-
tain tissues in the μM range [19–22]. Connecting this previously established knowledge led us
to further investigate whether other microbial metabolites activate HCA3.
Table 2. Total and cell surface expression levels of HCA1, HCA2 and HCA3 orthologs as determined by ELISA. Cell surface expression levels of mammalian HCAR
orthologs were measured by a cell surface ELISA. Specific optical density (OD) readings are given as percentage of the respective HA-tagged human HCAR. The non-spe-
cific OD value (empty vector) was 0.014 ± 0.002 (set 0%). The OD value of the HA-tagged human HCA1 (0.091 ± 0.012), of the HA-tagged human HCA2 (0.755 ± 0.007)
and of the HA-tagged human HCA3 (0.424 ± 0.038), each of which was set 100% to compare expression between orthologs. Total expression levels of mammalian HCAR
orthologs were measured by a sandwich ELISA. Specific optical density (OD) readings are given as a percentage of HA-tagged respective human HCAR. The non-specific
OD value (empty vector) was 0.011 ± 0.001 (set 0%). The OD value of the HA-tagged human HCA1 (0.057 ± 0.012), of the HA-tagged human HCA2 (0.591 ± 0.114) and of
the HA-tagged human HCA3 (0.092 ± 0.006), each of which was set 100%. Data is given as mean ± SEM of three independent experiments carried out in triplicates.
HCA1 HCA2 HCA3
cell surface expression
(% of human HCA1)
total expression
(% of human HCA1)
cell surface expression
(% of human HCA2)
total expression
(% of human HCA2)
cell surface expression
(% of human HCA3)
total expression
(% of human HCA3)
human 100 100 100 100 100 100
chimp 69 ± 3 87 ± 9 83 ± 4 57 ± 4 68 ± 5 68 ± 9
gorilla 59 ± 4 76 ± 3 81 ± 2 56 ± 3 138 ± 11 138 ± 12
orang utan 98 ± 10 41 ± 10 60 ± 9 22 ± 4 141 ± 15 126 ± 6
siamang 110 ± 3 91 ± 9 26 ± 2 20 ± 3 95 ± 6 106 ± 15
white-cheeked
gibbon
225 ± 34 113 ± 11 60 ± 6 29 ± 2 - -
mouse 185 ± 19 139 ± 21 48 ± 1 19 ± 1 - -
https://doi.org/10.1371/journal.pgen.1008145.t002
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Lactic acid bacteria derived metabolites are highly potent agonists at HCA3
LAB are known to produce metabolites structurally related to 3HO and D-Phe, such as
3-hydroxydecanoate (3HDec) and D-PLA, respectively [23, 24]. PLA has been detected in μM
concentrations in fermented food such as Sauerkraut for which remarkably stable microbial
associations over time and region have been shown (Literature summarized in S1 Table) [25].
Moreover, LAB represent 0.01–1.8% of the total bacterial community found in the human
intestine where some of them are colonizers and others are passengers [26]. Additional sup-
port for the link between LAB and D-PLA is provided by analyses of patients with short bowel
syndrome (SBS) with their microbiota known to be imbalanced to Lactobacillus (L. mucosae,
L. acidophilus, L. fermentum) [27, 28] as the major resident bacteria (increased from� 1%
up to 60% of the fecal flora). These patients exhibit highly increased urinary levels of D-PLA
[29–33].
To our knowledge, the present study is the first in which D-PLA, L-phenyllactic acid
(L-PLA) and indole 3-lactic acid (ILA), a metabolite derived from Trp metabolism, were func-
tionally tested for their agonistic activity at the human HCA3. Using the DMR technology we
found that all three metabolites activate the human HCA3, but not HCA1 and HCA2 (Fig 3A).
D-PLA and ILA (each 1 μM) induced a response comparable to that of 100 μM 3HO, the
known endogenous agonist indicating an about 100-fold higher potency of the LAB-derived
compounds (Figs 1D and 3A).
Next, we functionally analyzed all HCA3 orthologs with the newly identified agonists using
cAMP inhibition assays to determine their potencies (Table 3). Unfortunately, the individual
potencies of D- and L-ILA could not be determined since only the DL isomeric mixture was
commercially available. L-PLA activates HCA3 orthologs in the μM range. However, D-PLA
activates HCA3 with an EC50 value of 150 nM, thus being an about 35-fold more potent agonist
Table 3. Functional characterization of HCA3 orthologs stimulated with aromatic D-amino acids and their metabolites. CHO-K1 cells were transfected with receptor
constructs and cAMP accumulation was determined. The basal cAMP level of mock-transfected CHO-K1 stimulated with 2 μM forskolin (control) in HBSS was 13.8 ± 1.3
nmol/well and set 100%. Emax values are referred to % of mock-transfected CHO-K1 stimulated with 2 μM forskolin in absence of agonist. Emax and EC50 values were deter-
mined from concentration-response curves of agonists using GraphPad Prism. A general explanation of EC50 and Emax values is provided in the results section Functional
hominoid HCAR analyses with known endogenous agonists. Data is given as mean ± SEM (Emax) and geometric mean with 95% confidence interval (EC50) of at least three
independent experiments each performed in triplicates.
Emax


















human HCA3 21.0 ± 2.3 36.1 (17.7–73.5) 14.7 ± 1.0 20.5 (11.7–36.2) 18.7 ± 2.3 31.9 (22.3–45.8)
chimpanzee
HCA3
23.4 ± 2.4 37.4 (23.2–60.2) 22.2 ± 2.2 62.1 (47.6–81.0) 25.7 ± 1.2 141(97.5–205)
gorilla HCA3 17.9 ± 2.3 45.7 (27.1–77.1) 17.8 ±1.5 24.4 (23.2–25.8) 25.8 ± 2.7 37.3 (23.0–60.3)
orangutan
HCA3
24.6 ± 2.4 129 (103–161) 24.7 ± 1.5 50.7 (30.8–83.4) 28.4 ± 3.1 62.7 (39.8–98.7)
siamang HCA3 22.9 ± 5.2 202 (101–406) 24.3 ± 1.2 56.7 (38.8–82.5) 35.6 ± 1.0 102 (59.9–175)
D-PLA L-PLA ILA
human HCA3 20.5 ± 2.8 0.15 (0.05–0.42) 33.4 ± 2.9 5.2 (3.0–9.1) 32.9 ± 2.9 0.18 (0.08–0.39)
chimpanzee
HCA3
23.7 ± 1.8 0.13 (0.08–0. 22) 25.4 ± 1.1 4.0 (2.4–6.5) 32.6 ± 4.9 0.23 (0.16–0.33)
gorilla HCA3 19.9 ± 1.4 0.085 (0.032–0.21) 36.5 ±3.0 6.2 (4.3–8.9) 36.3 ±1.7 0.073 (0.053–0.10)
orangutan
HCA3
29.3 ± 3.3 1.2 (0.60–2.2) 39.3 ± 3.2 6.5 (3.1–13.7) 42.0± 1.0 0.068 (0.030–0.15)
siamang HCA3 20.4 ± 1.7 0.28 (0.14–0.56) 36.3 ± 3.5 17.2 (8.9–33.6) 33.6 ± 1.2 0.17 (0.11–0.28)
https://doi.org/10.1371/journal.pgen.1008145.t003
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Fig 3. D-Phenyllactic acid is a potent agonist acting at HCA3. (A) CHO-K1 cells were transiently transfected with human HCA1, HCA2, HCA3, and empty vector
(control), seeded in fibronectin-coated Epic plates and DMR responses were recorded upon stimulation with 1 μM D-phenyllactic acid (D-PLA), 100 μM L-
phenyllactic acid (L-PLA) and 1 μM indole lactic acid (ILA) to reveal potential differences in receptor activation kinetics. Shown is the agonist-induced shift in pm of
three independent experiments carried out in triplicates. (B) The agonist-induced inhibition of forskolin-induced cAMP accumulation was determined in CHO-K1
cells transiently transfected with HCA3 orthologs and empty vector. Concentration-response curves upon stimulation with D-PLA, L-PLA and ILA are depicted as fold
over over forskolin-stimulated cAMP level in the absence of agonist of each ortholog. Data is given as mean ± SEM of at least three independent experiments each
carried out in triplicates. A general explanation of EC50 values is provided in the results section Functional hominoid HCAR analyses with known endogenous
agonists. (C) log EC50 values (corresponding to EC50 values shown in Table 3) are plotted as mean ± 95% confidence interval. Statistical analyses were performed using
an ordinary One-Way ANOVA (Dunnett’s multiple comparisons test) testing against orang utan HCA3.
#� 0.1, � P� 0.05; �� P� 0.01; ��� P� 0.001.
https://doi.org/10.1371/journal.pgen.1008145.g003
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than the L-enantiomer and about 10-fold and 240-fold more potent than the known agonists
3HO and D-Phe, respectively (Tables 1 and 3).
Further, both D-PLA and D-Phe exhibit higher potencies at the HCA3 of human, chimpan-
zee and gorilla when compared to the orangutan ortholog (Fig 3B, 3C and S4 Fig). In contrast,
the more hydrophobic agonists 3HDec, D-Trp and ILA are less potent at the chimpanzee
HCA3 ortholog when compared to the other great ape HCA3 orthologs (Fig 3B, 3C and S4
Fig). The Trp metabolite ILA acted at human HCA3 with a potency comparable to that of
D-PLA. Thus, D-PLA is the most potent agonist at human HCA3 for which sufficient presence
in LAB-fermented food has been previously described (S1 Table).
D-lactate dehydrogenase is abundant in the human gut microbiome
Accumulating evidence suggests that only a small number of LAB species are true inhabitants
of the human intestinal tract. The majority of LAB is derived from fermented food, the oral
cavity or more proximal parts of the gastrointestinal tract, like the esophagus [34]. However,
we asked whether the gene for D-lactate dehydrogenase (EC 1.1.1.28), the enzyme that has
been shown to produce D-PLA [35–37], is present in the human microbiome.
We found that genes encoding D-lactate dehydrogenase are very common among bacteria
and are also found in some of the very common and abundant gut bacteria (S5 Fig, S4 Table).
However, the question remains, if these D-lactate dehydrogenases are capable of converting
the aromatic amino acids to the respective lactic acid in the human intestine. Even if this ability
is restricted to LAB possessing this gene, they are still detectable to some degree in the human
intestinal microbiome [38].
Oral uptake of pure or Sauerkraut-derived D-PLA results in increased
plasma and urine levels
To further substantiate D-PLA resorption from gut and its urinary elimination, a pharmacoki-
netic study was performed determining PLA levels using Liquid Chromatography Mass Spec-
trometry (LC-MS) in human plasma and urine samples. As shown in Fig 4A, PLA plasma
levels are increased already 30 minutes after oral application of 100 mg D-PLA and subse-
quently decline rapidly due to renal excretion as determined in concomitantly collected urine
samples. PLA plasma levels reached concentrations (>20 μM) capable to maximally activate
the human HCA3 (Fig 3B). To verify this, we tested whether PLA-containing plasma and urine
samples elicit an HCA3-specific, pertussis toxin (PTX) sensitive decline in intracellular cAMP
levels of transiently transfected CHO-K1 cells (Fig 4B, S5 Table). Thus, plasma and urine sam-
ples were diluted and assayed by addition to transfected CHO-K1 cells. Indeed, we found that
PLA containing urine and to a lesser extend plasma activated specifically and concentration-
dependent HCA3 transfected cells (Fig 4B, S5 Table).
Interestingly, we also found basal plasma levels of PLA of about 0.4 μM before oral D-PLA
administration (Fig 4A, S6 Fig). Our established LC-MS measurement method does not dis-
criminate between L-PLA and D-PLA. Blood levels of L-PLA in the μM range are only found
in patients with phenylketonuria [39]. L-PLA is 35-fold less potent than D-PLA at HCA3
(Table 3) and plasma samples from basal conditions (0.4 μM) were sufficient to inhibit forsko-
lin-induced cAMP formation via HCA3 (S5 Table), potentially due to presence of D-PLA
derived from alimentary microbiota sources.
Sauerkraut is known to contain high levels of LAB as well as D-PLA. A recent study showed
that Sauerkraut exhibits remarkably stable microbial associations over time and regions [40].
Therefore, we asked whether ingestion of Sauerkraut (5–6 g per kg body weight) can cause an
increase in plasma and urinary D-PLA levels. Using LC-MS we found that levels of PLA in
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Fig 4. D-PLA is absorbed from the human gut, reaches μM plasma concentrations and activates HCA3 in human monocytes. (A) Upon oral ingestion of 100 mg
D-PLA (one individual) plasma and urine PLA levels were measured using LC-MS. Details about experimental setup are stated in Materials and Methods, section
Determination of PLA in human plasma and urine. (B) PLA containing plasma (23 μM, corresponding to the 30 min time point from (A)) and urine (285 μM,
corresponding to the 80 min time point from (A)) were stepwise 1:2-diluted and tested in cAMP inhibition assays. (C) Upon oral uptake of 5–6 g Sauerkraut per kg
body weight (n = 4 individuals, each individual labeled with a different color), plasma and urine PLA levels were measured using LC-MS. Details about experimental
setup are stated in Materials and Methods, section Determination of PLA in human plasma and urine. (D) PLA containing plasma (1.4 μM, 2 h postprandial) and
urine (14.3 μM, 3 h postprandial) were stepwise 1:2-diluted and tested in cAMP inhibition assays. (B, D) Data is shown as fold over unstimulated cAMP level, given as
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plasma (before = 0.2 μM; after = 0.9 μM) and urine (before = 0.7 μM; after = 9.1 μM) are
increased 2 h postprandial in four individuals (Fig 4C, S6A Fig). Further, we found that plasma
and urine containing increased concentrations of PLA after Sauerkraut ingestion induced an
HCA3-specific, PTX-sensitive inhibition of intracellular cAMP levels (Fig 4D, S6B Fig, S5
Table). This clearly indicates that fermented food, such as Sauerkraut, can be a source of
D-PLA leading to functionally relevant concentrations of this bacterial metabolite in humans.
mRNA expression of human HCA3 is highest in immune cells
Until recently, mRNA expression datasets based on microarrays constituted the main source
for expression data. However, due to their high nucleotide sequence similarity (97%) these
datasets did not enable the distinction between human HCA2 and HCA3. High quality, paired-
end, RNA-Sequencing datasets are in principle suitable to distinguish between those highly
similar sequences. Indeed, public resources provide quantitative expression data (FPKM: frag-
ments per kilobase million, TPM: transcripts per kilobase million) for both HCA2 and HCA3.
Quantification of transcripts in RNA-Sequencing projects is based on counting small RNA
fragments mapped to a gene (read lengths 70–100 bp). Because long nucleotide sequence
parts of HCA2 and HCA3 transcripts are identical it was not clear whether the used bioinfor-
matic tools are precise enough to properly distinguish and quantify human HCA2 and HCA3
transcripts. Therefore, we manually reanalyzed a publicly available dataset (Bioproject:
PRJNA326727) (S6 Table, S7 Fig). We mapped all relevant reads to HCA2 or HCA3 and
excluded those matching to both receptors. We found no significant differences between the
provided FPKM values and our manually curated read counts (S7 Fig).
Mining of publicly available RNA-Sequencing data reanalyzed and provided as TPM values
revealed highest expression of HCA3 in immune cells such as neutrophils and monocytes and
a pattern distinct from that of HCA2 (S7 Fig, S7 Table). Expression of HCA3 mRNA, especially
in adipose tissue, skin and lung, is considerably lower compared to HCA2 (S7 Fig). However,
both receptors are up-regulated in ulcerative colitis and inflammatory bowel disease patients
compared to controls (S6 Table, S7 Fig).
LAB-derived metabolites induce a chemotactic response in human
monocytes through activation of HCA3
As described above, HCA3 is expressed in a variety of human immune cells including macro-
phages, neutrophils, and monocytes (S7 Table). First, we used freshly isolated human periph-
eral blood mononuclear cells (PBMCs), which include lymphocytes (T cells, B cells, and NK
cells), monocytes, and dendritic cells. We observed a significant reduction in cAMP levels for
all HCA3 agonists except of 10 μM L-PLA in PBMCs (S6C Fig). However, PTX sensitivity of
this reduction could only be observed for 3HO and D-PLA, but not the other HCA3 agonists
(S6C Fig). We assume that this is likely due to inter-individual variation in cell counts of the
different cell types in PBMCs. Thus, we isolated human monocytes and performed cAMP
mean ± SEM (n = 3) and is summarized in S5 Table. (E) 3HO, D-PLA, L-PLA, and ILA induced a pertussis-toxin (PTX) sensitive reduction in cAMP levels and (F)
migratory responses in human monocytes. (E) Data is given as percent of cAMP level in monocytes stimulated with 10 μM forskolin without agonist. The
mean ± SEM (n = 3 different donors) is shown. (F) Data is shown as percent migrated monocytes of total monocytes (min to max bars with line at mean, n = 7
different donors). (G) siRNA-mediated knock-down of HCA3 in human monocytes diminished the agonist-induced reduction of cAMP levels still present in negative
control siRNA (siNC) transfected monocytes. Data is shown as mean ± SEM (n = 7 different donors). (H) D-PLA is absorbed from ingested LAB-fermented food
(Sauerkraut) and induces HCA3-dependent migration in human monocytes. This opens up new perspectives to study the role of HCA3 activation by LAB-derived
metabolites in both immune function and energy homeostasis. (E, G) Paired two-tailed t-tests were performed to analyze the effect of PTX and siRNA transfection.
(E, F, G) Statistical analyses were performed using an ordinary One-Way ANOVA (Dunnett’s multiple comparisons test) testing against control (CTRL, vehicle
EtOH). #� 0.1, � P� 0.05; �� P� 0.01; ��� P� 0.001.
https://doi.org/10.1371/journal.pgen.1008145.g004
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inhibition assays. We found that 10 μM 3HO as well as 1 μM D-PLA and ILA induced a
decrease of cAMP in human monocytes that can be blocked by PTX (Fig 4E). Using a transwell
migration assay we showed that D-PLA can trigger chemotactic responses with high potency
in isolated monocytes (Fig 4F). Both, a PTX-sensitive reduction in cAMP levels and migratory
responses were also observed for D-Phe and D-Trp with freshly isolated human monocytes,
however, 1000-fold higher concentrations were required (S6D Fig).
Finally, we performed siRNA-mediated knock-down of HCA3 in freshly isolated human
monocytes (S6E Fig) and determined cAMP levels upon stimulation with 3HO and D-PLA in
comparison to scrambled negative control siRNA (siNC)-transfected cells (Fig 4G). In contrast
to control (siNC)-transfected monocytes the reduction in intracellular cAMP levels was abol-
ished in siHCAR3-transfected monocytes demonstrating HCA3 specificity of the D-PLA
induced effect (Fig 4G).
Discussion
A recent paleogenetic study provides a comprehensive summary of existing evidence for large-
scale ecological transitions occurring during hominid evolution that caused changes of the
habitat accompanied by changes in diet and the microbial environment [8]. The exposure to
an altered microbial environment most likely posed a selective pressure and required host
adaptation but may also have provided the advantage to access new ecological niches.
In the present study, we provide evidence for such a unique example, where genetic events
potentially improved the availability of a new food repertoire under changed ecological condi-
tions that possibly triggered the fixation of a duplicated gene with new functions in hominids.
Through analyses of the evolutionary history of the HCA receptor family, we now show
that HCA3, being absent in non-hominoid primates and all other vertebrates, resulted from a
gene duplication that occurred before the split of gibbons from great apes (Fig 1B). In apes, we
found gradual fixation of amino acid positions in HCA3 (Fig 1C). We discovered new LAB-
derived agonists acting at all ape HCA3 orthologs. Both, D-PLA and ILA, activate human
HCA3 with an about 10-fold higher potency when compared to the endogenous agonist 3HO
(Tables 1 and 3). Further, our functional analyses of great ape HCA3 orthologs revealed, that
potencies of D-PLA are significantly higher in human, chimpanzee and gorilla compared to
orangutan (Fig 4C). This led us to do an extensive literature search to identify potential global
environmental changes that conceivably coincided with dietary changes and are archaeologi-
cally accepted to have occurred when the last common ancestor of human, chimpanzee and
gorilla lived on earth. As mentioned at the beginning of the discussion, a recent study showed
that about 10 million years, ago a mutation in the class IV alcohol dehydrogenase appeared in
the common ancestor that humans share with gorillas and chimpanzees, which allowed an
increased tolerance of alcohol [8]. In this study, a scenario was projected in which the large-
scale ecological transitions caused the common ancestor to move out of the trees and lead a
more terrestrial life [8]. Carrigan et al. conclude that this new life style rendered fruit picking
directly from the trees to be less likely but increased the probability that food that had started
to ferment was collected from the ground [8]. This is suggested to have posed the selective
pressure that increased the tolerance to dietary alcohol before human-directed fermentation
[8]. In this context, not only the increased activity of ethanol-metabolizing enzymes (e.g.
ADH4) might have provided a selective advantage but also an immune system that can sense
high levels of D-PLA ingested with lacto-fermented food (including plants, fish, meats, milk)
[35]. Our functional data combined with the described archaeologically documented evolu-
tionary context gives rise to the hypothesis that in the last common ancestor of human, chim-
panzee and gorilla, increased ingestion of fermented food was likely associated with increased
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ingestion of LAB accompanied by increased levels of D-PLA. D-PLA is a metabolite, produced
in high concentrations by LAB in the process of lactic fermentation and has a broad antimicro-
bial activity against bacteria and fungi [35].
We demonstrate, using LC-MS that D-PLA is quickly absorbed from the gastrointestinal
tract upon ingestion of LAB-fermented Sauerkraut, can reach physiologically relevant plasma
concentrations and is renally eliminated in humans (Fig 4A and 4C). These diet-induced PLA
plasma concentrations are sufficient to activate HCA3 in human monocytes and potentially
modulate human immune functions (Fig 4E–4G).
The beneficial effects of LAB-fermented food on human health are numerous, ranging
from protection of the intestinal barrier, limitation of inflammatory cytokine production to
improved fasting insulin levels and glucose turnover rates among many others [41]. HCA3 is
expressed in many different immune cells but also adipose tissue (S7 Table). We hypothesize
that the LAB-mediated, HCA3-dependent physiological impact likely extends to influences on
the human host energy storage. This would also be plausible in an evolutionary context, since
it is known that the nutritional and functional properties of food are enhanced by LAB-fer-
mentation due to the transformation of substrates and the formation of bioactive or bioavail-
able end-products [25].
In summary, our work provides multifaceted evidence supporting the hypothesis that
HCA3 evolved as a GPCR activated by LAB metabolites. Our data suggests that this might have
improved tolerance to the increased ingestion of LAB in the last common ancestor of human,
chimpanzee and gorilla. As LAB-derived D-PLA is specifically recognized by HCA3 expressed
in monocytes (Fig 4H) and numerous studies describe increased hypo-responsiveness of the
immune system through anti-inflammatory processes for D-PLA and LAB (S1 Table), we
speculate that HCA3 plays a role in mediating at least some of those effects (Fig 4H). In the
present study, we identified a new set of microbial-derived metabolites acting as classical sig-
naling molecules in the human host through recognition by a specific receptor. The question
remains how D-PLA affects monocyte functions. Future studies shall address whether HCA3
activation by D-PLA impacts phagocytic capacity of monocytes or influences differentiation
of monocytes to macrophages. Does D-PLA, through activation of HCA3, prime monocytes
to either increase of pro-inflammatory host response to concomitantly ingested pathogenic
bacteria or reduction of pro-inflammatory response to LAB? At last, our study opens-up the
interesting question of how D-PLA ingested with LAB-fermented food can influence energy
storage in HCA3-expressing adipocytes.
Materials and methods
Ethics statement
The studies on humans and with human materials were conducted in accordance with the
Declaration of Helsinki and with the recommendations of “Ethik-Kommission an der Medizi-
nischen Fakultät der Universität Leipzig” with written informed consent from all blood
donors. The protocol was approved by the aforementioned committee (313/14-ek).
HCAR ortholog identification
Mining of NCBI trace archives. HCAR sequences of various mammalian species were
obtained from extensive database mining followed by assembly, analysis and manual proof-
reading. Trace identifier, NCBI accession or SRA accession numbers are listed in S2 Table. All
newly obtained HCAR sequences have been deposited in the GenBank database: accession no.
KU285431-KU285452, as listed in S2 Table.
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Amplification, sequencing and cloning of HCAR orthologs from apes and mouse. To
analyze the sequence of HCAR orthologs, genomic DNA samples were prepared from tissue of
various species (sources are given in S8 Table). Tissue samples were digested in lysis buffer (50
mM Tris/HCl, pH 7.5, 100 mM EDTA, 100 mM NaCl, 1% SDS, 0.5 mg/ml proteinase K) and
incubated at 55˚C for 18 h. DNA was purified by phenol/chloroform extraction and ethanol
precipitation. Degenerated primer pairs (S9 Table) were used to amplify HCAR-specific
sequences. Primer pairs, positioned in the 5’- and 3’- UTR, were designed to simultaneously
amplify HCA2 and HCA3. PCR reactions were performed with Taq and Pfu polymerase under
variable annealing and elongation conditions. A standard PCR reaction (50 μl) contained
genomic DNA (100 ng) with primers (1.5 μM each), ThermoPol reaction buffer (1x), dNTP
(250 μM, each) as well as Taq and Pfu polymerase (1 U, NEB, Frankfurt am Main, Germany).
The reactions were initiated with denaturation at 95 ˚C for 1 min, followed by 35 cycles of
denaturation at 95 ˚C for 30 s, annealing at 55 ˚C for 30 s and elongation at 72 ˚C for 1 min. A
final extension step was performed at 72 ˚C for 10 min. Specific PCR products were subcloned
into the pCR2.1-TOPO vector (Invitrogen, Paisley, UK) and sent to Seqlab for sequencing. All
newly obtained HCAR sequences have been deposited in the GenBank database (accession no.
KU285431-KU285452, S2 Table). Protein sequence alignments are depicted in S3 Fig.
The full-length HCAR were inserted into the mammalian expression vector pcDps [42] and
epitope-tagged with an N-terminal hemagglutinin (HA) epitope and a C-terminal FLAG-tag
by a PCR-based overlapping fragment approach. Identity of all constructs and correctness of
all PCR-derived sequences were confirmed by restriction analysis and sequencing.
Sequence alignments and PAML analyses
HCA1, HCA2 and HCA3 of 54 selected vertebrate species were aligned to infer the phylogenetic
model of HCAR evolution as shown in Fig 1 (S1 Fig). Mammalian HCA1 and HCA2 were
aligned to infer a phylogenetic tree of 88 mammalian species. All nucleotide alignments were
generated with the ClustalW algorithm (Bioedit Sequence Alignment Editor 7.0.9 [43]) followed
by manual trimming where gaps were deleted. Phylogenetic evolutionary history was inferred by
the Maximum Likelihood method based on the General Time Reversible model using MEGA6
[44]. The resulting tree (S2 Fig) with a 75% cut-off value was used for PAML analyses. Tests of
selection (ω = dN/dS) were accomplished by maximum likelihood using a codon-based substitu-
tion model implemented in PAML version 4.2 [11]. Branch models [45] that allow ω to vary
among branches in the phylogeny were applied to determine ω ratios along particular lineages.
Likelihood ratio tests (LRT) were performed to test nested competing hypotheses (S3 Table).
Cell culture and functional assays
CHO-K1 cells were grown in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and
100 μg/ml streptomycin. Cells were maintained at 37 ˚C in a humidified 5% CO2 incubator.
For transient transfection Lipofectamine 2000 (Life Technologies, Darmstadt, Germany) was
used. Cells were split into 25 cm2-cell culture flasks (0.9 x 106 cells/flask) and transfected with a
total amount of 3 μg of plasmid the following day.
ALPHAScreen cAMP assay. cAMP content of cell extracts was determined by a non-
radioactive assay based on the ALPHAScreen technology according to the manufacturers’ pro-
tocol (Perkin Elmer LAS, Rodgau-Jügesheim, Germany) [46]. One day after transfection cells
were split into 96-well plates (2 x 104 cells/well). Stimulation with various agonist concentra-
tions (all compounds from Sigma-Aldrich, Seelze, Germany) or diluted human urine and
plasma samples was performed 48 h after transfection. Reactions were stopped by aspiration of
Lactic acid bacteria-derived D-phenyllactic acid activates HCA3
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008145 May 23, 2019 15 / 22
33
media and cells were lysed in 20 μl of lysis buffer containing 1 mM 3-isobutyl-1-methylxan-
thine (IBMX). From each well 5 μl of lysate were transferred to a 384-well plate. Acceptor
beads and donor beads were added according to the manufacturers’ protocol. Cyclic AMP
accumulation data were analyzed using GraphPad Prism version 6.03 (GraphPad Software,
San Diego California USA).
Dynamic mass redistribution assay. To measure label-free receptor activation, a dynamic
mass redistribution (DMR) assay (Corning Epic Biosensor Measurements) with CHO-K1 cells
transiently expressing HCAR orthologs was performed. One day after transfection, cells were
detached using Versene solution and transferred into a fibronectin-coated 384-well Epic
microplate (1.2 x 104cells per well) and cultured for 24 h to reach confluent monolayers. After
2 h of equilibration in HBSS buffer with 20 mM HEPES (pH 7.4), incubation with various
compound concentrations was performed and DMR was recorded for 60 min.
ELISA. Cell surface expression of N-terminal HA-tagged receptor constructs was deter-
mined using an indirect cellular ELISA and total receptor expression of full-length HA/FLAG
double-tagged HCA constructs was assessed using a “sandwich-ELISA” both described in [46].
Manual reanalysis and comparison to FPKM values of a publicly available
RNA-Sequencing dataset
All 134 RNA-sequencing samples belonging to Bioproject: PRJNA326727, (GEO Accession:
GSE83687) [47] were manually reanalyzed and compared to available FPKM values as stated
in S6 Table and S7 Fig.
Mining of human microbiome data for genes of enzymes with ability to
produce D PLA
Two large collections of metagenomic data from the human gut microbiome were searched
for D-lactate dehydrogenase (EC 1.1.1.28), the enzyme that catalyzes the conversion of D-lac-
tate to pyruvate, but has also been shown for some LAB to convert phenylpyruvate to D-PLA.
Metagenomic data from 1,885 human stool samples from the curated Metagenomic Dataset
(https://github.com/waldronlab/ curatedMetagenomicData) [48] were searched for 1,443
EC 1.1.1.28-related UniRef100 entries. In addition, genes with the K03778 annotation were
searched in the Integrated Gene Catalogue (IGC) [49] reference data set for the human gut
microbiome, which comprises data from just over 1,000 individuals. Detailed information, a
representative tree of the detected genes and a list of all entries are summarized in the Supple-
mentary Information (S5 Fig, S4 Table).
Peripheral blood mononuclear cells (PBMCs) and monocytes
Monocyte isolation. PBMCs were obtained by Ficoll-Paque (GE Healthcare) density gra-
dient centrifugation. After repeated washing in PBS containing 0.3 mM EDTA, untouched
monocytes were isolated by negative magnetic depletion using the human Monocyte Isolation
Kit II (Miltenyi Biotec) according to the manufacturer’s protocol. The cell preparations were
>95% monocytes as determined by morphology and flow cytometry.
Monocyte migration. For migration analysis, ThinCert cell culture inserts (Greiner) with
8 μM pores were placed in a 24-well cell culture plate. To each well of the cell culture plate
1,000 μl of HBSS buffer supplemented with 20 mM HEPES (pH 7.4) and 1% FBS with or with-
out chemoattractant were added. Pelleted freshly isolated monocytes in PBS with 0.3 mM
EDTA and 1% FBS were labeled for 30 min at 4˚C with 2 μM calcein AM (Thermo Scientific).
Subsequently monocytes were washed and resuspended in HBSS buffer with 20 mM HEPES
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(pH 7.4) and 1% FBS to a final concentration of 5 × 105 monocytes per ml. 200 μl of the mono-
cyte suspension were added to each insert or for control purposes directly to the bottom well
and incubated at 37˚C and 5% CO2. After 1 h the inserts were discarded, plates spun for 5 min
at 700 rpm and imaged as well as analyzed using the Celigo S Imaging Cytometer (Nexcelom).
Monocyte siRNA transfection. Freshly isolated human monocytes were transfected with
siRNA specifically targeting HCAR3 (OriGene), as shown in Stäubert et al. (2015) [50], using
Viromer Green (Lipocalyx) according to the manufacturer’s protocol. 10 μL of siRNA-Viro-
mer mix were preplated into a 96-well plate before the addition of freshly isolated monocytes
resuspended in RPMI supplemented with 10% FBS (1.5 x 105 monocytes/well) which were
then incubated 14 h at 37 ˚C in a humidified 5% CO2 incubator. cAMP assays were performed
as described below. To monitor the transfection efficiency a red fluorescent siRNA (OriGene)
and Hoechst 33342 (Sigma-Aldrich) were used. The viability of transfected monocytes was
determined by staining with propidium iodide (PI) (Thermo Fisher Scientific) and Hoechst
33342. Transfection efficiency and viability were analyzed using the Celigo S Imaging Cytome-
ter (Nexcelom). The transfection efficiency was found to be� 80% with less than 50% of
monocytes being PI-positive (S6 Fig).
Monocyte cAMP assay. Freshly isolated monocytes or PBMCs were resuspended in
HBSS buffer with 20 mM HEPES (pH 7.4) and 1 mM IBMX, seeded in 96-well plates (1 x 105
monocytes/well, 2 x 105 PBMCs/well) with or without PTX (100 ng/ml) and incubated for 1 h
at 37 ˚C. Stimulation with or without agonists was performed in presence of 10 μM forskolin
for 1 h at 37 ˚C. Measurement of accumulated cAMP was performed as described above.
Determination of PLA in human plasma and urine
100 mg of D-PLA were dissolved in 30 ml H2O and ingested by a healthy male subject (78 kg,
1.80 m). 2.5 ml of EDTA blood samples were taken right before and 30 min, 60 min, and
then every hour up to 7 h after ingestion. In a subsequent, chronically separate experiment
the same healthy male subject adapted to a lacto-vegetarian diet, including uptake of 500 g
per day of fresh (non-pasteurized) Sauerkraut (Spreewaldhof, Germany) for three days. 2.5
mL of EDTA blood samples were taken before diet, 2 h postprandial over three days and 5
days after having stopped the above described diet. Further, urine samples were taken over
the time course. Similarly, three healthy female subjects ingested 5–6 g of fresh (non-pasteur-
ized) Sauerkraut per kg body weight for one day. 2.5 mL of EDTA blood samples and urine
samples were taken before ingestion and 2 h postprandial. Fresh whole blood samples were
centrifuged for 10 min at 4 ˚C and 800xg to isolate plasma, which was stored in 500 μl ali-
quots at -80 ˚C until further analyses. Urine was collected and the total volume was deter-
mined. 10 μl of human plasma and urine were treated with 90 μl precipitating agent
(acetonitrile including the internal standard phenyl-d5-lactate at 10 ng/ml), thoroughly
mixed and centrifuged for 5 min at 13,000xg. Supernatants were transferred to autosampler
vials and 10 μl were injected into the Liquid Chromatography Mass Spectrometry (LC-MS)
system. It consisted of a Prominence UFLC system from Shimadzu (Duisburg, Germany)
and a QTRAP 6500 from SCIEX (Framingham, MA, USA). Chromatographic separation
took place on a Luna HILIC column (3 μm, 50 x 2 mm) from Phenomenex (Darmstadt, Ger-
many) via gradient elution at a flow rate of 0.4 ml/min. The mobile phase was 15 mmol/l
ammonium acetate buffer (pH 6) in acetonitrile and water. Electrospray ionization was
applied in negative mode. Mass transitions were m/z 165>103 and m/z 170>108 for phenyl-
lactate and phenyl-d5-lactate, respectively. Quantitation was carried out using a semi-quanti-
tative approach following Eq 1 with c and A as the concentration and the peak area of the
analyte (An) and the internal standard (IS). The response factor (RF) was determined from
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S1 Fig. Phylogenetic tree of HCA1, HCA2 and HCA3 for 54 selected species to infer the
model shown in Fig 1B.
(TIF)
S2 Fig. Phylogenetic tree of 88 mammalian species used for HCA1 and HCA2 PAML analy-
ses.
(TIF)
S3 Fig. Amino acid sequence alignment of all functionally tested HCA orthologs.
(TIF)
S4 Fig. Human HCA3 but not HCA1 or HCA2 shows a DMR response upon stimulation
with D-Phe, D-Trp and 3HDec and comparison of potencies of different agonists acting at
ape HCA3 orthologs.
(TIF)
S5 Fig. Phylogenetic tree of D-lactate dehydrogenase-related genes and metagenomic pro-
portion of EC 1.1.1.38.
(TIF)
S6 Fig. Plasma and urine PLA levels, reduction in intracellular cAMP levels of freshly iso-
lated human peripheral blood mononuclear cells (PBMCs) and monocytes upon stimula-
tion with HCA3 agonists and siRNA transfection efficiency of human monocytes.
(TIF)
S7 Fig. Comparison of manually curated RNA-sequencing data (A) versus reported Frag-
ments Per Kilobase Million (FPKM) values (B) for HCAR2 and HCAR3 and Transcripts
Per Kilobase Million (TPM) values for tissues/organs/cell types as deposited in Expression
Atlas (https://www.ebi.ac.uk/gxa/home).
(TIF)
S1 Table. D-PLA sources as described in literature.
(PDF)
S2 Table. NCBI database accession numbers and sequence description of one representa-
tive HCAR1 ortholog of Chondrichthyes, Actinopterygii, Coelacanths and Amphibia and
mammalian HCAR orthologs.
(PDF)
S3 Table. Maximum likelihood estimates of dN/dS ratios (ω) for 88 mammalian HCA1 and
HCA2 orthologs, for 5 ape HCA1, HCA2 and HCA3 orthologs and for 5 Hylobatidae HCA1
and HCA2 orthologs under different branch-specific models using PAML.
(PDF)
S4 Table. Bacterial species carrying genes for EC 1.1.1.28 that were detected in human gut
microbiota of the curated Metagenomic Dataset.
(PDF)
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S5 Table. Testing of PLA-containing human urine and plasma samples on transiently with
human HCA2 or HCA3 or empty vector transfected CHO-K1 cells.
(PDF)
S6 Table. Comparison of manually curated RNA-Sequencing data versus reported FPKM
for HCAR2 and HCAR3.
(PDF)
S7 Table. TPM values as downloaded from https://www.ebi.ac.uk/gxa/home.
(PDF)
S8 Table. Sources of genomic DNA used for HCAR amplification.
(PDF)
S9 Table. Primers used for HCA1, HCA2 and HCA3 ortholog amplification, sequencing
and introduction of epitope tags.
(PDF)
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Formal analysis: Anna Peters, Petra Krumbholz, Anna Heintz-Buschart, Mehmet Volkan
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Correction:
foods are highly potent agonists of human hydroxycarboxylic acid 
receptor 3
Fig 4E is identical to Fig 4G. The authors have provided a corrected Fig 4 here, which shows the 
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Natural biased signaling of
hydroxycarboxylic acid receptor 3 and G
protein-coupled receptor 84
Anna Peters1, Philipp Rabe1, Petra Krumbholz1, Hermann Kalwa2, Robert Kraft3, Torsten Schöneberg1 and
Claudia Stäubert1*
Abstract
Background: Medium-chain fatty acids and their 3-hydroxy derivatives are metabolites endogenously produced in
humans, food-derived or originating from bacteria. They activate G protein-coupled receptors, including GPR84 and
HCA3, which regulate metabolism and immune functions. Although both receptors are coupled to Gi proteins,
share at least one agonist and show overlapping tissue expression, GPR84 exerts pro-inflammatory effects whereas
HCA3 is involved in anti-inflammatory responses. Here, we analyzed signaling kinetics of both HCA3 and GPR84, to
unravel signal transduction components that may explain their physiological differences.
Methods: To study the signaling kinetics and components involved in signal transduction of both receptors we
applied the label-free dynamic mass redistribution technology in combination with classical cAMP, ERK signaling
and β-arrestin-2 recruitment assays. For phenotypical analyses, we used spheroid cell culture models.
Results: We present strong evidence for a natural biased signaling of structurally highly similar agonists at HCA3
and GPR84. We show that HCA3 signaling and trafficking depends on dynamin-2 function. Activation of HCA3 by 3-
hydroxyoctanoic acid but not 3-hydroxydecanoic acid leads to β-arrestin-2 recruitment, which is relevant for cell-
cell adhesion. GPR84 stimulation with 3-hydroxydecanoic acid causes a sustained ERK activation but activation of
GPR84 is not followed by β-arrestin-2 recruitment.
Conclusions: In summary, our results highlight that biased agonism is a physiological property of HCA3 and GPR84
with relevance for innate immune functions potentially to differentiate between endogenous, non-pathogenic
compounds and compounds originating from e.g. pathogenic bacteria.
Keywords: HCAR, Hydroxycarboxylic acid receptors, GPR109b, GPCR, HCA3, GPR84, Dynamin-2
Background
G protein-coupled receptors (GPCRs) activated by me-
tabolites originating from diet, host- and microbiota me-
tabolism gain more and more attention due to their role
as regulators of the host (patho)-physiological state [1–
4]. Medium-chain fatty acids (MCFAs), which are satu-
rated fatty acids with 8 to 12 carbons, and their 3-
hydroxy derivatives are metabolites acting as agonists at
the hydroxycarboxylic acid receptor 3 (HCA3) and
GPR84 [5–9]. MCFAs originate from medium-chain
triacylglycerols present in dairy products and reach
plasma levels up to 18 μM, which are further increased
under medium-chain triacylglycerol diet [10–17]. 3-
hydroxy derivatives of MCFAs are derived from en-
dogenous and exogenous sources. Although basal
plasma concentrations of 3-hydroxyoctanoic acid (3HO)
and 3-hydroxydecanoic acid (3HDec) rarely exceed
0.4 μM, they are both increased in patients undergoing a
ketogenic diet and in patients with diabetic ketoacidosis
or defects of mitochondrial β-fatty acid oxidation [5, 11,
18, 19]. 3-hydroxy fatty acids of 10–14 carbon chain
lengths are also components of lipopolysaccharides
(LPS) of Gram-negative bacteria and have been used as
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endotoxin markers in clinical and environmental sam-
ples [20–23].
HCA3 is activated by both, 3HO and 3HDec [5].
3HDec is also an agonist at GPR84 [7]. Although the
role of MCFAs (C10 – C14), specifically decanoic acid
(C10), as endogenous agonists at GPR84 is disputed
[24], recent work supports their relevance as major en-
dogenous ligands [8, 9]. Both, HCA3 and GPR84, are Gi
protein-coupled receptors and expressed in immune
cells, such as neutrophils, macrophages and monocytes
[6, 7, 25–27]. GPR84 promotes chemotaxis and pro-
inflammatory cytokine release in leukocytes and macro-
phages [6, 7, 27]. Moreover, chemotaxis of neutrophils
and monocytes upon HCA3 activation has been reported
[25, 26]. However, HCA3 is rather suggested to elicit
hypo-responsiveness of the immune system through me-
diation of anti-inflammatory processes [25, 28].
Although HCA3 and GPR84 exhibit an obvious over-
lap in agonist / G-protein specificity and in immune cell
expression, their physiological functions appear to be
opposed. Therefore, we investigated whether differences
in their signaling kinetics and trafficking may explain
this apparent contradiction.
We found for both, HCA3 and GPR84, that different,
yet structurally highly similar agonists have distinct sig-
naling kinetics at the same GPCR, which are not due to
differences in their G protein-coupling specificity. We
identified differences in Gβγ signaling and in the de-
pendence of receptor internalization on dynamin-2
(dyn-2) and β-arrestin-2 (also named arrestin-3). The
distinct agonist- and receptor-dependent recruitment of
dyn-2 and β-arrestin-2 triggers activation of different
downstream signaling cascades constituting the molecu-




All compounds and inhibitors were purchased from
Sigma-Aldrich, Cayman Chemical, Santa Cruz Biotech-
nology if not stated otherwise.
Amplification, sequencing and cloning of GPCR and dyn-2
constructs
Genomic DNA was isolated from human cancer cell
lines using the Wizard Genomic DNA Purification Kit
(Promega). Primer pairs, positioned in the 5′- and 3′-
UTR were used to amplify GPR84 (Table S1). Prof. Ralf
Jacob kindly provided the wild-type (wt) rat dyn-2 con-
struct [29]. It was used as template to introduce K44A
and R399A mutations as well as the YFP-tag (primer
pairs in Table S1). Cloning of human, gorilla and orang-
utan HCA3 was previously described [25]. The ProLink
Cloning Vector Bundle was purchased from Eurofins
DiscoverX and human HCA3 and GPR84, respectively
were inserted in the pCMV-ProLink Vector (primer
pairs indicated in Table S1).
PCR reactions were performed with Q5 High-Fidelity
DNA Polymerase following the manufacturer’s instruc-
tions. The PCR reaction (50 μl) contained genomic DNA
with primers (0.5 μM each), Q5 Reaction buffer (1x),
dNTP (200 μM), and 0.02 U/μl Q5 polymerase (NEB,
Frankfurt am Main, Germany). The reactions were initi-
ated with denaturation at 98 °C for 30 s, followed by 35
cycles of denaturation at 98 °C for 20 s, annealing at
63 °C for 45 s and elongation at 72 °C for 1 min. A final
extension step was performed at 72 °C for 10 min.
GPR84 was epitope-tagged with an N-terminal
hemagglutinin (HA) epitope and a C-terminal FLAG-tag
by a PCR-based overlapping fragments approach and
inserted into the mammalian expression vector pcDps.
Similarly, rat dyn-2 was C-terminally tagged with YFP
and human HCA3 C-terminally tagged with mRuby.
Identity and correctness of the constructs were con-
firmed by sequencing (SeqLab). The β-arrestin-2-YFP
construct was a gift from Robert Lefkowitz (Addgene
plasmid #36917) [30].
Cell culture and transfection
All cells were maintained at 37 °C in a humidified 5%
CO2 incubator. The Chinese hamster ovary cell line
CHO-K1 (ATCC CCL-61) and the human embryonic
kidney cell line HEK293-T (ATCC CRL-3216) were ob-
tained from the American Type Culture Collection. The
esophageal squamous cell carcinoma cell line Colo680N
(ACC 182) was obtained from the Leibniz Institute
DSMZ (German Collection of Microorganisms and Cell
Cultures). The CHO-K1 cells stably expressing HCA3
(cAMP Hunter CHO-K1 GPR109B Gi Cell Line) were
purchased from Eurofins DiscoverX.
CHO-K1 cells were grown in Dulbecco’s Modified
Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) and
HEK293-T cells in DMEM. Colo680N cells were grown
in Roswell Park Memorial Institute (RPMI) 1640
Medium with high glucose. All media were supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin. CHO-K1 cells
stably expressing HCA3 were cultured in commercially
available AssayComplete Cell Culture Kit 107 Medium
supplemented with 800 μg/ml geneticin. The enzyme ac-
ceptor- (EA) tagged β-arrestin-2 cell line was generated
according to the manufacturer’s protocol (Eurofins Dis-
coverX). In brief, 1 × 106 HEK293-T cells were seeded in
10 cm culture dishes and infected with PathHunter-β-
arrestin-2-EA retroparticles (Eurofins DiscoverX 93–
1087) at a concentration of at least 1 × 106 pfu/ml. Cells
were subsequently selected for hygromycin resistance
(final concentration 500 μg/ml Invivogen ant-hg-5).
Peters et al. Cell Communication and Signaling           (2020) 18:31 Page 2 of 19
43
Individual clones were isolated and tested for the pres-
ence of residual viral particles in compliance with BSL-2
safety regulations. Cells considered to be stable and safe
were then exploited for subsequent G protein activation
assays. HEK293-T cells stably expressing β-arrestin-2-
EA were cultured in DMEM, supplemented with 10%
FBS and 250 μg/ml Hygromycin B (Thermo Fisher
Scientific).
For transient transfection Lipofectamine 2000
(Thermo Fisher Scientific) was used. Cells were split into
25 cm2-cell culture flasks (CHO-K1: 0.9 × 106 cells/flask,
CHO-K1-HCA3: 1.2 × 10
6 cells/flask, HEK293-T: 1.6 ×
106 cells/flask, HEK293-T cells stably expressing β-
arrestin-2-EA: 2 × 106 cells/flask, Colo680N: 1.6 × 106
cells/flask). The following day cells were transfected with
plasmid (total amount of DNA: CHO-K1: 3 μg, HEK293-
T: 2 μg (single construct) or 4 μg (co-transfection),
HEK293-T cells stably expressing β-arrestin-2-EA:
0.05 μg, Colo680N: 4 μg).
For cAMP-, ERK-, ELISA-assays, calcium imaging and
CQ1 analyses cells were serum-starved 16 h prior to the
experiments. In case inhibitors were used, cells were in-
cubated for 30 min at 37 °C prior to the experiment
using the following concentrations: 10 μMU0126, 80 μM
dynasore, 100 μM barbardin, 3 mM MβCD, 50 μM gal-
lein, 25 μM ZA, 100 μM NSC23766 and 25 μM
LY294002.
3D spheroid growth analyses
Cells were cultured in ultra-low attachment spheroid
microplates (Corning Life Sciences for CHO-K1; Nexce-
lom for Colo680N) to form spheroids and analyze recep-
tor function in 3D structures. For stimulation
experiments cells (CHO-K1 & CHO-K1-HCA3: 1 × 10
4
cells/well, Colo680N: 2 × 104 cells/well) were seeded in
their culture medium with or without agonist. For ex-
periments with dyn-2 mutants, cells were seeded 24 h
post-transfection with dyn-2 constructs. Images were
taken and analyzed every 24 h for up to 72 h using the
Celigo Image Cytometer (Nexcelom). At 72 h cells were
stained for dead (propidium iodide (PI), 1 μg/ml Thermo
Fisher Scientific) and total cells (Hoechst 33342, 1 μg/
ml, Sigma-Aldrich) and imaged as well as analyzed using
the Celigo Image Cytometer.
Dynamic mass redistribution assay
To measure label-free receptor activation, a dynamic
mass redistribution (DMR) assay (Corning Epic Biosen-
sor Measurements; Corning Life Sciences) with CHO-K1
cells transiently transfected with receptor construct or
empty vector was performed. One day after transfection
cells were detached using Versene solution (Life Tech-
nologies) and transferred into a fibronectin-coated Epic
384-well microplate at a density of 1.2 x 104cells per well
and cultured for 24 h to reach confluent monolayers.
After 2 h of equilibration in HBSS/HEPES, stimulation
with various agonist concentrations was performed and
DMR was recorded for 50 min. In DMR measurements,
polarized light is passed through the bottom of the bio-
sensor microplate, and a shift in wavelength in pm of
reflected light indicates intracellular mass redistribution
triggered by receptor activation.
ALPHAScreen cAMP assay
cAMP content of cell extracts was determined by a non-
radioactive assay based on the ALPHAScreen technology
according to the manufacturer’s protocol as previously
described (Perkin Elmer LAS) [25].
Alpha SureFire Ultra Multiplex pErk 1/2 & total Erk assay
pErk/total Erk content of cell extracts was determined
by the Alpha SureFire Ultra Multiplex p-ERK 1/2 + Total
ERK assay according to the manufacturer’s protocol
(Perkin Elmer LAS). The kit measures both, the phos-
phorylation (Thr202/Tyr204) and total levels of en-
dogenous ERK 1/2 in cellular lysates. The signal at 615
nm (Eu) corresponds to the phosphorylated ERK level,
and the signal at 545 nm (Tb) corresponds to the total
ERK levels.
One day after transfection cells were split into 96-well
plates (2 × 104 cells/well). Stimulation with agonists was
performed 48 h after transfection in HBSS/HEPES for
10 min at 37 °C if not indicated otherwise. When inhibi-
tors were used cells were pre-incubated with inhibitor in
HBSS/HEPES at 37 °C for 30 min prior to agonist stimu-
lation. Two-fold concentrated agonist was added to
inhibitor-containing wells to prevent wash-out effects.
Reactions were stopped by aspiration of media and cells
were lysed in 50 μl of supplied lysis buffer. From each
well 10 μl of lysate were transferred to a 384-well plate.
Acceptor beads and donor beads were added according
to the manufacturer’s protocol.
CQ1 confocal imaging
HEK293-T cells co-transfected with HCA3-mRuby or
GPR84-mRuby and either YFP-tagged rat dyn-2 variants
or YFP-tagged rat β-arrestin-2 were plated in poly-L-
lysine treated black Greiner 96-well plates with clear
bottom (Greiner No 655090). Forty-eight hours post-
transfection, medium was changed to HBSS/HEPES and
after 30 min incubation images were acquired using the
Yokogawa CQ1 (Cenibra). Subsequently, buffer with or
without agonist was added to the cells. Then cells were
incubated for another 30 min and images acquired of the
same cells. Per condition several images were acquired
with a 40x objective and at least 30 cells analyzed.
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ELISA
Cell surface expression of N-terminal HA-tagged recep-
tor constructs was determined using an indirect cellular
ELISA as described previously [25].
Calcium imaging
CHO-K1 and HEK293-T cells were transfected with
plasmids encoding for mRuby-tagged HCA3 and
mRuby-tagged GPR84, respectively. Transfected cells
(2 × 105 cells/well) were seeded into 24-well plates on
glass cover slips and calcium imaging was carried out
24–48 h post-transfection. CHO-K1 and HEK293-T cells
were loaded with 5 μM fura-2 AM (Molecular Probes) in
standard solution containing 140 mM NaCl, 10 mM
HEPES, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 10
mM glucose for 60 and 30 min, respectively. Fura 2-
based calcium imaging was performed in single trans-
fected CHO-K1 and HEK293-T cells using a
monochromator-based imaging system and the imaging
software TILLvisION 4.0 (T.I.L.L. Photonics). Emitted
fluorescences (excited at 340 nm and 380 nm) were ac-
quired with a CCD camera (PCO Imaging) at intervals
of 2 s and corrected for background fluorescence. Trans-
fected cells were detected by emitted mRuby fluores-
cence, excited at 550 nm. Agonists of GPR84 and HCA3
as well as ATP were dissolved in standard solution and
applied to the cells by bath perfusion.
PathHunter β-arrestin assay (Eurofins DiscoverX)
One day after transfection 5 × 103 cells/well were plated
in a poly-L-lysine-treated white 384-well plate with clear
bottom (Greiner No 781098). On the day of the assay,
media was removed and cells were stimulated with 25 μl
of agonist solution in HBSS/HEPES for 90 min at 37 °C
and 5% CO2. Subsequently, 12.5 μl detection solution
was added following the manufacturer’s instructions.
After 1 h incubation in the dark at room temperature,
luminescence was determined using the EnVision 2105
(Perkin Elmer).
Data analyses
All data were analyzed and visualized using GraphPad
Prism version 7 for Windows (GraphPad Software, www.
graphpad.com). A repeated measure one-way ANOVA
(Dunnett’s multiple comparisons test) or paired two-
tailed t-test was applied to analyze differences in spher-
oid area and number of cells. Unpaired two-tailed t-tests
were applied to analyze differences in cell surface ex-
pression. Unpaired two-tailed t-tests were applied to
analyze the effect of inhibitors and dyn-2 mutants for
cAMP inhibitory signaling. Paired two-tailed t-tests were
performed to analyze the effect of inhibitors and dyn-2
mutants on ERK activation. # P ≤ 0.1; * P ≤ 0.05; ** P ≤
0.01; *** P ≤ 0.001.
Results
cAMP inhibitory signal of HCA3 and GPR84
First, we confirmed that HCA3 and GPR84 induce
cAMP inhibitory signaling in our experimental setup.
Both, HCA3 and GPR84, exhibited increased basal activ-
ity in the Gi protein-mediated pathway, which was
reflected in the reduced cAMP levels in CHO-K1 cells
heterologously expressing the receptors compared to
empty vector-transfected cells (Figure S1A). As expected,
we also observed a concentration-dependent decrease of
intracellular cAMP levels upon stimulation of HCA3 and
GPR84 with their respective agonists (Fig. 1a, Table S2).
Agonist stimulation usually results in receptor internal-
ization reducing the receptor number at the cell surface
(Figure S1B, β2-adrenergic receptor (ADBR2) and V2
vasopressin receptor (V2R)). However, only 3HO in-
duced a significant reduction in cell surface expression
of HCA3 (Figure S1B). These analyses confirmed previ-
ously published results on G-protein specificity and pro-
vided first evidences for agonist- and receptor-specific
differences in the internalization of HCA3 and GPR84.
Thus, we used the dynamic mass redistribution technol-
ogy (DMR; Corning Epic System) to analyze the signal-
ing kinetics of HCA3 and GPR84 in transiently
transfected CHO-K1 cells.
Differential activation kinetics of HCA3 and GPR84 upon
agonist stimulation
The DMR technology provides the advantage of time-
resolved recording (kinetics) of cellular responses inde-
pendent of the activated signaling cascade. In DMR as-
says, HCA3 was also activated by 3HO and 3HDec but
not by C10 (Figs. 1b, S2, S3, Table S2). In contrast, C10
and 3HDec but not 3HO activated GPR84 (Figs. 1b, S2,
S3, Table S2). 100 ng/ml PTX treatment overnight com-
pletely abolished DMR responses of HCA3 and GPR84.
Interestingly, we observed differences in receptor signal-
ing kinetics. The maximum DMR response was reached
faster when HCA3 was stimulated with 3HO compared
to 3HDec (Fig. 1b). Moreover, the 3HDec-induced DMR
response of GPR84 declined more rapidly compared to
C10 (Fig. 1b). Despite equal PTX sensitivity, our DMR
analyses revealed significant differences in agonist-
induced signaling kinetics for both receptors, potentially
due to different desensitization/internalization
mechanisms.
3HDec-induced HCA3 DMR signal inhibited by dynasore
Responses recorded with the DMR technology reflect a
sum of dynamic changes and signaling events induced
by stimulation of a GPCR by its agonists, thus also in-
cluding internalization and recruitment of signaling
components. The neuropeptide Y receptor family is an
example for receptors sharing agonists but exhibiting
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different internalization mechanisms upon activation
[31]. We first used DMR assays to analyze whether
HCA3 and GPR84 signaling is dependent on the small
GTPase dyn-2, which is involved in the membrane scis-
sion step during endocytosis / internalization of some
GPCRs and many other cellular processes [32, 33]. We
applied the dyn inhibitor dynasore, a cell-permeable
non-competitive inhibitor of the GTPase activity of dyn
[34–36], in DMR analyses of GPR84 and HCA3 activa-
tion. We found that presence of dynasore differentially
affected the DMR response of HCA3 and GPR84. The
3HO-induced HCA3 signal was reduced in presence of
dynasore at earlier time points, whereas the 3HDec-
induced DMR response of HCA3-transfected cells was
completely abolished (Figs. 1b, S2, S3).
HCA3 is the evolutionarily youngest ortholog of the
hydroxycarboxylic acid receptor (HCAR) family and only
present in humans and apes [25]. We tested whether the
observed differences for HCA3 activated by different ag-
onists in the presence of dynasore is common in the
HCAR family and thus evolutionarily conserved. We an-
alyzed HCA1 and HCA2 DMR responses to different ag-
onists in absence and presence of dynasore. Lactate, the
endogenous agonist of HCA1, induced a DMR response,
which was not inhibited but prolonged by dynasore (Fig-
ure S4A). A similar observation was made when HCA1
was stimulated with the surrogate agonist 3,5-dihydroxy-
benzoic acid (3,5-DHB) (Figure S4A). Similarly, the
DMR responses of HCA2 to the endogenous agonist 3-
hydroxybutyrate and the surrogate agonist monomethyl
fumarate were sustained in presence of dynasore (Figure
S4B). Therefore, the observed activation kinetics and
dynasore-sensitivity of HCA3 are specific for this HCAR
subtype. DMR responses of GPR84 were also affected by
dynasore. The C10-induced signal was reduced in
GPR84-transfected cells over the whole recording time
whereas the 3HDec-induced signal was only affected at
earlier time points (Figs. 1b, S2, S3).
In sum, our data highlights a differential dynasore-
sensitivity of both receptors depending on the activating
compound.
Differential effects of the internalization inhibitors
dynasore and sucrose on Gi protein- and ERK signaling of
HCA3 and GPR84
Next, we asked whether the observed differences in
agonist-induced DMR signals in the presence of dyna-
sore are accompanied by differences in second
Fig. 1 Differential agonist-dependent receptor activation kinetics and dynasore sensitivity of HCA3 and GPR84 DMR responses. CHO-K1 cells were
transiently transfected with receptor constructs. a cAMP inhibition assays in presence of 2 μM forskolin (fsk) were performed which showed
activation of HCA3 by 3-hydroxyoctanoic acid (3HO) and 3-hydroxydecanoic acid (3HDec). C10 and 3HDec activated GPR84. cAMP level of HCA3-
or GPR84-transfected cells in absence of agonist is set 100%, respectively. b Transfected CHO-K1 cells were seeded in fibronectin-coated Epic
plates and DMR responses were recorded. 3HO and 3HDec induced a pertussis toxin (PTX, 100 ng/ml)-sensitive DMR response in HCA3-, C10 and
3HDec in GPR84-expressing CHO-K1 cells. DMR responses in absence of dynasore showed distinct receptor activation kinetics for both, HCA3 and
GPR84, when comparing the shown agonists, respectively. Dynasore (80 µM) diminished the 3HDec-induced DMR response of HCA3-expressing
cells completely. Time points 10 min, 20 min and 40 min were used to generate bar graphs (concentration-response curves see Figures S2, S3) to
highlight, that DMR responses of HCA3 to 3HO and GPR84 to 3HDec were affected by dynasore only at earlier time points. The DMR responses of
HCA3 to 3HDec and of GPR84 to C10 were diminished over the whole time recorded. Shown is the agonist-induced wavelength shift in pm of
three to five independent experiments, each carried out in triplicates as mean ± SEM. ns, not significant; # P ≤ 0.1; * P≤ 0.05; ** P ≤ 0.01
Peters et al. Cell Communication and Signaling           (2020) 18:31 Page 5 of 19
46
messenger levels. In addition to dynasore, we used
hyperosmolar sucrose, a non-specific inhibitor of recep-
tor endocytosis, to test whether their presence results in
prolonged HCA3- or GPR84-mediated cAMP inhibition
(Fig. 2a, b) [37]. Hyperosmolar sucrose cannot be used
in DMR assays because the induced cell shrinkage
causes a constant shift in the reflected wavelength and
destroys the assay window [38]. Hyperosmolar sucrose
inhibits both, clathrin-mediated endocytosis and other
endocytic routes, such as the caveolar pathway, but does
not interfere with dyn-2 function or cAMP accumulation
[39–41].
We pretreated CHO-K1 cells transiently transfected
with HCA3 and GPR84 with 80 μM dynasore and 0.4M
Fig. 2 Effect of dynasore and sucrose on HCA3 and GPR84 cAMP inhibitory and ERK signaling. a Scheme summarizing all inhibitors and their
targets used in the present study. b, c CHO-K1 cells were transiently transfected with HCA3 or GPR84. b 80 μM dynasore reduced cAMP inhibitory
signaling of HCA3 upon 3HO and 3HDec and of GPR84 upon C10 but not 3HDec stimulation. Sucrose (0.4 M) significantly inhibited only the
3HDec-induced HCA3-mediated reduction of intracellular cAMP levels. cAMP level of HCA3- or GPR84-transfected cells in absence of agonist is set
to 100%, respectively. c The agonist-induced phosphorylation of ERK1/2 was measured in absence and presence of dynasore or sucrose. All
agonists induced an increase in pERK/total ERK levels upon stimulation of HCA3 and GPR84, respectively. Dynasore blocked the signal of 100 μM
3HO and 100 μM 3HDec completely and sucrose partially in HCA3–transfected cells. Dynasore did not fully block the signal of 100 μM C10 and
100 μM 3HDec in GPR84-transfected cells. The residual ERK signals of GPR84 in presence of 3HDec and dynasore or sucrose did not differ. pERK/
total ERK of HCA3- or GPR84-transfected cells in absence of agonist is set 1. b, c Data is given as mean ± SEM of at least three independent
experiments each carried out in triplicates. * P ≤ 0.05; ** P≤ 0.01
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sucrose for 30 min as previously described [39] and per-
formed cAMP inhibition assays with the two respective
agonists. In the presence of dynasore the 3HO-induced
HCA3-mediated and the C10-induced GPR84-mediated
reductions in cAMP levels were decreased (Fig. 2b,
Table S3). Further, dynasore inhibited the 3HDec-
induced reduction of cAMP levels in HCA3- but not in
GPR84-transfected cells (Fig. 2b). Thus, the presence of
dynasore did not prolong but inhibited the HCA3-medi-
ated cAMP inhibitory signaling of all agonists tested.
Dynasore inhibits dyn-2, which is not only a key protein
of endocytosis but also of the intracellular membrane
trafficking machinery [38]. Thus, the observed effects of
dynasore on cAMP inhibitory signaling could be due to
dyn-2-dependent trafficking of HCA3.
Moreover, we found that hypertonic sucrose signifi-
cantly reduced the 3HDec-induced HCA3-mediated
cAMP inhibition (Fig. 2b). No significant effect of su-
crose on the GPR84-mediated inhibitory cAMP signal
for either C10 or 3HDec was observed (Fig. 2b). Neither
dynasore nor sucrose caused an effect in empty vector-
transfected control cells (Figure S5).
Activation of both, HCA3 and GPR84, resulted in
phosphorylation of extracellular-signal regulated kinase
(ERK) (Figure S6A, Table S2). We did not observe cal-
cium signals upon stimulation of either receptor (Figure
S6B) which partially contrasts previous findings [42, 43].
However, the previously reported calcium signals in
HCA3-transfected CHO-K1 cells have been reported at
very high agonist concentrations, i.e. 100 μM of the syn-
thetic agonist 1-isopropylbenzotriazole-5-carboxylic acid
(IPBT5CA) [42], which has been reported to activate
HCA3 with an EC50 value of 0.4 μM [44]. Additionally,
Gaidarov et al. showed that GPR84 activation evoked
calcium responses only in human macrophages but not
in transfected HEK293 cells which is in line with our
findings [43].
The presence of the MEK inhibitor U0126 (10 μM, Fig.
2a), which inhibits ERK signaling directly upstream of
ERK [45], diminished the agonist-induced ERK phos-
phorylation of HCA3 and GPR84 completely (Figure
S6C). Next, we analyzed the influence of 0.4M sucrose
and 80 μM dynasore on ERK signaling. Dynasore com-
pletely blocked the signal of HCA3 in response to both,
3HO and 3HDec, and sucrose inhibited it partially (Fig.
2c, Table S4). The C10-induced ERK signal of GPR84
was completely inhibited by the presence of dynasore
but to a significantly lesser degree in the presence of su-
crose (Fig. 2c). In contrast, dynasore and sucrose did not
fully inhibit the ERK signal of GPR84 induced by 3HDec
(Fig. 2c).
In summary, the ERK signal of both, HCA3 and
GPR84, is dynasore- and to some extent sucrose-
sensitive, and therefore internalization-dependent.
Diminished signaling and altered subcellular distribution
of HCA3 in the presence of dyn-2 mutants
Since dynasore affected signal transduction of HCA3 and
GPR84, we next co-transfected CHO-K1 cells with
HCA3 or GPR84 and functionally altered dyn-2 variants
to further investigate the role of dyn-2 for receptor traf-
ficking, signaling and internalization. In the K44A dyn-2
mutant, the GTP-binding ability is impaired causing
lower GTP hydrolysis, which blocks the coated vesicle
formation without affecting the coat assembly and inva-
gination [46]. Moreover, we used the R399A dyn-2 vari-
ant with an impaired self-assembly and membrane
localization [47]. Using ELISA, we found that cell surface
expression of HCA3 and GPR84 was reduced in the
presence of either dyn-2 mutant (Fig. 3a). No internal-
ization of HCA3 upon stimulation with 3HO was de-
tected when dyn-2 K44A or R399A were co-transfected
(Fig. 3a).
Analyses of co-expression of HCA3 with dyn-2 wt and
mutants in cAMP inhibition assays revealed significantly
increased basal cAMP levels in the presence of K44A in-
dicating a reduced basal activity of HCA3 (Fig. 3b).
These higher cAMP levels in the presence of K44A per-
sisted when HCA3 was activated with 3HO or 3HDec,
whereas the presence of R399A did not cause altered
cAMP signaling (Fig. 3b). In contrast, co-expression of
GPR84 with dyn-2 K44A compared to dyn-2 wt did not
affect basal activity of GPR84, but reduced receptor acti-
vation by both C10 and 3HDec (Fig. 3b). Moreover, we
found that agonist-induced activation of ERK by HCA3
and GPR84 was significantly reduced in the presence of
both, K44A and R399A, compared to dyn-2 wt (Fig. 3c).
Next, we used HEK293-T cells due to their better suit-
ability for image analyses and at first confirmed that
HCA3 and GPR84 also exhibit a basal activity in
HEK293-T cells (Figure S7A). In addition, we showed
that in HEK293-T cells, similar to our observations in
CHO-K1 cells, a concentration-dependent decrease in
intracellular cAMP levels was observed upon stimulation
of HCA3 with 3HO and 3HDec as well as of GPR84 with
C10 and 3HDec (Figure S7A). Further, also in HEK293-
T cells only stimulation with 3HO induced a significant
reduction in cell surface expression levels of HCA3 (Fig-
ure S7B). However, using ELISA we found that in con-
trast to CHO-K1 cells, in HEK293-T cells only HCA3
but not GPR84 cell surface expression was significantly
reduced in the presence of either dyn-2 mutant (Figure
S7C).
Next, we transiently co-transfected HEK293-T cells
with mRuby-tagged HCA3 or mRuby-tagged GPR84 and
YFP-tagged dyn-2 variants for subcellular localization
analyses. HCA3 was expressed at the plasma membrane,
where it co-localized with dyn-2 wt (Fig. 3d). In case of
co-expression of HCA3 with either of the dyn-2 mutants
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K44A or R399A, co-localization was found in peri-
nuclear vesicles as well as in certain areas at the plasma
membrane indicating that expression of dyn-2 mutants
impairs HCA3 trafficking and thereby reduces its cell
surface expression (Fig. 3d). Substantiating our findings
from ELISA analyses, we found that in HEK293-T cells
GPR84 plasma membrane expression was not reduced
in presence of dyn-2 mutants and GPR84 was not found
co-localized with either dyn-2 mutant in perinuclear ves-
icles (Figs. 3d, S7C).
Finally, we performed ELISA analyses in CHO-K1 cells
in the presence of dynasore. Cell surface expression of
ADRB2 and V2R, serving as controls, were reduced by
only 15%, while HCA3 and GPR84 cell surface expres-
sion levels were decreased by about 50 and 30%, respect-
ively (Figure S8).
Fig. 3 Effect of dyn-2 mutants on HCA3 and GPR84 cell surface expression, cAMP inhibitory signaling and ERK activation. a-c CHO-K1 cells were
transiently co-transfected with HCA3 or GPR84 and dyn-2 wt, dyn-2 K44A or R399A mutants. a In comparison to dyn-2 wt co-transfected cells
HCA3 and GPR84 cell surface expression was significantly reduced when K44A or R399A were co-transfected. b Basal activity of HCA3 but not
GPR84 was diminished in presence of K44A. Agonist-induced (HCA3: 6.25 μM 3HO, 25 μM 3HDec; GPR84: 100 μM C10, 25 μM 3HDec) inhibition of
forskolin-stimulated cAMP accumulation was reduced in presence of K44A compared to dyn-2 wt whereas R399A did not affect cAMP inhibitory
signaling. c Agonist-induced increase of pERK/total ERK level of HCA3 (25 μM 3HO, 100 μM 3HDec) and GPR84 (25 μM C10, 25 μM 3HDec) was
reduced in presence of K44A and R399A compared to dyn-2 wt. a-c Data is given as mean ± SEM of at least three independent experiments each
carried out in triplicates. * P≤ 0.05; ** P≤ 0.01, *** P ≤ 0.001 (d) Images of HEK293-T cells transiently co-expressing HCA3-mRuby (red) or GPR84-
mRuby and dyn-2-YFP variants (green). In presence of dyn-2 wt, HCA3 was detected intracellularly and at the plasma membrane where it co-
localized with dyn-2 wt. In case of co-expression of HCA3 with the dyn-2 mutants K44A and R399A, co-localization was detected in perinuclear
vesicles as well as certain areas at the plasma membrane. GPR84 was in presence of all dyn-2 variants found mostly at the plasma membrane
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No effect of methyl-β-cyclodextrin (MβCD), an inhibitor of
caveolar endocytosis, on 3HDec-induced GPR84 signaling
The best-characterized internalization routes of GPCRs
are clathrin-mediated or caveolae-dependent pathways
[37]. Dynasore alone does not allow discrimination of the
two pathways because both depend on dyn-2. However,
caveolar endocytosis is sensitive to cholesterol depletion
by MβCD and previous studies showed that 3mM of
MβCD selectively inhibit caveolar endocytosis of ADRB2
and the dopamine D2 receptor [37]. Thus, we tested the
impact of MβCD on HCA3 and GPR84 signaling to reveal
potential differences in caveolar endocytic processes.
MβCD abolished the 3HO-induced HCA3-mediated and
C10-induced GPR84-mediated reduction in cAMP levels
(Fig. 4a, Table S3). However, MβCD inhibited the 3HDec-
induced reduction of cAMP only in HCA3 but not in
GPR84-transfected CHO-K1 cells (Fig. 4a). MβCD did not
cause an effect in empty vector-transfected control cells
(Figure S5). Further, the 3HDec- but not the 3HO-
induced ERK activation in HCA3-expressing cells was re-
duced in the presence of MβCD (Fig. 4b). On the contrary,
the presence of MβCD inhibited the ERK signal of GPR84
induced by C10 but did not diminish the GPR84-
mediated activation of ERK by 3HDec (Fig. 4b, Table S4).
β-arrestin-2 recruitment upon activation of HCA3 by 3HO
but not 3HDec
Several adaptor and accessory proteins are involved in the
process of GPCR internalization, including arrestins and
the adaptor protein complex 2 (AP2) with the subunit β2-
adaptin [48]. Therefore, we analyzed whether β-arrestin-2
is involved in mediating signal transduction of HCA3 and
GPR84. We used 100 μM barbardin, which is a selective
arrestin/β2-adaptin inhibitor that blocks agonist-promoted
arrestin-dependent and clathrin-mediated endocytosis,
but does not interfere with the translocation of arrestin to
the receptor or with the interaction of AP2 with other
components of the endocytic machinery [49].
We found that barbardin diminished only the 3HO-
induced HCA3-mediated cAMP inhibitory signaling but
not the 3HDec-induced HCA3-dependent or the
GPR84-mediated signaling (Fig. 4a, Table S3). No effect
of barbardin was observed in empty vector-transfected
control cells (Figure S5). Barbardin treatment only inhib-
ited the HCA3-mediated ERK signal upon 3HO stimula-
tion, but had no effect on the 3HDec-induced HCA3-
mediated ERK signal or the GPR84-mediated ERK signal
induced by either agonist (Fig. 4b, Table S4).
This data suggests that arrestin recruitment only oc-
curs when HCA3 is activated by 3HO. To further sub-
stantiate this finding, we set out for co-localization
analyses of mRuby-tagged HCA3 and YFP-tagged β-
arrestin-2. We used fluorescence confocal microscopy of
living HEK293-T cells to analyze the subcellular
distribution of HCA3 and β-arrestin-2 before and after
stimulation with 3HO or 3HDec, respectively. Formation
of internalized vesicles, where HCA3 and β-arrestin-2
are co-localized, was observed following incubation with
3HO, but not with 3HDec. When stimulated with
3HDec, HCA3 remained localized mostly at the plasma
membrane (Fig. 4c). Finally, we used the PathHunter β-
Arrestin assay (Eurofins DiscoverX) in HEK293-T cells
stably expressing β-arrestin-2-EA to quantify 3HO and
3HDec-induced β-arrestin-2 recruitment of HCA3.
Again, we found that activation of HCA3 by 3HO but
not 3HDec leads to β-arrestin-2 recruitment (Fig. 4d).
Next, we used the HEK293-T cells stably expressing β-
arrestin-2-EA to support our observation that GPR84
does not interact with β-arrestin-2 upon activation with
C10 and 3HDec. Activation of GPR84 by neither C10
nor 3HDec induced a significant recruitment of β-
arrestin-2 in HEK293-T cells as analyzed using both, the
PathHunter β-Arrestin assay as well as co-localization
analyses of mRuby-tagged GPR84 and YFP-tagged β-
arrestin-2 (Figures S7D, S7E).
Finally, we tested whether barbardin affects cell surface
expression of HCA3 and GPR84. We found that cell sur-
face expression of ADRB2 and V2R, previously shown to
internalize via β-arrestin-dependent and clathrin-
mediated endocytosis, was reduced by about 15% in the
presence of barbardin (Figure S8) [49]. No effect of bar-
bardin on cell surface expression of GPR84 was ob-
served, but a reduction for HCA3 cell surface expression
by about 15% (Figure S8).
Activation of HCA3 by LAB-derived metabolites caused β-
arrestin-2 recruitment
Recently, we analyzed the evolutionary history of HCA3
and identified metabolites of lactic acid bacteria (LAB)
as highly potent agonists [25]. This discovery prompted
us to ask the following questions: First, is it possible to
determine structurally relevant residues that could help
to understand the different trafficking of HCA3 com-
pared to HCA1 and HCA2 (Figs. 1, S4)? Second, are
LAB-derived agonists equally distinguishable, like 3HO
and 3HDec, when comparing their DMR response in the
presence of dynasore? To answer the first question, we
analyzed the gorilla and orangutan HCA3 orthologs in
DMR assays and found that Tyr86 and Trp142 might be
indirectly or directly involved in the interaction of HCA3
with dyn-2 (Supplementary results and discussion, Fig-
ure S9). To answer the second question, we performed
DMR analyses with 4 μM D-phenyllactic acid (D-PLA),
4 μM indole 3-lactic acid (ILA), 250 μM D-phenylalanine
(D-Phe), and 400 μML-phenyllactic acid (L-PLA) on hu-
man, gorilla and orangutan HCA3 (Figure S9). These
HCA3 agonists did not activate GPR84 (Figure S10A).
Our analyses showed that dynasore affected the DMR-
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Fig. 4 Role of β-arrestin-2 for HCA3 and GPR84 signaling and effect of methyl-β-cyclodextrin (MβCD). a, b CHO-K1 cells were transiently
transfected with HCA3 or GPR84. a MβCD inhibited both, the 3HO- and 3HDec-induced reduction of forskolin (fsk)-induced cAMP levels in HCA3-
transfected cells. For GPR84, only the C10-induced but not the 3HDec-induced decrease in cAMP was inhibited. Barbardin (100 µM) inhibited only
the 3HO-induced HCA3-mediated reduction of cAMP levels. cAMP levels of HCA3- or GPR84-transfected cells in absence of agonist are set 100%,
respectively. b 3 mM MβCD did not affect HCA3-mediated activation of ERK by 3HO, but caused a decrease of the signal induced by 100 μM
3HDec. Presence of MβCD caused a decrease in C10-induced GPR84-mediated ERK activation and had no effect on the 3HDec-induced ERK
activation. The HCA3-mediated activation of ERK by 3HO, but not 3HDec, was inhibited in presence of barbardin. Barbardin had no effect on the
GPR84-mediated activation of ERK by 3HDec and C10. pERK/total ERK of HCA3- or GPR84-transfected cells in absence of agonist is set 1,
respectively. c Live-cell images of HEK293-T cells co-expressing HCA3-mRuby (red) and β-arrestin-2-YFP (green) were acquired before stimulation
and 30 min post-stimulation with 100 μM 3HO or 100 μM 3HDec. d HEK293-T cells stably expressing β-arrestin-2-EA cells transiently transfected
with HCA3 were stimulated with 3HO and 3HDec. Quantification of β-arrestin-2 recruitment using the PathHunter β-arrestin assay (Eurofins
DiscoverX) showed recruitment of β-arrestin-2 by HCA3 following 3HO but not 3HDec stimulation. Luminescence of HCA3 or empty vector
transfected cells in absence of agonist is set 1, respectively. a, b, d Data is given as mean ± SEM of at least three independent experiments each
carried out in triplicates. # P ≤ 0.1* P ≤ 0.05; ** P≤ 0.01
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response of human and gorilla HCA3 to D-Phe and L-
PLA in a similar manner like that to 3HDec, whereas
the DMR response of D-PLA and ILA was similarly af-
fected like the one to 3HO (Figure S9). At last, we per-
formed β-arrestin-2 recruitment assays and found that
activation of human HCA3 by both agonists, D-PLA and
ILA, indeed caused recruitment of β-arrestin-2 whereas
this was not the case for D-Phe (Figure S10B).
Gβγ-dependent HCA3 signaling and internalization
Gβγ subunits have been shown to interact with dyn, modu-
late its activity and thereby influence receptor internaliza-
tion as well as trafficking [50]. Thus, we performed ELISA
analyses to test whether gallein, an inhibitor of Gβγ signal-
ing, interferes with cell surface expression of HCA3 and
GPR84 [51]. We found that 50 μM gallein reduces HCA3
cell surface expression by about 20%, whereas it does not
affect GPR84, ADRB2 and V2R cell surface expression, thus
indicating that Gβγ subunits are involved in HCA3 traffick-
ing (Figure S8). Further, Gβγ subunits modulate many ef-
fectors including adenylyl cyclase isoforms and ERK [52].
Hence, we analyzed the effect of gallein on both, cAMP in-
hibitory signaling and ERK activation [51]. The cAMP in-
hibitory response of HCA3 to both agonists, 3HO and
3HDec, was inhibited by gallein (Fig. 5a, Table S3). In
contrast, presence of gallein diminished only the C10-
induced but not the 3HDec-induced reduction of cAMP
in GPR84-transfected CHO-K1 cells (Fig. 5a, Table S3).
Gallein caused no effect in empty vector-transfected con-
trol cells (Figure S5).
ERK analyses revealed that the 3HDec-induced signal
of HCA3 expressing cells was completely lost in the
presence of gallein, whereas ERK activation was still de-
tectable for 3HO (Fig. 5b, Table S4). Presence of gallein
caused a reduction but did not completely abolish the
GPR84-mediated ERK activation by C10 and 3HDec,
which indicates that this ERK signal is partially Gβγ
subunit-independent (Fig. 5b, Table S4).
PI3K, ras/rho and rac1 involved in ERK activation
downstream of HCA3
As shown above, HCA3 trafficking and signaling is
dependent on Gβγ subunits. Since other downstream ef-
fectors of Gβγ subunits include PI3-kinase γ and rac1,
which are crucial for chemotaxis in leukocytes, we next
analyzed the effect of inhibitors of ras/rho, rac1 and
PI3K on the agonist-induced ERK activation (Fig. 2a)
[51]. Zoledronic acid (ZA), an inhibitor of ras/rho, re-
duced the HCA3-mediated ERK activation by both
HCA3 agonists and the C10- but not the 3HDec-
Fig. 5 Effect of gallein, an inhibitor of Gβγ subunits, on agonist-induced reduction of cAMP levels and ERK activation of HCA3 and GPR84. CHO-K1
cells were transiently transfected with HCA3 or GPR84. a The HCA3-mediated reduction of forskolin (fsk)-induced cAMP levels induced by both,
3HO and 3HDec, was significantly diminished in presence of 50 μM gallein. The GPR84-induced decrease in cAMP levels in presence of gallein
was only reduced in case of activation by C10 but not 3HDec. cAMP level of HCA3- or GPR84-transfected cells in absence of agonist is set 100%,
respectively. b Gallein inhibited the 3HDec-induced HCA3-mediated increase in pERK/total ERK levels completely but the 3HO-induced increase
only partially. GPR84-mediated activation of ERK by both, C10 and 3HDec, was equally diminished in presence of gallein. pERK/total ERK of HCA3-
or GPR84-transfected cells in absence of agonist is set 1, respectively. a, b Data is given as mean ± SEM of at least three independent experiments
each carried out in triplicates. * P≤ 0.05; ** P≤ 0.01; *** P ≤ 0.001
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induced GPR84-mediated signal (Fig. 6a, Table S4).
Presence of 100 μM NSC23766, an inhibitor of rac1,
inhibited both, the 3HO- and the 3HDec-induced
HCA3-mediated ERK signal, but showed no effect on the
GPR84-mediated signal, independent of the agonist (Fig.
6a, Table S4). LY294002 (25 µM), a PI3K inhibitor,
caused a reduction of all agonist-induced HCA3- and
GPR84-mediated ERK signals (Fig. 6a, Table S4).
Sustained GPR84-mediated ERK activation by 3HDec after
agonist washout
Finally, we performed agonist-washout experiments to
test whether any of the observed agonist-dependent
Fig. 6 Components involved in HCA3 and GPR84 signal transduction. a, b Agonist-induced phosphorylation of endogenous ERK1/2 in cellular
lysates of HCA3 or GPR84 transfected CHO-K1 cells in absence and presence of 25 μM ZA (zoledronic acid - inhibitor of ras/rho), 100 μM
NSC23766 (inhibitor of rac1) and 25 μM Ly294002 (inhibitor of PI3K) was determined. a ZA, NSC23766 and Ly294002 partially inhibited the HCA3-
induced ERK activation of both agonists. ZA and Ly 294,002 caused a significant reduction of the GPR84-mediated ERK activation by C10, whereas
the ERK activation by 3HDec was only affected by presence of Ly294002. NSC23766 did not inhibit the GPR84-induced activation of ERK by either
agonist. b Both, the 3HO- and 3HDec-induced ERK activation of HCA3 did not persist upon removal of agonist. The GPR84-mediated activation of
ERK by 3HDec persisted, whereas the C10-induced activation was almost completely diminished 10min past agonist removal. a, b pERK/total ERK
of HCA3- or GPR84-transfected cells in absence of agonist is set 1, respectively. Data is given as mean ± SEM of at least three independent
experiments each carried out in triplicates. # P≤ 0.1; * P ≤ 0.05; ** P ≤ 0.01; *** P≤ 0.001. c 3HO- and 3HDec-induced cAMP inhibitory signaling of
HCA3 was dependent on Gαi, Gβγ subunits and dyn (internalization). Signaling components involved in HCA3-mediated ERK activation by 3HO an
3HDec included Gβγ subunits, PI3K, rac1 and ras/rho. HCA3 activation by 3HO led to β-arrestin-2 recruitment, which was not the case for 3HDec.
ERK signaling of HCA3 by 3HO involved clathrin and by 3HDec caveolin. GPR84 activation by C10 was dependent on Gαi, Gβγ subunits, dyn
(internalization), caveolin, ras/rho and PI3K. In contrast, 3HDec-induced cAMP inhibitory signaling was not dependent on Gβγ subunits, dyn,
caveolin or clathrin, thus internalization. ERK activation induced by GPR84 upon 3HDec stimulation persisted upon agonist removal and
involved PI3K
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differences observed for HCA3 and GPR84 can be ex-
plained by persistent signaling, i.e. ERK activation when
the respective agonist is removed. We found that 10 min
after agonist removal ERK activation was completely
abolished to basal levels in HCA3–transfected cells inde-
pendent of the agonist (Fig. 6b). In contrast, in GPR84-
expressing cells, 10 min after 3HDec removal, we still
detected a significant activation of ERK for both concen-
trations, 25 μM (3-fold over basal) and 100 μM (5-fold
over basal) (Fig. 6b). For C10, a significant residual ERK
signal was only detectable for 100 μM (2-fold over basal)
(Fig. 6b). This data suggests that 3HDec induces persist-
ent signaling of GPR84.
In summary, our functional analyses revealed that β-
arrestin-2-dependence is the major difference in 3HO-
versus 3HDec-induced HCA3 signaling (Fig. 6c). For
GPR84, we showed that C10 induces a signal depending
on Gβγ, dyn (internalization), caveolin, ras/rho and
PI3K. In contrast, cAMP inhibitory signaling of GPR84
upon stimulation with 3HDec is independent of Gβγ,
dyn, caveolin or clathrin and thus internalization (Fig.
6c). Comparing signaling components involved upon
stimulation of HCA3 and GPR84 with 3HDec, we found
that while the HCA3-mediated ERK activation is
dependent on caveolin, PI3K, rac1 and ras/rho, the
GPR84-mediated ERK activation only involves PI3K
(Figs. 4b, 6a, c). Moreover, dynasore, sucrose, MβCD
and gallein affect cAMP inhibitory signaling of HCA3
but not of GPR84 suggesting an involvement of internal-
ization as well as Gβγ subunits in HCA3-mediated sig-
naling upon stimulation with 3HDec which is not the
case for GPR84 (Figs. 2b, 4a, 5a).
For GPR84 it has recently been demonstrated that dif-
ferent surrogate ligands differentially induce chemotaxis
in macrophages while similarly enhancing the levels of
phagocytosis [53]. However, for HCA3 no information is
available analyzing the biological consequences and po-
tential differences upon activation of HCA3 by different
agonists. Here, we used in vitro spheroid models to
analyze whether the agonists differentially influence
growth or density.
CHO-K1 cell spheroid formation affected by HCA3
First, we used a stably HCA3-expressing CHO-K1 cell
line and analyzed the effect of 3HO and 3HDec on
spheroid formation, structure and growth in comparison
to a wt CHO-K1 cell line by culturing both in ultra-low
attachment (ULA) plates. The spheroids were monitored
for 72 h using the Celigo Image Cytometer. Three di-
mensional cell culture models mimic the physiological
state regarding cell-cell contacts and nutrient gradients
more closely than 2D cultures [54]. We observed that
spheroids of HCA3-expressing CHO-K1 cells become
denser over time in comparison to those of CHO-K1
cells that do not express the receptor (Fig. 7a, b). We at-
tribute this observation to the fact that HCA3 exhibits
basal activity (Figure S1A). On the contrary, activation
of HCA3 by 3HO resulted in significantly larger but less
dense spheroids compared to unstimulated HCA3-ex-
pressing CHO-K1 cells, whereas 3HDec did not have
this effect (Fig. 7a). To substantiate this further, we
stained the spheroids with Hoechst 33342 (blue) for total
cell count and PI (red) for dead cell count. We found
that blue and red pixel intensities for both, 3HO- and
3HDec-stimulated HCA3-expressing spheroids, were
higher compared to unstimulated (Fig. 7a). However, the
ratio of dead cells to total cells (PI/Hoechst) did not sig-
nificantly differ between the different treatments. This
again suggests that HCA3 activation by 3HO influences
cell-cell adhesion and not proliferation or cell death (Fig.
7a). Both agonists did not have this effect in wt CHO-K1
cells (Fig. 7b).
Since HCA3 did not only exhibit basal activity but also
dyn-2-dependent trafficking and signaling (Figs. 3, S8),
we tested whether the mutants affected cell-cell adhe-
sion in our spheroid model. We transfected the stably
HCA3-expressing CHO-K1 cell line with either dyn-2 wt
or one of the aforementioned mutants and cultured
them for 48 h to allow spheroid formation. We found
that the presence of dyn-mutants caused HCA3-express-
ing spheroids to be smaller 24 h post-seeding, but less
dense 48 h post-seeding, whereas no such effects of the
dyn-2 mutants were observed in CHO-K1 cells that did
not express HCA3 (Fig. 7c).
In summary, these observations suggest that HCA3 ex-
hibits a basal interaction with dyn-2, which mediates in-
creased cell-cell adhesion and is interrupted upon
activation with 3HO accompanied by β-arrestin-2-re-
cruitment. Thus, both β-arrestin-2 recruitment and pres-
ence of dyn mutants result in less dense spheroids (Fig.
7).
3HO influence on spheroid density of the endogenously
HCA3 expressing esophageal carcinoma cell line
Colo680N
We tested whether similar effects on spheroid formation
can be observed in an endogenously HCA3-expressing
cell line. We confirmed presence of HCA3 by functional
characterization of the Colo680N cell line. We per-
formed cAMP inhibitory assays and found PTX-sensitive
activation by 3HO, 3HDec and other HCA3-specific ago-
nists, but not by GPR84-specific agonists (Figs. 8a, S11).
ERK activation was detectable for 3HO but not for
3HDec (Fig. 8b). Further, in the presence of 3HO
Colo680N spheroids were always less dense compared
to control as determined by volume measurement of
the spheroids as well as Hoechst 33342 and PI stain-
ing (Fig. 8c). This resembled our findings for HCA3-
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expressing CHO-K1 spheroids (Figs. 7a, 8c). Similarly,
the observation that disruption of dyn-2 function
caused less dense spheroids was also confirmed in
Colo680N cells (Fig. 8d).
Discussion
A recent study provides insight in GPR84-mediated
biased agonism, with the described agonists being surro-
gate ligands [53]. Although several agonists are also
known to activate HCA3, to our knowledge, no study so
far aimed to understand signaling outcome of HCA3 ac-
tivation by different agonists. The facts that GPR84 and
HCA3 are both Gi-coupled receptors, often co-expressed
in immune cells and activated by structurally highly
similar agonists raise the question: what is the evolu-
tionary advantage of expressing two apparently redun-
dant GPCRs in the same cell? Potential explanations
could be that beyond the Gi-protein signaling both
receptors differ in downstream signal transduction,
signaling kinetics and/or internalization mechanisms.
Internalization and endocytosis of GPCRs are not
only relevant for termination of receptor signaling but
are a crucial part of the receptor-mediated signal
transduction. The GTPase dyn, arrestins and several
other components have been shown to play an im-
portant role in these processes [55].
Fig. 7 Growth and density of HCA3-expressing CHO-K1 spheroids. CHO-K1 cells stably expressing HCA3 (Eurofins Discover X) and CHO-K1 control
cells were cultured in 96-well ultra-low attachment plates in absence and presence of 3HO and 3HDec (a, b) or after transfection with dyn-2 wt,
K44A or R399A for the indicated time (c). Acquisition of images and analyses of the average spheroid volume was performed every 24 h using a
Celigo Image Cytometer. a Presence of 3HO, but not 3HDec, caused significantly larger HCA3-expressing CHO-K1 spheroids. Total (Hoechst 33342
staining) and dead cell (propidium iodide (PI) staining) pixel counts for spheroids in presence of 3HO and 3HDec were significantly higher than in
absence of HCA3 agonists but the ratio of dead cells to total cells did not differ. b CHO-K1 control cells spheroids were smaller in presence of
3HO or 3HDec. Total (Hoechst 33342 staining) and dead cell (propidium iodide (PI) staining) pixel counts for spheroids were significantly lower in
presence of 3HDec. The ratio of dead cells to total cells did not differ. c The size of HCA3-expressing CHO-K1 spheroids was differentially affected
by the presence of dyn-2 mutants whereas no effect was observed on spheroid growth of CHO-K1 control cells. a-c Data is shown as average
spheroid volume in μm3 (box and whiskers min to max of n = 4 independent experiments, each carried out in 6 replicates). # P ≤ 0.1; * P ≤ 0.05; **
P ≤ 0.01; *** P ≤ 0.001
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Using kinetic DMR analyses, we found that dyna-
sore, a cell-permeable non-competitive inhibitor of
the GTPase activity of dyn, differentially affected sig-
naling of both receptors when comparing their two
respective agonists analyzed here [35]. Dyn is essential
for clathrin-coated vesicle formation in endocytosis,
for transport from the trans-Golgi network, as well as
for ligand uptake through caveolae [36].
Comprehensive analyses of HCA3 and GPR84 down-
stream signaling upon activation with respective se-
lected agonists in the presence of different inhibitors
revealed the involvement of different signaling and
endocytosis components (Fig. 6c).
We found that signaling and internalization of HCA3
upon stimulation with 3HO is dependent on dyn-2, cla-
thrin and β-arrestin-2. In contrast, the stimulation with
Fig. 8 Spheroid density of the HCA3 expressing esophageal squamous cell carcinoma cell line Colo680N affected by HCA3 agonists and dyn
mutants. Colo680N cells express HCA3. a cAMP inhibitory response induced by the HCA3 agonists 3HO and 3HDec was detected and sensitive to
PTX. b Only 25 μM 3HO but not 100 μM 3HDec induced an ERK activation in Colo680N cells. c, d Colo680N cells were cultured in 96-well ultra-
low attachment plates (Nexcelom) in absence and presence of 3HO and 3HDec (c) or after transfection with dyn-2 wt, K44A or R399A (d) for the
indicated time. Acquisition of images and analyses of the average spheroid volume was performed every 24 h using a Celigo Image Cytometer. c
Presence of 3HO, but not 3HDec, caused significantly larger Colo680N spheroids. Hoechst 33342 (total number of cells) and propidium iodide (PI,
dead cells) staining revealed higher pixel counts for spheroids in presence of 3HO but the ratio of dead cells to total cells did not differ. d The
size of Colo680N spheroids was affected by the presence of dyn-2 mutants K44A and R399A. c, d Data is shown as average spheroid volume in
μm3 (box and whiskers min to max of n = 3 independent experiments, each carried out in 8 replicates). # P ≤ 0.1; * P ≤ 0.05; ** P ≤ 0.01;
*** P ≤ 0.001
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3HDec, though also dependent on dyn-2, did not lead to
β-arrestin-2 recruitment and did not require clathrin but
rather caveolin (Fig. 6c). We observed that these differ-
ences in signal transduction influenced cell-cell adhesion
as seen in 3D cell culture models (Figs. 7, 8). Further, we
showed that dyn-2 is not only a crucial component in
HCA3 signaling but also plays an important role for
localization and trafficking of HCA3 which again influ-
enced growth and density of spheroids (Figs. 7, 8). Inter-
estingly, we found that, in contrast to HCA3, the
presence of dynasore caused a sustained signaling of the
evolutionarily closest HCA3 relatives HCA1 and HCA2
(Figure S4). Both, HCA1 and HCA2 exhibit a 22 aa and
24 aa shorter C terminus, respectively and instead of
Trp142 (HCA3) an Arg at this position (HCA1: Arg
130,
HCA2: Arg
142) [25]. These structural differences are pos-
sibly responsible for the differing interaction with dyn-2.
Signaling of GPR84 induced by both agonists, C10 and
3HDec, was also dependent on dyn-2. GPR84 internal-
ization upon activation by C10 was rather dependent on
caveolin than clathrin whereas the opposite was true for
3HDec (Fig. 6c). No internalization inhibitor applied had
an effect on the 3HDec-induced cAMP inhibitory signal-
ing of GPR84 suggesting that this part of its signaling is
independent of internalization (Fig. 6c). Further, barbar-
din, an inhibitor of the tripartite interaction between
arrestin, AP2 and clathrin did not diminish cAMP in-
hibitory signaling or ERK activation by both agonists
and no β-arrestin-2 recruitment was detectable (Figs. 4,
S7D, S7E).
An interaction with dyn has also been shown for the
Gβγ complex thereby modulating its activity and influ-
encing receptor internalization as well as trafficking [50].
We applied the inhibitor gallein, which blocks Gβγ sig-
naling without affecting GPCR-dependent Gα activation
[56]. Activation of both, HCA3 and GPR84, by either
agonist subsequently caused decreased intracellular
cAMP levels through inhibition of adenylyl cyclase,
which was completely lost in the presence of PTX.
Nevertheless, presence of gallein still partially inhibited
the 3HO and 3HDec-induced HCA3-mediated and the
C10-induced GPR84-mediated reduction in intracellular
cAMP levels (Fig. 5) suggesting an involvement of both,
Gαi and Gβγ, being responsible for this signaling out-
come. Golgi-localized Gβγ subunits are also involved in
regulating protein transport from the trans-Golgi Net-
work to the cell surface, which is also true for dyn-2 [36,
57]. Thus, our finding that gallein also negatively af-
fected cell surface expression of HCA3 indicates that, be-
sides dyn-2, Gβγ subunits are involved in HCA3
trafficking (Figure S8). In contrast, gallein had no effect
on the 3HDec-induced GPR84-mediated decrease in
intracellular cAMP levels suggesting that activation only
by C10 but not 3HDec involved Gβγ signaling that
influences intracellular cAMP levels. At last, we found
that GPR84-mediated ERK activation only by 3HDec
persisted upon washout of agonist (Fig. 6b).
As mentioned above, GPR84 functions as an enhancer
of inflammatory signaling in macrophages once inflam-
mation is established whereas a contrary role is sug-
gested for HCA3 [25, 27]. Further, both receptors are co-
expressed in different types of immune cells (Table S5),
and share the agonist 3HDec. Interestingly, our findings
revealed marked differences in the involved signaling
components depending on the activated receptor, indi-
cating that 3HDec will induce distinct signaling events
in cells co-expressing HCA3 and GPR84. Specifically, in
contrast to GPR84, HCA3 signaling upon stimulation
with 3HDec is internalization- as well as Gβγ-
dependent, involves rac1 and ras/rho and does not per-
sist upon agonist-washout (Fig. 6c). Signal integration of
both, HCA3 and GPR84, could potentially play a role for
immune cells to decide whether to induce a pro- or
anti-inflammatory response. That this assumption could
be relevant in a physiological setting is supported by our
recent findings that besides 3HO and D-Phe [26] the
LAB-derived metabolite D-PLA is a highly potent HCA3
agonist [25]. We showed that D-PLA is resorbed from
gastrointestinal tract and acts as a chemoattractant for
monocytes. Our results suggested that fixation of HCA3
provided an evolutionary advantage potentially improv-
ing the tolerance to fermented food through activation
of HCA3 by these LAB-derived exogenous agonists while
simultaneously priming the immune system to avoid in-
fections by pathogenic bacteria [25]. Interestingly, D-
PLA showed a similar activation kinetic like 3HO at
HCA3 whereas D-Phe and L-PLA resembled the 3HDec
response (Figure S9). Furthermore, 3HO originating
from increased lipolysis and D-PLA originating from
LAB-fermented food both activated HCA3 resulting in
β-arrestin-2 recruitment (Figs. 4b, S10B). This differen-
tial signaling outcome upon HCA3 activation potentially
constitutes a mechanism enabling immune cells to dif-
ferentiate between endogenous (3HO), non-pathogenic
compounds (D-PLA) versus compounds originating
from e.g. pathogenic bacteria (3HDec from LPS or D-
Phe). This is in line with the fact that pro-inflammatory
signaling induced by activation of GPR84 by e.g. 3HDec
will be appropriate to control infections.
Besides the different signaling outcome of HCA3 and
GPR84 in response to the same agonist, our study also
highlights differences in the signaling components and
endocytic pathways induced by different agonists at the
same receptor, indicating biased agonism at both HCA3
and GPR84. We are aware that biased agonism is
dependent on cell type but basic understanding of recep-
tor function is still deducible from signal transduction
analyses in heterologous expression systems. The
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observed differences in endocytosis and signaling poten-
tially result in distinct physiological responses in cells
endogenously expressing HCA3 and/or GPR84, like e.g.
cell adhesion and migration. In case of HCA3, this no-
tion is supported by the observation that 3HO but not
3HDec affected growth and density of HCA3-expressing
spheroids. In summary, understanding the distinct ef-
fects of different agonists acting on both receptors,
HCA3 and GPR84, poses a fundamental basis to
recognize their function in immune cells.
Conclusions
A better understanding of the components involved in
signal transduction of HCA3, GPR84 and their down-
stream effectors in immune cells will be mandatory to
assess their potential as drug targets. This is especially
crucial since recent clinical trials have e.g. explored the
potential of ligands blocking GPR84 function for the
treatment of ulcerative colitis [58]. Additionally, one re-
cent study illustrated that care has to be taken with re-
gard to on- and off-target effects of different orthosteric
and allosteric activators of GPR84 [9]. Our present study
adds to these findings, highlighting differences of natur-
ally occurring agonists not only activating GPR84 but
also HCA3, a receptor often co-occurring with GPR84
and also found overexpressed in patients with ulcerative
colitis. Future studies will have to focus on endogenously
HCA3- and GPR84- expressing cells of the innate im-
mune system, including neutrophils, monocytes and
macrophages, to unravel how the signal of different ago-
nists is integrated, thereby modulating pathways leading
to a pro−/anti-inflammatory response, migration, phago-
cytosis and ROS production.
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Metabolite-sensing G protein-coupled receptors (msGPCRs) are GPCRs that are activated by 
metabolites originating from various sources. The field of msGPCRs exists since about 20 years 
ago and since then numerous msGPCRs like e.g. the free fatty acid receptors (FFARs) and the 
hydroxycarboxylic acid receptors (HCAs) have been identified. In addition, many of the 
receptors that so far remain orphan may also be activated by metabolites of endogenous or 
exogenous origin. Several of the known msGPCRs are expressed on immune cells and 
adipocytes as well as the gut epithelium and metabolic tissues like the pancreas. The metabolites 
activating msGPCRs range from fatty acids and their hydroxylated derivatives to ketone bodies, 
citric acid cycle intermediates and products of tryptophan metabolism. Some of these known 
agonists are produced endogenously like succinate and 3-hydroxyoctanoic acid, while others are 
of exogenous origin. Examples are FFAR4-activating ω-3 and ω-6 fatty acids, which solely 




for agonists of exogenous origin. This includes e.g. short-chain fatty acids (SCFAs) like acetate, 
propionate and butyrate as well as products of amino acid metabolism. The expression profile 
and the nature of their agonists link msGPCRs to functions in the regulation of metabolic 
processes and immune cell responses.  
Both receptors investigated in my thesis project, hydroxycarboxylic acid receptor 3 (HCA3) and 
GPR84, are msGPCRs highly expressed on cells of the innate immune system such as 
neutrophils, monocytes, and macrophages. HCA3 is a member of the HCA family consisting of 
three receptors, which show high sequence homology. Especially HCA2 and HCA3 only differ in 
a few positions resulting in an amino acid sequence differing in 17 amino acids and the extended 
C-terminus of HCA3. While HCA1 and HCA2 are present in the genome of all mammals, HCA3 
is only present in higher primates such as chimpanzee, orangutan, and human. As a result, there 
is a lack of accessible animal models and the receptor is still insufficiently studied. 
3-hydroxyoctanoic acid (3HO), 3-hydroxydecanoic acid (3HDec) and aromatic D-amino acids 
D-phenylalanine (D-Phe) and D-tryptophan (D-Trp) are previously reported agonists of HCA3 
with 3HO being its endogenous agonist. Regarding its physiological function, it is known that 
the receptor is involved in a negative feedback loop in the regulation of lipolysis and fatty acid 
oxidation under prolonged fasting conditions in adipocytes. Further, it has been shown that 
aromatic D-amino acids induce chemotaxis in human neutrophils.  
GPR84 is a receptor for medium chain fatty acids (MCFAs) with a chain length of 9 to 14 carbon 
atoms (C9 - C14) and their hydroxylated derivatives. Thus, GPR84 and HCA3 share 3HDec as a 
common agonist. Further, both receptors couple to Gαi proteins resulting in the inhibition of 
adenylyl cyclase and subsequent decrease of intracellular cyclic AMP (cAMP) levels, and induce 
the phosphorylation and activation of extracellular signal regulated kinase1/2 (ERK1/2). As 
opposed to HCA3, GPR84 is present in the genome of most mammals and various studies have 
linked GPR84 to pro-inflammatory functions and processes like phagocytosis, chemotaxis and 
upregulation of pro-inflammatory cytokine release. Most of these studies on GPR84 were 
performed using surrogate agonists.  
Because HCA3 is still poorly understood, the aim of my project was to shed some light on its 
function by evolutionary and functional analyses of HCA3 orthologs. Moreover, detailed 
analyses of its signal transduction and components involved in receptor-mediated downstream 
signaling events were performed as part of the present dissertation. Since HCA3 and GPR84 
share at least one agonist and are co-expressed in different types of immune cells, we studied 
signaling of both receptors simultaneously.  
Our functional analyses of human and great ape HCA3 orthologs using cAMP inhibition assays 




By further functionally analyzing the primate HCA3 orthologs, we found both aromatic D-amino 
acids, D-Phe and D-Trp, to activate human HCA3 with the highest potency. Although D-Phe and 
D-Trp were previously described to induce HCA3-mediated chemotaxis in neutrophils a link to 
where the two D-amino acids would originate from in sufficiently high concentrations in a 
physiological context was missing. After extensive review of literature, we found that some 
intestinal bacteria and bacteria used to ferment food and beverages produce and secrete D-amino 
acids. This led us to investigate whether other structurally related D-amino acid metabolites 
produced by bacteria also activate HCA3. These investigations resulted in the discovery of lactic 
acid bacteria (LAB)-derived metabolites as highly potent agonists of HCA3. We tested both the 
Phe-metabolites D-phenyllactic acid (D-PLA) and L-PLA as well as the racemic mixture of the 
Trp-metabolite indole-3-lactic acid (ILA). All three compounds specifically induced activation 
of HCA3, but we found D-PLA to be a 35-fold more potent agonist than the L-enantiomer. 
Further, D-PLA proved to be 10-fold more potent than 3HO and 240-fold more potent than 
D-Phe.  
Since D-PLA is known to be present in LAB-fermented foods such as Sauerkraut, we 
investigated whether D-PLA is absorbed and enters the blood circulation after oral ingestion of 
100 mg D-PLA or Sauerkraut (5-6 g per kg body weight), respectively. Both, ingestion of the 
pure compound and of Sauerkraut resulted in a significant increase of D-PLA in the plasma post-
prandial resulting in concentrations sufficiently high to activate HCA3.  
Finally, using trans-well migration assays, we tested the chemotactic potential of the newly 
identified HCA3 agonists and detected significant induction of chemotactic migration of primary 
human monocytes in response to all three LAB-derived metabolites.  
To examine HCA3 signaling and the involved components in more detail, we used several 
inhibitors of internalization and signaling components. The goal was to examine whether there 
are differences in the activation of signaling pathways, recruitment of signaling components, 
internalization behavior and endocytic routes of HCA3 and GPR84 in response to 3HO vs 3HDec 
and decanoic acid (C10) vs 3HDec respectively.  
Initial analyses of the signaling kinetics of the two receptors, using dynamic mass redistribution 
(DMR) measurements, indicated differences between the two respective agonists for both HCA3 
and GPR84. DMR measurements allow for a time-resolved recording of the activated signaling 
cascades, independent of the activated pathways. We found that HCA3 signaling induced by 
3HO reached its maximum more rapidly than 3HDec-induced signaling, while GPR84 signaling 
in response to 3HDec declined faster than that in response to C10. Additional use of pertussis 
toxin to inhibit Gαi proteins and dynasore to block dynamin-2 function revealed that signaling of 




activation, but differentially dependent on dynamin-2 function suggesting differences in 
desensitization and internalization mechanisms.  
Using cAMP inhibition and ERK1/2 activation assays, we further investigated the role of 
internalization for HCA3 and GPR84 signal transduction. Interestingly, ERK1/2 activation 
downstream of both receptors was strongly reduced when internalization was inhibited, while 
cAMP inhibitory signaling of HCA3 induced by both 3HO and 3HDec and GPR84 signaling 
induced by C10 were significantly reduced by blocking dynamin-2 function but not 
internalization in general. 3HDec-induced cAMP inhibition downstream of GPR84 was 
completely insensitive to inhibition of both.  
Further experiments using dominant negative dynamin-2 mutants verified dependence of HCA3-
mediated Gαi and ERK1/2 signaling on dynamin-2 function. Moreover, qualitative analysis of 
images of human embryonic kidney cells (HEK293T) expressing mRuby-tagged receptors and 
either wild-type or mutant YFP-tagged dynamin-2 revealed that subcellular distribution of HCA3 
but not GPR84 is altered when dynamin-2 function is impaired.  
Interestingly, analysis of β-arrestin 2 recruitment by a luminescence-based assay (DiscoverX 
PathHunter) and imaging of HEK293T cells expressing mRuby-tagged receptor and YFP-tagged 
β-arrestin 2, showed that only 3HO- but not 3HDec-induced activation of HCA3 leads to 
recruitment of β-arrestin 2 and subsequent co-localization in intracellular vesicles. GPR84 data 
suggests that the receptor does not interact with β-arrestin 2 at all.  
Besides the Gα subunit, the closely associated Gβγ subunits of the heterotrimeric G protein also 
mediate downstream signaling of GPCRs. Thus, we analyzed the influence of Gβγ inhibition on 
cAMP inhibitory signaling and activation of ERK1/2. GPR84-mediated cAMP inhibitory 
signaling in response to 3HDec was completely insensitive to Gβγ inhibition, while C10-induced 
GPR84- and HCA3-mediated signaling in response to both agonists was reduced. Additionally, 
we showed that GPR84 exhibits sustained ERK1/2 activation in response to the agonist 3HDec, 
but not C10. Such an effect was not observed for HCA3.  
In addition, we used spheroid cell culture models to assess potential biological consequences and 
differences when HCA3 is activated by different agonists. To do so, we analyzed the growth and 
density of spheroids of HCA3-expressing cells stimulated with receptor agonists. These 
experiments revealed that activation of HCA3 in response to 3HO significantly changes spheroid 
density, resulting in less dense spheroids and implicating a function for HCA3 in the regulation 
of cell-cell adhesion.  
Finally, we also analyzed HCA3 signaling kinetics and β-arrestin 2 recruitment in response to the 
newly identified agonists D-PLA and L-PLA and the previously known agonist D-Phe. We 




PLA appears to be similar to 3HO. This was further supported by the fact that D-PLA also 
induced β-arrestin 2 recruitment, while L-PLA and D-Phe did not.  
Taken together, these findings advanced our understanding of HCA3 and GPR84. The work 
provides evidence that HCA3 evolved as a signaling system to communicate uptake of fermented 
food (together with fermenting bacteria) to the immune system. Our data in combination with 
literature reporting positive, anti-inflammatory properties of D-PLA and LAB in general 
suggests that at least some of the described positive effects are mediated by HCA3. 
Furthermore, we showed for the first time biased signaling of these two receptors in response to 
their natural agonists. Our work increases the knowledge about specific signaling components 
involved in downstream signaling of the respective receptor in response to the different agonists, 
potentially linking e.g. activation of HCA3 by 3HO and D-PLA, but not 3HDec and D-Phe, to 
the inhibition of pro-inflammatory cytokine release through β-arrestin 2 dependent mechanisms. 
Moreover, 3HDec-induced signaling downstream of GPR84 is very different from that 
downstream of HCA3. This suggests that 3HDec also triggers different physiological responses 
in immune cells depending on its local concentration and the expression levels of the two 
receptors. However, these findings still need to be validated in cells of innate immunity like 
neutrophils and macrophages that endogenously express both receptors. At last, the physiological 
consequences such as increased ROS-production, pro-/anti-inflammatory cytokine release, 
migration, and phagocytosis need to be addressed in future studies to get a better understanding 
of the function as well as interplay of HCA3 and GPR84 in innate immunity and their suitability 
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Supplementary Table S5 
Testing of PLA-containing human urine and plasma samples on transiently with human 
HCA2 or HCA3 or empty vector transfected CHO-K1 cells 



































  [nM]             
urine (80 min containing 285 µM PLA)  
1:20,480 13.9 82.3 ± 3.3 91.8 ± 3.6 96.4 ± 5.3 92.1 ± 6.3 97.7 ± 4.2 100.6 ± 2.7 
1:10,240 27.8 99.3 ± 5.5 84.8 ± 4.1 96.9 ± 5.0 92.4 ± 8.9 95.3 ± 2.4 95.4 ± 0.5 
1:5,120 55.7 95.6 ± 8.0 81.1 ± 3.5 95.1 ± 4.4 93.5 ± 4.6 92.3 ± 2.8 97.9 ± 3.6 
1:2,560  111.3 104.9 ± 1.7 68.8 ± 1.8 98.4 ± 4.0 91.1 ± 8.6 87.9 ± 0.7 96.7 ± 3.5 
1:1,280 222.7 93.3 ± 1.4 65.2 ± 0.6 91.7 ± 1.5 88.7 ± 4.8 86.4 ± 0.5 96.8 ± 6.5 
1:640 445.3 92.2 ± 5.9 56.0 ± 2.4 86.8 ± 3.3 82.1 ± 2.0 85.4 ± 3.8 99.7 ± 6.3 
1:320 890.6 85.5 ± 2.7 48.4 ± 3.6 80.5 ± 2.3 87.7 ± 5.2 86.4 ± 2.9 93.4 ± 5.4 
1:160 1781.3 72.1 ± 4.5 43.3 ± 4.0 74.1 ± 2.9 82.3 ± 5.9 76.5 ± 5.9 89.0 ± 9.6 
1:80 3562.5 54.8 ± 2.3 37.4 ± 2.8 66.6 ± 2.7 83.3 ± 9.53 75.7 ± 7.0 84.3 ± 9.5 
urine (340 min containing 33 µM PLA)  
1:1,280 25.8 91.2 ± 6.8 87.4 ± 8.8 81.7 ± 2.5 n.d. n.d. n.d. 
1:640 51.6 87.1 ± 0.8 74.5 ± 2.0 80.1 ± 4.7 n.d. n.d. n.d. 
1:320 103.1 75.5 ± 2.4 58.7 ± 1.9 71.2 ± 2.0 n.d. n.d. n.d. 
1:160 206.3 62.2 ± 4.0 52.8 ± 0.1 60.5 ± 4.5 n.d. n.d. n.d. 
urine (510 min containing 3.4 µM PLA)  
1:1,280 2.7 94.6 ± 5.0 85.9 ± 4.2 82.4 ± 9.3 n.d. n.d. n.d. 
1:640 5.4 87.4 ± 0.5 77.3 ± 1.1 70.6 ± 2.1 n.d. n.d. n.d. 
1:320 10.8 85.0 ± 5.70 75.9 ± 7.0 76.1 ± 5.2 n.d. n.d. n.d. 
1:160 21.5 76.9 ± 3.0 67.5 ± 7.5 72.0 ± 0.7 n.d. n.d. n.d. 
plasma (30 min containing 23 µM PLA)  
1:20,480 1.1 96.2 ± 5.9 96.0 ± 0.3 99.3 ± 0.9 106.3 ± 3.0 102.5 ± 2.4 101.4 ± 0.1 
1:10,240 2.2 102.9 ± 2.8 90.2 ± 2.5 101.1 ± 2.7 101.5 ± 2.5 99.5 ± 4.1 95.7 ± 0.5 
1:5,120 4.5 97.8 ± 0.1 84.4 ± 3.9 101.0 ± 0.5 97.6 ± 3.1 94.9 ± 0.1 91.0 ± 4.8 
1:2,560  9.0 104.4 ± 5.1 88.0 ± 1.9 109.1 ± 5.6 102.0 ± 3.2 96.5 ± 4.0 98.6± 4.5 
1:1,280 18.0 102.0 ± 9.3 72.8 ± 2.5 102.5 ± 1.3 99.4 ± 4.5 94.5 ± 2.3 95.7 ± 0.2 
1:640 35.9 92.0 ± 3.1 67.1 ± 1.8 93.2 ± 1.6 100.2 ± 1.7 90.9 ± 0.5 97.5 ± 2.3 
1:320 71.9 79.5 ± 1.2 57.6 ± 6.8 85.7 ± 3.5 98.9 ± 3.1 95.7 ± 1.3 101.2 ± 2.8 
1:160 143.8 67.4 ± 4.7 47.1 ± 3.5 73.0 ± 0.6 95.5 ± 4.4 91.7 ± 6.0 98.0 ± 4.3 
1:80 287.5 47.8 ± 4.1 33.3 ± 0.9 58.9 ± 3.6 88.0 ± 5.8 87.1 ± 4.3 95.8 ± 0.3 
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plasma (0 min containing 0.42 µM PLA)  
1:320 1.3 75.1 ± 4.7 90.4 ± 1.0 91.0 ± 0.1 n.d. n.d. n.d. 
1:160 2.6 60.4 ± 6.8 70.1 ± 0.6 69.8 ± 1.8 n.d. n.d. n.d. 
plasma (60 min containing 8.9 µM PLA)  
1:320 27.8 80.1 ± 1.2 73.5 ± 5.4 83.9 ± 6.2 n.d. n.d. n.d. 
1:160 55.6 75.4 ± 0.7 59.3 ± 3.2 67.4 ± 3.7 n.d. n.d. n.d. 
plasma (120 min containing 2.9 µM PLA)  
1:320 9.1 76.8 ± 0.8 77.6 ± 6.3 82.4 ± 4.7 n.d. n.d. n.d. 
1:160 18.1 67.7 ± 4.2 61.5 ± 5.9 66.4 ± 4.7 n.d. n.d. n.d. 
plasma (180 min containing 0.8 µM PLA)  
1:320 2.5 78.1 ± 5.1 80.4 ± 2.3 88.6 ± 7.9 n.d. n.d. n.d. 
1:160 5.0 57.0 ± 2.7 70.6 ± 5.5 70.6 ± 2.5 n.d. n.d. n.d. 
plasma (240 min containing 0.6 µM PLA)  
1:320 1.9 66.2 ± 5.9 75.4 ± 3.5 77.7 ± 4.4 n.d. n.d. n.d. 
1:160 3.8 48.7 ± 1.3 57.1± 2.1 51.6 ± 1.1 n.d. n.d. n.d. 
plasma (300 min containing 0.35 µM PLA)  
1:320 1.1 70.8 ± 8.6 79.8 ± 5.5 85.7 ± 1.3 n.d. n.d. n.d. 
1:160 2.2 55.7 ± 0.8 63.8 ± 2.7 67.1 ± 4.5 n.d. n.d. n.d. 
plasma (360 min containing 0.29 µM PLA)  
1:320 0.9 77.8 ± 4.7 79.5 ± 6.7 85.7 ± 6.7 n.d. n.d. n.d. 
1:160 1.8 62.9 ± 3.9 65.2 ± 3.3 67.4 ± 1.1 n.d. n.d. n.d. 
plasma (420 min containing 0.31 µM PLA)  
1:320 1.0 83.8 ± 3.2 89.2 ± 7.2 95.1 ± 3.7 n.d. n.d. n.d. 
1:160 1.9 60.1 ± 0.8 72.4 ± 3.0 69.6 ± 1.3 n.d. n.d. n.d. 
                
Sauerkraut experiment 
plasma (before Sauerkraut containing 0.3 µM PLA)  
1:160 2.1 64.7 ± 6.5 58.9 ± 2.5 64.1 ± 5.9 110.2 ± 0.7 111.3 ± 4.3 104.4 ± 4.1 
1:320 1.1 86.2 ± 2.6 73.5 ± 1.1 87.7 ± 4.2 113.0 ± 3.7 104.7 ± 3.2 103.0 ± 3.6 
plasma (2h postprandial containing 1.4 µM PLA)  
1:160 8.8 67.8 ± 4.4 59.2 ± 3.6 86.6 ± 3.2 100.2 ± 2.8 107.1 ± 0.4 103.7 ± 4.9 
1:320 4.4 90.8 ± 6.1 74.7 ± 3.8 98.5 ± 3.7 103.1 ± 5.9 103.5 ± 2.2 105.1 ± 5.2 
urine (before Sauerkraut containing 1.8 µM PLA) 
1:160 11.5 56.4 ± 3.3 61.4 ± 3.7 79.0 ± 5.5 91.7 ± 3.5 91.9± 2.9 98.0 ± 2.8 
1:320 5.8 78.3 ± 1.7 69.3 ± 4.6 88.1 ± 5.0 95.4 ± 2.0 93.3 ± 1.5 93.0± 2.3 
urine (230 min postprandial containing 14.3 µM PLA) 
1:160 89.2 71.1 ± 5.3 50.5 ± 2.9 74.5 ± 0.7 95.3 ± 4.6 93.4± 4.9 101.8 ± 3.9 
1:320 44.6 89.0 ± 4.9 62.2 ± 3.3 83.5 ± 4.2 95.4 ± 0.3 92.0 ± 3.5 94.9 ± 1.2 
urine (540 min postprandial containing 6.3 µM PLA) 
1:160 39.2 77.8 ± 0.4 53.9 ± 1.7 80.8 ± 4.9 90.8 ± 2.2 95.0 ± 2.8 88.6 ± 2.6 
1:320 19.6 89.5 ± 2.1 62.8 ± 5.9 82.1 ± 6.4 98.7 ± 0.7 92.6 ± 3.1 88.5 ± 3.4 
urine (1080 min postprandial containing 3.1 µM PLA) 
1:160 19.2 73.8 ± 4.6 63.0 ± 3.2 85.0 ± 1.6 101.6 ± 4.7 108.4 ± 2.0 105.1 ± 2.3 
1:320 9.6 83.4 ± 2.1 73.8 ± 2.0 88.7 ± 1.6 102.1 ± 1.5 101.6 ± 3.9 100.9 ± 3.7 
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urine (1230 min postprandial containing 1.8 µM PLA) 
1:160 11.6 63.0 ± 4.5 63.6 ± 3.1 84.2 ± 0.6 n.d. n.d. n.d. 
1:320 5.8 79.4 ± 3.3 73.5 ± 2.3 87.3 ± 0.3 n.d. n.d. n.d. 
urine (180 min postprandial containing 5.0 µM PLA) 
1:160 31.4 81.1 ± 5.6 60.1 ± 2.4 90.4 ± 5.7 n.d. n.d. n.d. 
1:320 15.7 87.0 ± 4.6 69.4 ± 2.2 92.8 ± 5.3 n.d. n.d. n.d. 
urine (390 min postprandial containing 1.9 µM PLA) 
1:160 11.8 73.1 ± 4.9 59.2 ± 0.6 80.1 ± 6.0 n.d. n.d. n.d. 
1:320 5.9 78.1 ± 3.4 70.7 ± 1.6 86.3 ± 0.3 n.d. n.d. n.d. 
urine (540 min postprandial containing 1.4 µM PLA) 
1:160 8.6 69.6 ± 3.3 64.2 ± 2.0 79.0± 3.9 n.d. n.d. n.d. 
1:320 4.3 85.6 ± 1.6 71.1 ± 2.8 84.1 ± 4.4 n.d. n.d. n.d. 
urine (1425 min postprandial containing 3.1 µM PLA) 
1:160 19.6 77.1 ± 5.0 70.6 ± 2.5 87.6 ± 4.1 n.d. n.d. n.d. 
1:320 9.8 82.5 ± 2.8 75.6 ± 1.9 93.7 ± 0.9 n.d. n.d. n.d. 
urine (360 min postprandial containing 10.3 µM PLA) 
1:160 64.3 76.7 ± 2.0 53.0 ± 1.8 82.6 ± 3.4 88.6 ± 0.6 93.1 ± 2.4 93.7 ± 2.9 
1:320 32.2 82.6 ± 5.2 64.1 ± 1.9 91.7 ± 4.0 91.1 ± 2.7 96.4 ± 1.2 98.4 ± 2.5 
urine (after sauerkraut containing 1.5 µM PLA) 
1:160 9 68.7 ± 2.2 72.5 ± 4.5 90.8 ± 4.2 n.d. n.d. n.d. 
1:320 4.5 84.7 ± 1.1 77.8 ± 4.4 93.4 ± 5.9 n.d. n.d. n.d. 
 
CHO-K1 cells were transfected with receptor constructs and cAMP accumulation was determined with the 
ALPHAScreen™ technology (see Material and Methods). Data is given as mean ± SEM of three independent 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S7 
TPM values as downloaded from https://www.ebi.ac.uk/gxa/home [8] 
 
organism part/tissue/cell type Expression Atlas HCAR1 HCAR2 HCAR3 
blood E-MTAB-5214 0.1 97 42 
neutrophil, mature E-MTAB-3827 0.9 85 103 
monocyte, CD14-positive, CD16-negative classical  E-MTAB-3827 0.4 72 82 
neutrophil, segmented of bone marrow E-MTAB-3827 0.6 53 58 
dendritic cell, conventional  E-MTAB-3827 0.3 5 6 
macrophage, alternatively activated  E-MTAB-3827 1 2 6 
macrophage, inflammatory  E-MTAB-3827 0.1 3 5 
macrophage E-MTAB-3827 0.3 1 3 
thymocyte, CD4-positive, alpha-beta  E-MTAB-3827 9 2 2 
eosinophil, mature  E-MTAB-3827 0.2 1 2 
granulocyte monocyte progenitor cell E-MTAB-3819 0.8 0.1 2 
hematopoietic stem cell E-MTAB-3819 1 3 1 
megakaryocyte cell, CD34-, CD41+, CD42+  E-MTAB-3819 0.7 1 1 
T cell, CD8-positive, alpha-beta E-MTAB-3827 0.2 0.7 0.7 
metamyelocyte, neutrophilic  E-MTAB-3827 0.3 0.7 0.5 
erythroblast E-MTAB-3827 0.2 0.4 0.2 
thymocyte, CD3-positive, CD4-positive, CD8-positive, 
double positive  E-MTAB-3827 1 0.1 0.1 
B cell, CD38-negative naive  E-MTAB-3827 0.4 - 0.1 
erythroblast E-MTAB-3819 0.2 - 0.1 
leukocyte E-MTAB-513 0.5 36 11 
lymphocyte, EBV-transformed  E-MTAB-5214 0.3 0.8 2 
vermiform appendix E-MTAB-2836 0.2 43 24 
bone marrow E-MTAB-2836 - 36 20 
spleen E-MTAB-2836 6 58 23 
spleen E-MTAB-4344 5 12 15 
spleen E-MTAB-5214 5 22 7 
tonsil E-MTAB-2836 0.2 25 14 
lymph node  E-MTAB-513 1 6 2 
lymph node E-MTAB-2836 0.3 1 0.9 
thymus E-MTAB-3871 0.4 1 0.2 
skin E-MTAB-2836 0.5 48 21 
skin E-MTAB-5214 0.4 34 5 
skin E-MTAB-5214 0.4 31 4 
urinary bladder E-MTAB-2836 5 15 13 
urinary bladder E-MTAB-5214 1 3 0.6 
lung E-MTAB-4344 1 19 9 
lung E-MTAB-513 1 32 7 
lung E-MTAB-2836 1 35 6 
lung E-MTAB-5214 0.5 9 2 
adipose tissue E-MTAB-4344 7 17 5 
adipose tissue E-MTAB-2836 17 39 3 
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adipose tissue, subcutaneous E-MTAB-5214 3 11 0.9 
adipose tissue E-MTAB-513 6 9 0.8 
breast E-MTAB-513 26 39 3 
breast E-MTAB-5214 11 8 1 
vagina E-MTAB-5214 0.8 21 1 
ectocervix E-MTAB-5214 2 0.7 0.1 
endocervix E-MTAB-5214 3 0.3 0.1 
endometrium E-MTAB-2836 1 0.8 - 
ovary E-MTAB-5214 0.6 0.2 - 
ovary E-MTAB-4344 2 0.3 0.3 
ovary E-MTAB-513 4 0.1 0.1 
ovary E-MTAB-2836 1 - - 
fallopian tube E-MTAB-5214 2 0.5 0.2 
fallopian tube E-MTAB-2836 8 2 0.8 
placenta E-MTAB-3871 0.6 0.3 0.1 
placenta E-MTAB-2836 3 10 2 
prostate gland E-MTAB-5214 1 3 0.3 
prostate gland E-MTAB-513 7 9 3 
prostate gland E-MTAB-2836 5 3 0.7 
testis E-MTAB-5214 2 4 0.1 
testis E-MTAB-4344 2 4 0.3 
testis E-MTAB-3716 2 4 0.4 
testis E-MTAB-513 3 2 0.1 
testis E-MTAB-2836 2 5 0.3 
salivary gland E-MTAB-5214 3 13 0.5 
salivary gland E-MTAB-2836 7 3 0.6 
esophagus E-MTAB-2836 0.2 61 18 
esophagus mucosa E-MTAB-5214 0.3 45 5 
stomach E-MTAB-5214 2 0.7 0.1 
stomach E-MTAB-3871 4 - - 
stomach E-MTAB-2836 3 1 0.3 
small intestine E-MTAB-3871 3 1 0.3 
small intestine E-MTAB-2836 0.1 2 0.4 
duodenum E-MTAB-2836 0.2 2 0.3 
large intestine E-MTAB-3871 3 0.9 0.1 
colon E-MTAB-513 2 0.8 - 
colon, transverse E-MTAB-5214 0.2 0.4 - 
gall bladder E-MTAB-2836 0.3 3 1 
greater omentum E-MTAB-5214 6 13 1 
kidney, cortex E-MTAB-5214 1 2 0.4 
kidney E-MTAB-4344 1 - - 
kidney E-MTAB-3716 1 4 0.3 
kidney E-MTAB-513 3 1 0.4 
kidney E-MTAB-2836 2 1 0.3 
kidney, left E-MTAB-3871 8 0.4 0.2 
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kidney, right E-MTAB-3871 8 0.6 0.3 
kidney, renal cortex E-MTAB-3871 7 0.3 0.2 
kidney, renal cortex left E-MTAB-3871 7 0.5 0.3 
kidney, renal cortex, right E-MTAB-3871 5 0.2 0.2 
kidney, renal pelvis E-MTAB-3871 7 0.3 0.1 
kidney, renal pelvis left E-MTAB-3871 7 0.6 0.2 
kidney, renal pelvis, right E-MTAB-3871 6 0.3 0.3 
thyroid gland E-MTAB-5214 3 0.6 0.2 
thyroid gland E-MTAB-513 3 0.4 0.2 
thyroid gland E-MTAB-2836 5 0.3 0.2 
brain E-MTAB-513 0.9 0.1 - 
brain E-MTAB-4344 2 - 0.1 
temporal lobe E-MTAB-3716 0.3 0.6 1 
pituitary gland E-MTAB-5214 0.8 0.4 0.1 
 
Experiments included: E-MTAB-2836 (Raw Data Provider: The Human Protein Atlas), E-MTAB-5214 (The 
Genotype-Tissue Expression (GTEx) pilot analysis) [49] , E-MTAB-513 (RNA-Seq of human individual tissues 
and mixture of 16 tissues), E-MTAB-4344 (The ENCODE (Raw Data Provider: Encyclopedia of DNA Elements) 
Consortium), E-MTAB-3827 and E-MTAB-3819 (These studies makes use of data generated by the Blueprint 
Consortium. A full list of the investigators who contributed to the generation of the data is available 
fromwww.blueprint-epigenome.eu. Funding for the project was provided by the European Union's Seventh 
Framework Programme (FP7/2007-2013) under grant agreement no 282510 – BLUEPRINT.), E-MTAB-3871 
(Integrative analysis of 111 reference human epigenomes.) [50], E-MTAB-3716 (The evolution of gene 







Supplementary Table S8 
Sources of genomic DNA used for HCAR amplification 
 
species   source 
Gorilla gorilla Western Gorilla 
Dr T. Haaf, MPI Molecular Genetics Berlin, Germany;  
Dr L. Vigilant, MPI, Leipzig, Germany 
Homo sapiens human 
Dr M. Stoneking, MPI, Leipzig, Germany;  
D. Sere, MPI, Leipzig, Germany 
Mus musculus house mouse Dr A. Orth, University of Montpellier, France 
Nomascus leucogenys white-cheeked Gibbon Dipl. Biol. C. Roos, Primate Center Göttingen, Germany 
Pan paniscus bonobo 
Dr W. Enard, MPI, Leipzig, Germany;  
Dr L. Vigilant, MPI, Leipzig, Germany 
Pan troglodytes chimpanzee 
Dr T. Haaf, MPI Molecular Genetics Berlin, Germany;  
Dr W. Enard, MPI, Leipzig, Germany 
Pongo pygmaeus Orangutan 
Dr M. Rocchi, University of Bari, Italy;  
Dr W. Enard, MPI, Leipzig, Germany 
Symphalangus syndactylus siamang 
Dipl. Biol. C. Roos, Primate Center Göttingen, Germany; 





Supplementary Table S9 
Primers used for HCA1, HCA2 and HCA3 ortholog amplification, sequencing and 
introduction of epitope tags 
 
ID sequence (5´- 3´) purpose 
789 gtgcaaatcaaagaactgctcctc pcDps forward (amplification/sequencing) 
790 cctggttctttccgcctcagaag pcDps reverse (amplification/sequencing) 
2291 cgccgcactagttcacttatcgtcatcgtccttatagtc FLAG-uni-Spe I_AS 
2292 cgccgggtacctcactcacttatcgtcatcgtccttatagtc FLAg-uni-KpnI_AS 
2285 cgcgaattccccaccatgtacccctacgacgtccccgactacgcc HA-uni-Kozak-Eco RI_S 
2289 cgccccgggcccaccatgtacccctacgacgtccccgactacgcc HA-uni-Kozak-Xma I_S 
250 CTGTTCATGTAGGTGAAGCTGAG GPR81-AS-apes-830 
251 TTGGCCGACTCCATGAT GPR81-AS-apes-540 
252 CCGACAGAATGAGAAGGATGC GPR81-AS-apes-3UTR 
253 ACTCACTTCAATCAACTGGAACCT GPR81-AS-apes-3UTR2 
254 GCGACCCGGTTCATCAT GPR81-S-apes-660 
255 CACCACGCGGTGAACACTAT GPR81-S-apes-370 
256 GGTGAGTGCTAACGCTCAGAT GPR81-S-apes-5UTR 
257 TTTCCTGGCTGAAGTTTCTCTTC GPR81-S-apes-5UTR2 
258 TCCCTGAGTCCATTTCTGCTAA GPR109-AS-apes-3UTR2 
259 CTTGCAACCAGTCTCCCACT GPR109-AS-apes-3UTR 
260 AAGAGATGATGGCTGCTGTCC GPR109-AS-apes-440 
261 ATGTAGGTGAAGCTGAGAGTGATAAAG GPR109-AS-apes-820 
262 GACTGGAAGTTTGGGGACATC GPR109-S-apes-280 
263 CGCTYCATCGGACYMMCT GPR109-S-apes-5UTR 
264 AGCCTGCGGCAGAGACA GPR109-S-apes-640 
265 CACTCATGAATCSGCACCA GPR109-S-apes-ATG 
266 GCTGATGCTCTTCATGTTGG GPR109a-S-apes-310 
267 TTCTGGATCGGCATCTTCTTCT GPR109a-AS-apes-500 
268 GGCTGGTGCTCTTCATGTTT GPR109b-S-apes-310 
269 CAGTGCCATTCTGGATCAGC GPR109b-AS-apes-500 
270 CAACACCCTGACATGACATAAAG GPR109-S-apes-5UTR2 
271 ACACACTTGGAGATCCCACTG mouse-GPR81-AS-wo-TGA 
272 GACAACGGGTCGTGCTGT mouse-GPR81-S-wo-ATG 
273 ACGAGATGTGGAAGCCAGATAAG mouse-GPR109-AS-wo-TGA 
274 AGCAAGTCAGACCATTTTCTAGTGATA mouse-GPR109-S-wo-ATG 
275 ccccgactacgccGACAACGGGTCGTGCTGT mouse-GPR81-S-HA-adaptor 
276 cgtcatcgtccttatagtcACACACTTGGAGATCCC mouse-GPR81-AS-FLAG-adaptor 
277 ccccgactacgccAGCAAGTCAGACCATTTTC mouse-GPR109-S-HA-adaptor 
278 cgtcatcgtccttatagtcACGAGATGTGGAAGCCA mouse-GPR109-AS-FLAG-adaptor 
279 ccccgactacgccTACAACGGrTCGTGCTG GPR81S-apes-HA-adaptor 
280 cgtcatcgtccttatagtcGTGCCACTCAACAATGT GPR81AS-apes-wo-gibbon-orang-FLAG-adaptor 
281 cgtcatcgtccttatagtcTTTGTCACACTGATGCC GPR81AS-orang-FLAG-adaptor 
282 cgtcatcgtccttatagtcCTCAACAATGTGGGGAT GPR81AS-gibbon-FLAG-adaptor 
283 ccccgactacgccAATCGGCACCATCTGCAG GPR109-S-apes-wo-orang109b-HA-adaptor 
284 ccccgactacgccAATCCGCACCATCCG GPR109b-S-orang-HA-adaptor 
285 cgtcatcgtccttatagtcAGGAGAGGTTGGGCC GPR109-AS-apes-wo-orang109ab-FLAG-adaptor 
286 cgtcatcgtccttatagtcAGGGGArGTTGGGC GPR109-AS-orang109ab-FLAG-adaptor 
287 tggcgaggcatatctgtgta mouseGPR109-S-504 
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Figure S1 Basal activity and agonist-induced receptor internalization of HCA3 and GPR84. CHO-
K1 cells were transiently transfected with receptor constructs or empty vector (control). (A) Both, HCA3 
and GPR84, exhibited a basal cAMP inhibitory activity (cAMP level of empty vector-transfected 
forskolin-stimulated cells is set to 100 %) (B) The β2-adrenergic receptor (ADBR2) and V2 vasopressin 
receptor (V2R) served as control, which showed 22 % and 9 % reduction of cell surface expression upon 
stimulation with 10 µM isoprenalin and 10 µM arginine vasopressin (AVP), respectively. 100 µM 3HO 
but not 100 µM 3HDec induced a significant reduction in cell surface expression of HCA3. GPR84 cell 
surface expression levels were increased in presence of 100 µM C10 and 100 µM 3HDec. Cell surface 
expression levels of respective receptor construct in absence of agonist is set to 100 %. Data is shown 
as mean ± SEM of at least three independent experiments each carried out in triplicates. * P ≤ 0.05; ** 
P ≤ 0.01. 
Figure S2 
 
Figure S2 Differential, agonist-specific dynasore-sensitivity of HCA3 and GPR84 in DMR 
analyses. CHO-K1 cells were transiently transfected with receptor constructs or empty vector, seeded 
in fibronectin-coated Epic plates and DMR responses were recorded. 3-hydroxyoctanoic acid (3HO) 
activated HCA3 but not GPR84. Decanoic acid (C10) specifically activated GPR84 but not HCA3. 
3-hydroxydecanoic acid (3HDec) activated both, HCA3 and GPR84. No DMR response upon agonist 
stimulation was observed in cells transfected with empty vector. 80 µM dynasore was used. Shown is 
the agonist-induced wavelength shift in pm as mean ± SEM of three to five independent experiments, 
each carried out in triplicates. DMR at time points 10 min, 20 min and 40 min were extracted to generate 




Figure S3 Concentration-response curves derived from DMR analyses of HCA3 and GPR84. CHO-
K1 cells were transiently transfected with receptor constructs or empty vector, seeded in fibronectin-
coated Epic plates and DMR responses were recorded. Concentration-response curves in absence and 
presence of dynasore were derived from time points 10 min, 20 min and 40 min (Figure S2). Shown is 
the agonist-induced wavelength shift in pm as mean ± SEM of three to five independent experiments, 
each carried out in triplicates.  
Figure S4 
 
Figure S4 DMR analyses of HCA1 and HCA2. CHO-K1 cells were transiently transfected with 
receptor constructs or empty vector, seeded in fibronectin-coated Epic plates and DMR responses were 
recorded. (A) The lactate- and 3,5-dihydroxybenzoic acid (3,5-DHB)-induced DMR response of HCA1 
transfected CHO-K1 cells and (B) the 3-hydroxybutyrate (3HB) and monomethylfumarate induced 
response of HCA2 transfected CHO-K1 cells were at later time points affected by presence of dynasore. 
Shown is the agonist-induced wavelength shift in pm as mean ± SEM of three to five independent 




Figure S5 No influence of dynasore, sucrose, gallein, MβCD, and barbardin on intracellular cAMP 
levels in empty vector transfected CHO-K1 cells in the presence of HCA3 and GPR84 agonists. 





Figure S6 Time course of ERK activation for HCA3 and GPR84. No calcium signals detected upon 
stimulation of HCA3 and GPR84. (A) Agonist-induced phosphorylation of endogenous ERK 1/2 in 
cellular lysates of HCA3 or GPR84 transfected CHO-K1 cells over time. (B) Fura 2-based calcium 
imaging experiments were performed in CHO-K1 and HEK293-T cells transiently transfected with 
either GPR84 or HCA3 (both mRuby-tagged). The fluorescence ratio (F340/F380) represents the time 
course of calcium in mRuby-positive (mRuby+) and mRuby-negative (mRuby-) cells from the same 
coverslip. Each trace represents the average calcium signal ± SEM from 10 CHO-K1 or 20 HEK293-T 
cells. The GPR84 agonists 3HDec (400 µM), 6OAU (5 µM), and C10 (200 µM) were unable to induce 
calcium signals. The endogenous agonist ATP (100 µM) evoked prominent calcium responses. 
Similarly, the HCA3 agonists 3HDec (400 µM), IPBT5CA (5 µM), and 3HO (100 µM) were ineffective, 
whereas ATP induced strong signals. (C) ERK activation of both HCA3 and GPR84 was completely 
inhibited by 10 µM U0126. (A, C) Data is given as mean ± SEM of at least three independent 





Figure S7 Basal activity and cAMP inhibitory signaling of HCA3 and GPR84 in HEK293-T cells. 
(A) HCA3 and GPR84 showed a basal activity in HEK293-T cells (cAMP level of empty vector-
transfected fsk-stimulated cells is set to 100 %). Both receptors were activated in a concentration-
dependent manner by their respective agonists as determined by cAMP inhibition assays (cAMP level 
of HCA3 and GPR84 transfected cells in absence of agonist is set to 100 %, respectively.) (B) 100 µM 
3HO but not 100 µM 3HDec induced a significant reduction in cell surface expression of HCA3. No 
reduction of cell surface expression was measured upon stimulation of GPR84 with 100 µM 3HDec and 
100 µM C10. Cell surface expression level in absence of agonist is set to 100 %. (C) In comparison to 
dyn-2 wt, cell surface expression of HCA3 but not GPR84 was significantly reduced when K44A or 
R399A were co-transfected. Cell surface expression level of dyn-2 wt co-transfected cells is set to 100 
%. (D) HEK293-T cells stably expressing β-arrestin-2-EA cells transiently transfected with GPR84 were 
stimulated with C10 and 3HDec. Quantification of β-arrestin-2 recruitment using the PathHunter β-
arrestin assay (Eurofins DiscoverX) showed no recruitment of β-arrestin-2 by GPR84 following agonist 
stimulation. Luminescence of GPR84 or empty vector transfected cells in absence of agonist is set 1, 
respectively. (E) Live-cell images of HEK293-T cells co-expressing GPR84-mRuby (red) and β-
arrestin-2-YFP (green) were acquired before stimulation and 30 min post-stimulation with 100 µM C10 
or 100 µM 3HDec. (A-D) Data is given as mean ± SEM of at least three independent experiments each 





Figure S8 Cell surface expression of HCA3, GPR84, ADBR2, and V2R in the presence of dynasore, 
barbardin, and gallein. CHO-K1 cells were transiently transfected with receptor constructs and cell 
surface expression in absence of agonists but presence of 80 µM dynasore, 50 µM gallein and 100 µM 
barbardin was determined. Cell surface expression level of respective receptor construct in absence of 
inhibitor is set to 100 %. Data is shown as mean ± SEM of four independent experiments each carried 





Figure S9 Dynasore-sensitivity of agonist-induced DMR responses of human, gorilla and 
orangutan HCA3. CHO-K1 cells were transiently transfected with HCA3 orthologs, seeded in 
fibronectin-coated Epic® plates and DMR responses were recorded. Presence of dynasore similarly 
affected the DMR response of human HCA3 (A) and gorilla HCA3 (B) expressing CHO-K1 cells to 
3HO, D-phenyllactic acid (D-PLA) and indole 3-lactic acid (ILA). In contrast, responses to 3HDec and 
D-phenylalanine (D-Phe) and L-phenyllactic acid (L-PLA) were almost completely diminished in 
presence of dynasore. (C) Orangutan HCA3 DMR responses to different agonists in presence of dynasore 
showed a distinct pattern when compared to human and gorilla HCA3. A rather prolonged activation of 
the receptor in presence of dynasore was observed as also seen for human HCA1 and HCA2 (Figures 
S4A, S4B). Shown is the agonist-induced wavelength shift in pm as mean ± SEM of three independent 
experiments, each carried out in triplicates. (D) Amino acid sequence alignment of human, gorilla and 




Figure S10 Lactic acid bacteria-derived HCA3 agonists do not activate GPR84 and HCA3 recruits 
β-arrestin-2 (A) CHO-K1 cells were transiently transfected with receptor constructs or empty vector, 
seeded in fibronectin-coated Epic plates and DMR responses were recorded. None of the depicted HCA3 
agonists: D-phenyllactic acid (D-PLA), indole 3-lactic acid (ILA) and D-phenylalanine (D-Phe) 
activated GPR84 or empty vector-transfected CHO-K1 cells. Shown is the agonist-induced shift in pm 
as mean ± SEM of three to five independent experiments, each carried out in triplicates. (B) HEK293-T 
cells stably expressing β-arrestin-2-EA were transiently transfected with HCA3. Quantification of 
β-arrestin-2 recruitment using the PathHunter β-arrestin assay (Eurofins DiscoverX) shows recruitment 
of β-arrestin-2 by HCA3 following D-PLA, ILA, IPBT5CA but not D-Phe stimulation. Luminescence 
of HCA3 or empty vector-transfected cells in absence of agonist is set 1, respectively. Data is given as 





Figure S11 PTX-sensitive cAMP inhibitory response of Colo680N cells when stimulated with 
HCA3 agonists but no signal upon stimulation with GPR84 agonists. cAMP inhibition assays in the 
absence and presence of 100 ng/ ml pertussis toxin (PTX) confirmed presence of HCA3 and absence of 
GPR84 in Colo680N cells. Data is shown as mean ± SEM of three independent experiments each carried 





Supplementary Table S1 
Primers used for GPR84, dynamin-2, HCA3 amplification, sequencing and introduction of 
epitope tags 
 
ID sequence (5´- 3´) purpose 
789 GTGCAAATCAAAGAACTGCTCCTC pcDps forward (amplification/sequencing) 
790 CCTGGTTCTTTCCGCCTCAGAAG pcDps reverse (amplification/sequencing) 
2291 CGCCGCACTAGTTCACTTATCGTCATCGTCCTTATAGTC FLAG-uni-Spe I_AS 
2292 CGCCGGGTACCTCACTCACTTATCGTCATCGTCCTTATAGTC FLAg-uni-KpnI_AS 
2285 CGCGAATTCCCCACCATGTACCCCTACGACGTCCCCGACTACGCC HA-uni-Kozak-Eco RI_S 
2289 CGCCCCGGGCCCACCATGTACCCCTACGACGTCCCCGACTACGCC HA-uni-Kozak-Xma I_S 
311 TCCACCCTCTGCCTCTTTAG human GPR84-33-5UTR-S 
312 TGTTGTGAAAATGCCCACAT human GPR84-105-3UTR-AS 
313 GATAGTGCTGGCACTGGTGA human GPR84-408-ORF-S 
314 GCTCAGATGAAATCCCCTCA human-GPR84-772-ORF-AS 
315 TGAAGCCTAACTGTCCACCA human GPR84-6-mRNA-S 
316 GCTGGGGAGAGATTGTTGTG human GPR84-1411-mNA-AS 
317 ACGTCCCCGACTACGCCTGGAACAGCTCTGACGCC human GPR84- HA-adaptor 
318 TCACTTATCGTCATCGTCCTTATAGTCATGGAGCCTATGGAAACTCCG human GPR84-FLAG-adaptor 
596 TGAGGATGGCTGTCTCG mRuby-342-Seq-S 
597 GGCATCTTGATGTTCCCG mRuby-581-Seq-AS 
586 GCCAGAGCGCCGGCAAGAGTTCGGTGCTC rat_dynamin-2_Lys44-S 
587 GAGCACCGAACTCTTGCCGGCGCTCTGGC rat_dynamin-2_Lys44-AS 
590 GAACATCCACGGAGTCGCGACGGGGCTCTTCAC rat_dynamin-2_Ala399_S 
591 GTGAAGAGCCCCGTCGCGACTCCGTGGATGTTC rat_dynamin-2_Ala399_AS 
604 AACCGAATTCCCCACCATGGGCAACCGCG rat_dynamin-2_EcoRI-Kozak-S 
605 CAGTACTAGTTCAGTCGAGCAGGGACGG rat_dynamin-2_TGA-SpeI-AS 
606 CGTCCCTGCTCGACGTGAGCAAGGGCGA rat_dynamin-2_YFP-S 
607 TCGCCCTTGCTCACGTCGAGCAGGGACG rat_dynamin-2_YFP-AS 
608 CAGTACTAGTTTACTTGTACAGCTCGTCCA YFP-SpeI_TGA-AS 
609 ACTTGGTGGACTCCTATGTG rat_dynamin-2-S-1989S-seq 
610 GGACCACAGAATGTGTTTGC rat_dynamin-2-S-2456S-seq 
576 AACCGAATTCCCCACCATGAATCGGCACCATCTG EcoRI-ATG-HCAR3-sense 
711 ATTGCTAGCCCCACCATGAATCGGC HCAR3-PK1-NheI-S 
712 ACCTCCCAATTCGAAGCTTGACTCGATGCAACA HCAR3-PK1-HindIII-AS 
719 ATTGCTAGCCCCACCATGTGGAACAGC GPR84-PK1-NheI-S 
720 ACCTCCCAATTCGAGATCTGAATGGAGCCTATG GPR84-PK1-BglII-AS 
577 CTCTTCGCCCTTAGACACCTCGATGCAACAGCCC HCAR3-mRuby-AS 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S3 
CHO-K1 cells were transfected with receptor constructs and agonist-induced inhibition of cAMP 
accumulation was determined (see Methods). Data are given as cAMP level (% of forskolin stimulated 
w/o agonist) for each receptor construct (mean ± SEM of n ≥ 3 independent experiments each performed 
in triplicates). 
 








vehicle 50 µM  
gallein 
HCA3         
1.5 µM 
3HO 
61.5 ± 6.1 91.7 ± 2.9 72.1 ± 6.2 82.8 ± 1.7 92.4 ±3.4 91.8 ± 2.0 58.2 ± 2.1 77.8 ± 4.8 
6.25 µM 
3HO 
34.7 ± 2.1 54.9 ± 7.9 45.3 ± 5.6 66.7 ± 0.6 77.2 ± 3.4 78.3 ± 2.1 47.6 ± 1.9 61.1 ± 1.6 
25 µM 
3HO 
27.5 ± 3.9 48.9 ± 4.2 33.2 ± 3.1 57.1 ± 3.4 68.2 ± 4.1 67.0 ± 2.4 38.6  ± 1.5 44.3  ± 0.7 
6.25 µM 
3HDec 
77.9 ± 4.5 106.7 ± 8.1 92.1 ± 1.4 86.8 ± 2.8 88.0 ± 4.3 100.9 ± 2.4 75.2 ± 3.0 100.4 ± 7.2 
25 µM 
3HDec 
52.6 ± 4.4 105.4 ± 8.5 74.3 ± 2.7 82.7 ± 1.7 81.9 ± 2.5 91.4 ±2.1 65.9 ± 5.0 89.1 ± 5.0 
100 µM 
3HDec 
53.1 ± 5.5 77.9 ± 4.0 55.3 ± 5.5 73.0 ± 4.0 68.4 ± 4.6 84.5 ±2.1 53.7 ± 2.9 66.1 ± 4.6 
GPR84         
1.5 µM 
C10 
76.7 ± 4.0 92.8 ± 7.3 77.4 ± 1.8 74.8 ± 3.6 80.5 ± 4.8 90.4 ±3.0 72.6 ± 3.4 97.1 ± 5.1 
6.25 µM 
C10 
47.4 ± 1.3 61.8 ± 4.2 50.4 ± 2.6 61.1 ± 2.8 66.8 ± 3.3 78.7 ± 1.6 64.2 ± 1.9 85.5 ± 2.9 
25 µM 
C10 
33.4 ± 0.3 46.5 ± 3.7 35.0 ± 1.0 47.0 ±1.2 55.3 ± 3.5 64.5 ± 3.2 51.5 ±3.0 67.9 ± 4.8 
6.25 µM 
3HDec 
67.5 ± 5.0 75.9 ± 1.6 78.5 ± 7.1 47.1 ± 3.9 46.2 ±2.2 48.4 ± 2.6 56.0 ± 2.4 56.4 ± 3.2 
25 µM 
3HDec 
49.2 ± 4.9 52.0 ± 2.7 47.4 ± 3.1 36.0 ± 4.0 33.9 ±2.2 36.0 ± 3.0 44.0 ±2.5 45.6 ± 2.2 
100 µM 
3HDec 
36.8 ± 5.6 33.3 ± 4.3 34.4 ± 3.3 30.8 ± 1.9 27.9 ±1.1 27.5 ±2.0 47.2 ±2.3 42.1 ±2.4 
empty 
vector 
        
1.5 µM 
3HO 
99.5 ± 5.0 102.4 ± 4.5 96.4 ± 2.6 97.0 ± 2.1 102.9 ± 4.1 100.0 ± 2.4 103.6 ±7.5 103.6 ± 6.0 
6.25 µM 
3HO 
101.9 ± 6.5 85.6 ± 4.3 103.6 ± 3.1 92.6 ± 1.4 103.3 ± 1.1 96.9 ± 3.5 105.6 ± 13.3 103.4 ± 9.0 
25 µM 
3HO 
99.2 ± 8.9 78.3 ± 1.2 94.0 ± 5.1 94.0 ± 1.2 100.0 ± 2.2 100.9 ± 5.9 92.9 ± 4.7 106.4 ± 10.5 
1.5 µM 
C10 
99.2 ± 4.9 95.6 ± 5.1 105.7 ± 3.8 96.7 ± 4.4 97.1 ± 1.9 102.8 ± 4.7 105.1 ± 5.8 103.6 ± 6.0 
6.25 µM 
C10 
93.8 ± 2.9 87.5 ± 11.9 103.4 ± 12.1 97.4 ±2.3 98.0 ± 6.3 104.0 ± 5.8 91.6 ± 5.8 103.4 ± 9.0 
25 µM 
C10 
94.1 ± 3.7 91.6 ± 10.3 107.7 ± 6.2 100.6 ± 2.6 105.1 ± 4.1 103.2 ± 4.7 90.5 ± 4.7 106.4 ± 10.5 
6.25 µM 
3HDec 
99.3 ± 3.5 94.7 ± 5.5 100.1 ± 3.4 101.7 ± 5.6 98.7 ± 1.7 103.6 ± 4.8 99.3 ± 3.5 98.9 ± 6.8 
25 µM 
3HDec 
92.0 ± 2.9 92.1 ± 12.6 106.7 ± 5.2 102.3 ±5.9 94.5 ± 3.5 99.9 ± 3.2 92.0 ± 2.9 88.5 ± 2.7 
100 µM 
3HDec 





















































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S5 
TPM values as downloaded from https://www.ebi.ac.uk/gxa/home [1] 
 
organism part/tissue/cell type Expression Atlas HCAR3 GPR84 
blood E-MTAB-5214 42 17 
neutrophil, mature E-MTAB-3827 103 61 
monocyte, CD14-positive, CD16-negative classical  E-MTAB-3827 82 30 
neutrophil, segmented of bone marrow E-MTAB-3827 58 15 
macrophage, inflammatory  E-MTAB-3827 5 27 
macrophage E-MTAB-3827 3 3 
metamyelocyte, neutrophilic  E-MTAB-3827 0.5 61 
vermiform appendix E-MTAB-2836 24 22 
bone marrow E-MTAB-2836 20 30 
 
Experiments included: E-MTAB-2836 (Raw Data Provider: The Human Protein Atlas), E-
MTAB-5214 (The Genotype-Tissue Expression (GTEx) pilot analysis) [2],61 E-MTAB-3827 
(These studies make use of data generated by the Blueprint Consortium. A full list of the 
investigators who contributed to the generation of the data is available from www.blueprint-
epigenome.eu. Funding for the project was provided by the European Union's Seventh 
Framework Programme (FP7/2007-2013) under grant agreement no 282510 – BLUEPRINT.),  
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The human HCA3 differs from gorilla HCA3 only in three amino acids and a C terminus 
extended by 24 amino acids. The orangutan HCA3 has only two differences compared to the 
gorilla HCA3 (Tyr86; Trp142) (Figure S9D). We found that only for orangutan HCA3 we do not 
observe similar differences between 3HO- and 3HDec-induced DMR responses in presence of 
dynasore compared to human HCA3 (Figure S9). Thus, neither the extended C terminus nor the 
human HCA3 specific amino acids Val156, His253 and Ile317 are relevant for the observed 
reduction in 3HDec-induced DMR response in the presence of dynasore since gorilla HCA3 
DMR responses to different agonists are similarly affected by dynasore. This suggests a role of 
Tyr86 and/or Trp142 for the observed effect of dynasore. Asn86 of human HCA2 in TM2/ECL1 
has been shown to be crucial for nicotinic acid binding [3]. Tyr86 of HCA3 might more likely 
play an indirect role for the interaction of HCA3 with dyn-2 whereas Trp142, located at the 
transition of ICL2 to TM4, could be relevant for a direct interaction. The finding that presence 
of dynasore causes a sustained signaling of the evolutionarily closest HCA3-relatives HCA1 
(Arg130) and HCA2 (Arg142) further supports this hypothesis (Figure S4). DMR analyses of the 
gorilla and orangutan HCA3 with D-PLA, ILA, D-Phe and L-PLA revealed that activation 
profiles and dynasore sensitivity of the DMR response are conserved between human and 
gorilla HCA3 (Figure S9). In contrast, orangutan HCA3 is less potently activated by all agonists 
tested and presence of dynasore rather causes sustained or unchanged signaling than inhibition 
(Figure S9C).  
In summary, our analyses showed that dynasore affected the DMR response of human and 
gorilla but not orang utan HCA3 to D Phe and L-PLA in a similar manner like that to 3HDec, 
whereas the DMR response of D-PLA and ILA was similarly affected like that one to 3HO 
(Figure S9). Thus, the crucial involvement of dyn-2 in HCA3 signaling and trafficking is a 
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